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A scientist in his laboratory is not only a technician:
he is also a child confronting natural phenomena
that impress him as though they were fairy tales.
Marie Curie (1867-1934)

Preface
Over the last decades, the responsible gene defects have been identified in many inherited
diseases. This has certainly led to a better diagnosis of these diseases. Also, identifica-
tion of the underlying gene defect has helped enormously genetic counselling in affected
families resulting in better prevention of these disorders. Initially, it was thought that it
would also lead to the development of effective new treatments. Gene therapy consisting
of introducing a full-length gene into the affected tissues of the patient was harder than
scientists initially thought. Only a few disorders can nowadays be treated by gene therapy.
New techniques are being developed for intervention on the gene itself such as the exon-
skipping technique used, for example, as treatment of Duchenne disease. An alternative
way to treat patients with inborn defects is the administration of a small chemical substance
that blocks the molecular mechanism responsible for cell damage and cell death and by
this way prevents progression of the disease. For this purpose, a good knowledge of the
molecular pathophysiological mechanism is necessary. In the PhD work presented here,
three genetic disorders are studied: Giant Axonal Neuropathy (GAN), Ullrich Congeni-
tal Muscular Dystrophy (UCMD) and Pseudoxanthoma Elasticum (PXE). The underlying
gene defect in these disorders is known but the molecular mechanism leading to cell dam-
age is not. In the study presented here, much work has been done in an effort to gain better
insight into the underlying pathogenetic mechanism in these disorders. In all three disor-
ders, skin fibroblasts are involved in the disease process. Cultured skin fibroblasts are used
as a cell model for the disease. A proteomics quantification method is applied to study the
pathogenic alterations in these cells.
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GENERAL INTRODUCTION
1

1
Proteomics and mass spectrometry
The decoding of the human genome in 2003 [1] marked the beginning of the ‘post-genomic
era’. The disappointment surrounding the fact that the size of human genome turned out
to be about 75% smaller than had been anticipated, making it around the same size as the
genomes of roundworm and fruit fly, soon made way for a plethora of questions in the
scientific community [2]. The biggest question was: how do we manage to be so much
more complex with the same amount of genetic information? The answer, it soon turned
out, was that proteins, not genes, are responsible for an organism’s complexity. Thus the
‘proteome’, a contraction of the words ‘protein’ and ‘genome’ [3], which describes the
entire complement of proteins expressed in a cell, tissue or organism, is what ultimately
determines the functionalities and intricacies of any living organism.
3
4 INTRODUCTION
1.1 Proteomics
The central dogma of molecular biology [4] describes, in its simplest form, the flow of
biological information from deoxyribonucleic acid (DNA) via ribonucleic acid (RNA) to
the synthesized protein (Figure 1.1). While DNA only represents the plans of a cell, the
mRNA works as a messenger that sends pieces of information from one place to another,
and proteins are the ‘functional horses’ of a cell, displaying a variation that is much larger
than would be expected from looking at the genome alone.
Figure 1.1: The central dogma of molecular biology.
A single DNA sequence can encode multiple proteins due to a variation in translation
of ‘start’ and ‘stop’ sites, as well as translational frame shifting. In addition, in eukaryotes,
proteins can undergo a wide range of post-translational modifications (PTMs) that can pro-
foundly affect their function; some proteins form transient or permanent complexes with
other proteins, RNA or DNA molecules, and function only in the presence of their partners.
Due to the process of alternative splicing, human cells can produce several different pro-
teins from the same gene, which makes the proteome much more complex than the genome.
Thus, it can be easily understood that there is no simple correlation between the expression
levels of genes and proteins. Similarly, comparison of mRNA to protein abundances also
resulted in a poor correlation between mRNA and protein levels [5; 6]. This finding led to
the conclusion that transcript levels as measured by microarrays and PCR-based methods
do not provide comprehensive information on the proteome and shows that, compared to
the static nature of the genome, the proteome is highly dynamic and continuingly changes
in response to internal and external stimuli. Therefore, it is of great importance to study the
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proteome directly.
The word ‘proteomics’, derived from ‘proteome’ and ‘genomics’, has been defined
as the study of this complement expressed at a given time or under certain environmental
conditions. There’s little doubt that proteomics will have great impact in all areas of the life
sciences in the years to come and the reason is clear: since proteins are the functional units
in the cell, we need to understand how they work if we want to really grasp the course of
any biological process.
Apart from genomics and proteomics, transcriptomics (study of the transcriptome) and
metabolomics (the global analysis of metabolites, small molecules generated in the process
of metabolism) have also emerged as new research areas. By combining data from different
‘omics’, system biologists are able to organize and map complex biological systems.
1.2 Proteomics technologies
1.2.1 Introduction
The enormous complexity of the proteome makes the development of appropriate tech-
nology for its analysis extremely challenging, and no technique is currently available that
allows the complete profiling of the proteome. The reasons for this are diverse. Firstly,
proteins, unlike DNA and RNA, are distributed over all cell structures, and the study of
water-soluble cytoplasmic proteins requires approaches that are different from the extrac-
tion procedures of membrane-associated, integral membrane proteins or specific organel-
lar proteins. Secondly, proteomic technologies cannot benefit from amplification methods
equivalent to the polymerase chain reaction (PCR) for oligonucleotides. The protein com-
position in the analyzed sample reflects the relative protein abundances in the organism and
therefore sufficient material must be extracted from the sample in order to be able to study
proteins. Thirdly, cellular protein extracts contain a large number of different proteins,
together with an extremely wide concentration dynamic range. Therefore, effort to charac-
terize the total protein complement of cells requires extensive separation prior to analysis.
Two-dimensional polyacrylamide geleletrophoresis (2D-PAGE) is a very important and
well established proteomics technique whose introduction in 1975 by O’Farrell is generally
considered as the birth of proteomics [7]. By separating a complex protein mixture into two
dimensions, iso-electric focusing (IEF) separating proteins according to their isoelectric
points (pI) in one direction and sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) orthogonally separating them according to their size, a 2D map is made. In
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the beginning however, the identification of these proteins, was very difficult due to the
lack of a fast and sensitive analytical method for protein characterization. Determination
of a protein sequence by Edman degradation is tough, time-consuming, and not scalable
to high-throughput; protein science in general in that time was slow and difficult. Two
fundamental breakthroughs facilitated protein identification within unknown protein mix-
tures enormously: (i) complete sequencing of the genomes, and (ii) the development of two
fundamental mass spectrometry approaches.
The use of mass spectrometry (MS) for the analysis of biomolecules was a turning
point in protein analysis. The first mass spectrometers were developed in the beginning
of the 20th century and mainly used in chemistry for small molecules. Despite advances
in mass accuracy, mass range, and the ability to couple the instruments to chromatography,
even by the second half of last century MS still lacked the efficacy for biomolecule analysis.
Indeed biomolecules are large and polar molecules, which makes it difficult to generate gas
phase ions without decomposition during vaporization/ionization. The breakthrough came
in the late 1980s with the introduction of two ionization techniques: matrix-assisted laser
desorption/ionization (MALDI) [8] and electrospray ionization (ESI) [9], revolutionizing
the use of MS in life sciences by enabling the analysis of proteins and peptides. Since then,
mass analyzers with increasing sensitivity, resolution, mass accuracy and dynamic range
are constantly being developed. Important for proteomics is also the exploitation of tandem
mass spectrometers.
The importance of ESI and MALDI techniques was acknowledged in 2002, when the
developers Fenn and Tanaka were awarded the Nobel prize in chemistry. Their work in
ESI-MS and MALDI-MS made MS increasingly useful for sophisticated biological exper-
iments.
1.2.2 Shotgun proteomics
For protein separation by gel electrophoresis, several one and two dimensional methods
are available (e.g. 1D [10], 2D [11; 7], Blue Native [12; 13], and 16BAC [14; 15] gel
electrophoresis). 2D-PAGE is the most common approach, allowing for a resolution of
thousands of protein spots per gel [16]. However, this approach has limitations for hy-
drophobic, low abundant and extreme pI proteins. Additionally, this technique is labor
intensive and is not amenable for automatic high-throughput analysis. Liquid chromatog-
raphy based protein separation is not so popular, although several separation methods can
be used, including size exclusion chromatography (SEC), ion exchange chromatography
(IEC), hydrophobic interaction chromatography (HIC) and hydrophilic interaction chro-
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matography (HILIC). These are the so-called top-down approaches, in which proteins are
separated before proteolytic digestion into peptides (Figure 1.2A-C).
Figure 1.2: An overview of proteomic strategies to analyze complex protein mixtures. (A) 2D-
PAGE protein separation, (B) 1D-PAGE protein separation followed by chromatographic pep-
tide separation (C) multiple liquid chromatography-based protein separations, (D) multiple liquid
chromatography-based peptide separations.
Over the last few years most developmental efforts have been focused on mass spec-
trometry based gel-free approaches for proteome analysis [17], named bottom-up or shot-
gun proteomics where, after proteolytic digestion of the proteins, the generated peptides
undergo separation steps (Figure 1.2D). These multiple separation steps are necessary to
reduce sample complexity before the actual MS analysis because even high-resolution mass
spectrometers are unable to handle the huge complexity of peptides generated after diges-
tion of thousands of proteins.
In shotgun proteomics proteins digestion into peptides is usually done through trypsiniza-
tion, although other enzymes can be used (Figure 1.2D). Trypsin cleaves peptide bonds
specifically after the carboxyl group of arginine and lysine, and because of the biological
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distribution of arginine and lysine residues, the resulting peptide masses fit the range re-
quired for analysis by mass spectrometry [18]. Because digestion of proteins is the first step,
sample complexity dramatically increases, which creates the need for separation phases.
This fractionation of complex peptide mixtures can be achieved by high performance
liquid chromatography (HPLC) methods. In general, liquid chromatography (LC) is an ana-
lytical method in which analytes are retained on the stationary phase of an analytical column
and are gradually released for analysis or fractionation using a specific mobile phase. LC
enables peptide separation according to different physicochemical characteristics, such as
hydrophobicity (reversed phase, RP), specific affinity, molecular size (size exclusion) and
charge (ion exchange). RP HPLC is a frequently applied fractionation method in which
peptides are retained on an analytical column, consisting of an inert, non-polar stationairy
phase such as C18 bonded silica. As mobile phase, mixtures of water and organic solvent
(i.e. acetonitrile) are used to gradually fractionate the peptides. RP is fully compatible with
MS and the mineraturization to nanoLC, besides the increased sensitivity reduced the sol-
vent flow rate (typically a few hundreds of nanoliters per minute) and solvent consumption.
The use of pre-columns to trap peptides at faster flow rates, introduces an additional clean-
up step. A schematic presentation of a nanoLC-MS set-up is given in Figure 1.3.
Figure 1.3: Schematic representation of a nanoLC-MS/MS set-up. After sample loading, peptides
are eluted to a trapping column with a larger diameter (typically 1 mm id.) at a high flow rate. After
valve switching, peptides are eluted to an analytical column (typically 75 µm id.) for separation by
applying a linear hydrophobic (acetonitrile) gradient at nano flow rates.
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However, one-dimensional LC separation is not sufficient to separate a complete pro-
teome. Therefore, combination of multiple and/or different LC methods is required and
allows multidimensional fractionation.
The first published protocols [19–22] were two-dimensional peptide separation tech-
niques in which the familiar dimensions of 2D-PAGE protein separation were each replaced
by peptide equivalents. The iso-electric focusing for proteins was replaced by Strong Cation
Exchange chromatography (SCX) and the molecular weight (MW) separation was replaced
by RP-HPLC. This technique, in which biphasic columns were used, is termed Multidi-
mensional Proteome Identification Technique (MudPIT) [19–22] (Figure 1.4A).
From this MudPIT technique the now popular two-dimensional liquid chromatography
(2D-LC) separation has evolved, which uses two separate columns, an SCX and a RP, fur-
ther separating the co-eluent from the first column on the second column (Figure 1.4B).
The 2D-LC performance depends on separation orthogonality.
Aside from SCX-RP, several other 2D-LC setups were found to provide suitable orthog-
onality [23]. RP is generally used as the back-end separation due to its compatibility with
MS. An emerging alternative to SCX-RP separation using RP in both dimensions but at
different pH values has been described [24–26]. Here, the peptides are separated at high pH
(10) in the first dimension, followed by orthogonal separation at low pH (3) in the second.
Despite peptide sequence hydrophobicity remaining the major parameter influencing the
order of separation in both columns, sufficient differences in retention of the peptides are
observed under different pH, as determined by their unique pI. Charged peptide residues
(arg, his, lys, asp, glu) are particularly susceptible to variations in retention between pH
< pI and pH > pI conditions [24]; they either gain a charge and become hydrophilic or
lose their charge and become hydrophobic. As trypsin cleaves to the carboxyl end of a Lys
(K) or Arg (R) residue during proteolysis, most tryptic peptides should display different
retention behavior in the two dimensions. Although RP-RP was reported to be slightly less
orthogonal than SCX-RP [24; 25] it can provide superior peptide identification in complex
samples. This is likely due to the higher resolution and peak capacity of RP columns in
general compared to SCX columns. In addition, RP-RP separation yields a more evenly-
distributed elution profile for peptide separation than SCX-RP separation, without the loss
of highly hydrophobic peptides that occurs in SCX-RP separations [27; 28].
The coupling of two chromatographic columns can be performed either online or of-
fline (Figure 1.4B, C). In offline 2D-LC, the effluent of the first-dimension is collected and
the organic content evaporated prior to reinjection to the second-dimension. For the online
10 INTRODUCTION
(A) MudPIT
(B) Online 2D-LC
(C) Offline 2D-LC
Figure 1.4: Schematic representations of two-dimensional LC set-ups.
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version, the samples are directly transferred from the first-dimension column to the second-
dimension through the use of an appropriate interface. Online 2D-LC is generally regarded
as more desirable because of the automatability, reducing sample handling and the accom-
panying potential sample loss, contamination and batch-to-batch variability. Nevertheless,
offline 2D-LC has several distinct advantages of its own, such as the flexibility to control
the number or order of fractions to be further analyzed based on their intensity or the prefer-
ence of the analyst. In addition, any incompatible solvent from the first-dimension elution
can be evaporated prior to re-injection.
It is obvious that the proteolytic digestion of proteins into peptides before proteomic
analysis, aside from the higher sample complexity, also introduces significant redundancy
in the sample. However, this also increases the chance of detection and identification of a
larger number of proteins. Hydrophobic proteins, for example, which may be hard to de-
tect through other methods, will usually yield at least some peptides that are more readily
amenable to shotgun analysis techniques. The redundancy introduced by shifting to the
peptide level thus enables more straightforward identification of the parent protein. And
although the sample complexity is increased, the homogeneity allows high throughput, au-
tomated, standardized separations using 2D-LC.
Other techniques were developed in order to reduce the sample complexity that concen-
trate on selecting subsets of representative peptides. In contrast to the separation techniques,
the selection techniques also affect the protein coverage (the percentage of the protein se-
quence that is identified) since the total number of different peptides offered to the mass
spectrometer is typically significantly reduced. A major disadvantage of selection tech-
niques when compared to separation techniques is that not all proteins have a representative
peptide and these will be missed in the selection analysis. The pioneering peptide selection
method was the Isotope-Coded Affinity Tag (ICAT) method [29] (see also section 1.3.1).
In this method, cysteine containing peptides are covalently bound to tags containing biotin.
These tagged peptides can therefore be filtered from the peptide mixture via avidin chro-
matography. Another selection technique is COmbined FRActional Diagonal Chromatog-
raphy (COFRADIC) where a specific set of peptides is modified between two consecutive
HPLC runs. The modifications are chosen so that the modified peptides will have a differ-
ent retention time in the second HPLC run, thus allowing the shifted or the retained set to
be separated from the rest of the peptides. Different variations of this concept have been
developed [30–37].
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1.2.3 Mass spectrometry
Mass spectrometry (MS) is a sensitive technique used to detect and identify molecules based
on their mass (m) and charge (z). Mass spectrometers consist of three major components:
an ion source to produce gas phase ions from the sample, one (or more) mass analyzer(s)
to separate the ions according to their mass to charge (m/z) ratios, and an ion detector to
register the number of ions. The mass spectrometer is controlled by software which allows
processing the data and producing the mass spectrum in a suitable form.
Today, different sources and m/z analyzers are available. Among the various types of
ion sources available, ESI and MALDI dominate in the area of protein analysis. ESI is
the preferred ion source for online coupling between LC and MS, whereas MALDI is used
in offline analysis. Popular and commonly used mass analyzers for proteomics include the
time-of-flight (TOF), quadrupole (Q), ion-trap, Orbitrap and Fourier ransform ion cyclotron
resonance (FTICR) analyzers. They can be used individually, or hybridized in tandem, e.g.
Q-TOF, TOF-TOF, Q-Q-Q, LTQ-Orbitrap, LTQ-FT [38]. Traditionally, MALDI is coupled
to TOF analyzers, while ESI is mostly coupled to quadrupoles and ion traps [39].
The mass spectrometer used in this thesis (chapter 3-6) is a MALDI TOFTOF mass
spectrometer which is described in more detail below.
Matrix-assisted laser desorption ionization
Ionization is essential to turn molecules into gas phase ions. Matrix-assisted laser des-
orption ionization (MALDI) is an efficient ionisation technique for molecules with a MW
between 500 and 400000 Da [40]. In MALDI the sample is embedded in a low-molecular-
weight, UV-absorbing matrix (e.g. α-cyano-4-hydroxycinnamic acid for peptide analytes
and sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) for proteins [41; 42]) on a
solid, often metallic target plate on which the sample is crystallized from highly organic sol-
vents and in the presence of 0.1% tri-fluoroacetate (TFA). After evaporation of the solvent,
the matrix and analytes co-crystallize and because the matrix is present in vast excess of
sample, individual sample molecules are isolated. Ionization is then achieved by irradiating
the target with a pulsed laser, typically an Nd-YAG or N2 laser generating light in the UV-
spectrum, and relies on the absorption of the laser energy by the matrix molecules, causing
desorption of matrix and analytes and resulting in gas phase matrix and analyte molecules
(Figure 1.5). Analytes (A) are ionized by proton transfer from matrix (M) molecules:
MH+ + A→M + AH+
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Usually this procedure produces single charged ions that are accelerated by a voltage
applied to a grid or ring electrode to impel them into the mass spectrometer.
Figure 1.5: The principle of matrix-assisted laser desorption ionization (MALDI).
The advantage of MALDI over ESI is the simplicity of the generated spectra and the
low sensitivity to contaminating salts.
Time of flight analyser
A time of flight (TOF) analyzer is essentially a long vacuum tube with the inlet from the ion
source at one end and a detector at the other, and ions are separated based on their time of
flight through the analyzer. The cloud of ions commonly generated by MALDI is initially
accelerated by a strong electric field generated by a high voltage grid. This will transfer
kinetic energy to the ions according to the following equation: Ek = z.V = mv2/2 (with z
the charge of the ion, V the voltage applied, m the mass of the ion and v the speed of the
ion). The ions are then allowed to fly through a field-free tube of known length. Applying
the equation from Newton’s dynamics (x = v.t), we can resolve m and z for time (t) and
distance (x): m/z = 2.V.t2/x2
Since the length of the TOF tube and the voltage applied are known and the actual flight
time itself can be determined, it is possible to resolve mass over charge (m/z). According
to this equation, light ions reach the detector earlier than heavy ones, thus ions will be sep-
arated in the analyzer according to their m/z ratios. However, ions of the same mass often
show a distribution of kinetic energies in a linear TOF analyzer after being accelerated, and
consequently, by the time they hit the detector, a broadening effect is observed, decreasing
the resolution. This is attributed to the initial spatial spread and initial velocity of the ions.
For example, in a MALDI source, the ionization creates a burst of ions that will have differ-
ent kinetic energies and the ions will be at different distances from the detector. Therefore,
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ions with the same m/z value but with different kinetic energy or at different distances will
be detected at different times and will cause a decrease in resolution. This can be countered
through the use of a so-called reflectron field and a delayed extraction of ions from the ion
source.
A reflectron, or ion mirror, compensates for the initial energy spread of the ions as it
creates a retarding electrical field at the end of the flight tube that deflects the ions and sends
them back through the flight tube. The more energy the ion has, the further it penetrates the
retarding field of the reflectron before it is being reflected. Therefore, a more energetic ion
will travel a longer flight path and arrive at the detector at the same time as less energetic
ions with the same mass (Figure 1.6). Unfortunately a reflector limits the mass range to ±
12kDa.
Figure 1.6: Schematic of a reflectron time-of-flight mass analyzer. Two ions of the same mass but
different initial kinetic energies, E1 and E2, are produced and extracted into the first field-free region.
The ions are then reflected by the ion mirror, the reflectron, travel through the second field-free drift
region and are detected at the same time by the reflecting detector.
An alternative method to enhance resolution, also for larger ions is delayed extraction.
During delayed extraction, the voltage of the acceleration grid is switched on with a time
delay of a few hundred nanoseconds from the laser impulse. Once the acceleration grid
voltage is applied, ions with a higher start velocity will be further away from the target
than slower ions and receive a smaller portion of kinetic energy. Delayed extraction greatly
reduces start velocity distribution [46; 47].
MALDI-TOFTOF mass spectrometer
Throughout our experimental work , we used the 4800 Proteomics analyzer, a MALDI-
TOFTOF instrument from AB SCIEX (Figure 1.7). A schematic presentation of the inside
of this tandem mass spectrometer is shown in Figure 1.8. The instrument permits precursor
selection, followed by collision induced dissociation of the selected ion and recording the
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fragment ions. Ion selection and fragment detection are achieved by two TOF analyzers,
with a collision cell placed in between both. The two flight tubes form a continuum in the
MS-mode, while in MS/MS mode ions are initially separated according to their m/z in the
first TOF to allow precursor selection, followed by fragmentation of the selected parent ion
in the collision cell. The fragment ions generated in the second source are then analyzed in
the second TOF-tube.
Figure 1.7: Picture of the 4800 Plus MALDI TOF/TOF Analyzer.
LC-MALDI
Although HPLC is typically coupled online to ESI-MS, it can be easily used offline with
MALDI-MS. LC-MALDI is a way of sequentially ‘spotting’ LC fractions on a target plate
with simultaneous addition of the matrix using a spotting device (Figure 1.9). In that way
16 INTRODUCTION
Figure 1.8: Schematic overview of the 4800 Plus MALDI TOF/TOF Analyzer.
each spot contains a ‘snapshot’ of the eluent from an LC separation for a particular time
period and the chromatogram is actually frozen on the MALDI target plate.
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It is then possible to extract the total ion count from each spot and develop a total ion
current (TIC) chromatogram of overall ion intensities in an LC run. Resolution of an LC-
MALDI TIC is not dependant on mass spectrometer duty cycle, but on the number of spots.
Thus the mass spectrum acquisition is not restricted in the time dimension by peak width,
but rather by the number of spots on the target. Narrow peaks and rapid chromatography
means less spots, and reduces analysis time. In ESI-MS the mass spectrometer can only
acquire spectra as the compounds being analyzed elute from the column that is, for the
duration of a chromatic peak. In LC-MALDI it is usual to first scan the entire plate (MS),
determine the spot location where each precursor ion is most abundant, before calculating
and executing a second scan to acquire MS/MS spectra so that further structural information
can be obtained to identify the molecules being analyzed. This unique benefit of determin-
ing the relative abundance (peak area) of a particular peptide throughout an LC-MALDI
run and fragmenting only the most abundant cannot be done by ESI without repetition of
the sample injection.
The ability to archive plates containing chromatography and re-acquire data using mod-
ified data collection conditions increases confidence in peptide identifications without addi-
tional chromatography. Using an LC MALDI approach, the rate of the collection of MS/MS
data is decoupled from the chromatographic separation, allowing as much or as little time
as necessary for acquiring spectra without fear of missing components as they elute from
the HPLC column. In addition MALDI is also relatively insensitive to the presence of
nonvolatile additives and contaminants in the LC mobile phases. Disadvantages are that
analysis times are increased, as the complete separation of the sample is performed sepa-
rately to the MS sample analysis. Additionally, the duty cycle of an ESI MS is usually less
then 2-3 seconds on modern instruments, but it is rare for the LC resolution of LC-MALDI
spotting to be so rapid.
Mass spectrometric protein identification
Two MS-based methods are commonly used to identify proteins. Peptide mass fingerprint-
ing (PMF) by MS [48–52] and peptide fragment fingerprinting (PFF) by MS/MS [53; 54].
In both methods proteins are digested to peptides, which are then analyzed by mass spec-
trometry.
In Peptide Mass Fingerprinting (PMF), a proteolytic digest (generally by the enzyme
trypsin) of a protein, typically from a 2D-PAGE spot, is analyzed by a single stage of mass
spectrometry (MS), yielding a spectrum of peptide ion intensities versus their m/z ratios.
These series of different peptide masses in the MS spectrum are the unique fingerprint of a
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protein, and are then linked to a protein by a protein database matching algorithm that es-
sentially compares the experimental spectrum against a theoretical peptide mass spectrum
obtained from an in silico digest of a protein sequence from a protein database. Each exper-
imental to theoretical spectrum match is then rated by using a scoring function. Database
search algorithms often used are MASCOT [55], Sequest [56], X!tandem [57], and Paragon
[58]. In 2D-PAGE, spots or proteins can be identified via peptide mass fingerprinting (PMF)
and via the fragmentation profiles of their peptides (PFF).
In shotgun proteomics, proteins are typically identified via their peptide fragments in
MS/MS-mode only. This relies on peptide fragmentation after the first stage of mass spec-
trometry. Fragmentation can be achieved by collision induced dissociation (CID).
In the MS/MS instruments two mass analyzers are joined together. In the first analyzer,
a peptide with specific m/z ratio is selected from the complex mixture of peptides. The
selected peptide is then dissociated to multiple fragment ions by collision with an inert
gas (typically Ar or air) in the collision cell. The resulting fragment ion masses are then
measured in the second mass analyzer. The peptide bond is most sensitive to fragmenta-
tion. Fragmentation of other bonds of the peptide backbone are also observed, therefore a
standardised nomenclature was defined (Figure 1.10) [59].
Figure 1.10: Nomenclature for the product ions generated in the fragmentation of peptides by tan-
dem mass spectrometry.
The generated fragment ions form an (interrupted) ladder of masses, representing (seg-
ments of) the original peptide sequence. As such, the original peptide sequence can be
(partially) inferred from these so-called tandem-MS or MS/MS spectra. These obtained
(fragments of) peptide sequences are then mapped back against a protein database to infer
protein identifications.
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1.3 Quantitative proteomics
Rather than just providing a list of proteins identified in a certain sample as is the case for
profiling proteomics, quantitative proteomics yields information about differences between
samples. As such, this approach can be used to compare samples from healthy and diseased
individuals.
The oldest differential proteomics method uses the 2D-PAGE approach with additional
software-based image analysis tools to analyze and quantify individual protein spots on the
scanned images of the 2D-PAGE gels. Differential staining of gels with fluorescent dyes
(difference gel electrophoresis, DIGE) is an alternative approach to highlight differences
in the spot pattern [60]. Due to the disadvantages of the 2D-PAGE technique, proteomics
nowadays focuses on the MS-based strategies, as discussed in the above section 1.2.2. With
this growing popularity and development of MS-based techniques, several alternative strate-
gies have been developed for both relative and absolute quantification of proteins in shotgun
approaches. The methods for protein identification are identical to those used in general
(qualitative) proteomics, i.e. the digestion of extracted proteins into peptides and the sub-
sequent multi-dimensional chromatographic separation prior to MS analysis, but include
additional quantification. Although these strategies are more complex than mere protein
identification, quantitative proteomics is critical for understanding global protein expres-
sion and modifications, underlying the molecular mechanisms of biological processes and
disease states.
Relative quantification is most often used to compare peptides and finally protein abun-
dance from different cell states. The absolute signal intensity of a peptide ion measured
in the MS run does not necessarily reflect the abundance of the peptide present in the an-
alyzed sample. This is due to the variability in peptide ionization by ESI or MALDI, and
the influence of other ions in the sample on the measured ion intensity. Therefore the signal
intensity should be handled with caution, and in the event of absolute quantification, the
sample is spiked with synthetic standard peptides in known amounts during proteolysis of
the proteins or before LCMS/MS analysis. Absolute quantification is thus used to determine
the absolute amount (mass or mole) of proteins in a mixture.
The MS-based quantitative strategies can be divided into two main groups: methods
based on stable isotope labeling and label-free techniques (see Table 1.1 for a summary of
the most important and popular methods for relative and absolute quantification).
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1.3.1 Stable isotope labeling
Tags containing stable isotopes (13C, 15N, 18O or 2D) can be introduced into proteins or
peptides in a number of ways: (i) chemically (Isotope-coded affinity tags (ICAT), isobaric
tags for relative and absolute quantification (iTRAQ), absolute quantification (AQUA));
(ii) metabolically (stable isotope labeling by amino acids in cell culture (SILAC)); or (iii)
enzymatically (C-terminal labeling using 18O-labeled water).
Isotope-coded affinity tags (ICAT)
The ICAT approach has been pioneered by Gygi and co-workers [29]. The technique has
been further improved and now uses a protein tag with four main segments: a protein
reactive group (based on iodoacetamide) that specifically reacts with cysteinyl thiols; a
linker that incorporates stable isotopes (12C/13C), the heavy reagent with nine 13C atoms
is nine Daltons heavier than the light reagent; a biotin affinity tag allowing for affinity
purification; and an acid cleavage site to remove the biotin portion of the label and part of
the linker by adding TFA after purification. This reduces the overall mass of the tag on the
peptides and improves the overall peptide fragmentation efficiency (Figure 1.11).
Figure 1.11: ICAT reagent, consisting of a sulfhydryl-reactive moiety connected to a linker region
with deuterium or 13C substitutions to make the tag heavy. Biotin is connected to the linker region
to allow affinity purification of labeled peptides.
Cysteine side chains in complex mixtures of proteins from two different cell states are
reduced and alkylated using a heavy-tag for the proteins in one state and a light-tag for the
protein in another state. After labeling, the two samples are combined and subjected to pro-
teolysis, followed by the isolation of biotinylated peptides using avidin affinity capture. The
eluted labeled peptides are then fractionated by 2D-LC and quantitatively analyzed by MS.
Ion intensity ratios between heavy and light forms of specific peptide provide information
regarding peptides relative abundance.
An advantage of ICAT technology is that tagging and selective enrichment of cysteine-
containing proteins dramatically reduces the complexity of the analyzed peptide mixture,
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enabling identification and quantification of non-abundant proteins from complex samples.
However, this also means that proteins that do not contain any cysteines will not be detected.
Moreover, the avidin affinity purification introduces potential complications including non-
specific and irreversible binding.
Isobaric tags for relative and absolute quantification (iTRAQ)
iTRAQ is a popular technique and widely used in quantitative proteomics [61]. Contrar-
ily to ICAT, where isotopes are introduced at the protein level before proteolytic digest,
iTRAQ labeling is done on the peptide level. The introduction of isobaric mass tagging
techniques was a major breakthrough in quantitative proteomics, as this strategy allows for
accurate and precise relative quantification of multiple samples simultaneously (multiplex
analysis) [72]. The same principle is used for the TMT (tandem mass tag) [73]. The struc-
ture of the iTRAQ® reagent is shown in (Figure 1.12). The labeling reagent consists of a
reporter group (N-methylpiperazine) for quantification, a balance group (carbonyl), and a
protein reactive group (hydroxyl succinimide ester group) that reacts with the N-terminal
amino groups of peptides and the amino groups of lysine. There are eight variants of the
iTRAQ reagent, each having stable isotopes that are uniquely distributed between the bal-
ance and reporter groups, ensuring the same total mass (cfr. isobaric) of 305 Da for all
reagents. Identical peptides obtained from different samples will be labeled with different
iTRAQ reagents but keep the same mass. When iTRAQ-modified peptides are analyzed by
MS/MS, the reporter ions will be released allowing for the calculation of the ratios of pep-
tide quantities among different samples expressed as signal intensity ratios of the reporter
groups (m/z: 113, 114, 115, 116, 117, 118, 119, and 121).
After denaturation, reduction, alkylation and proteolytic digestion, all peptides in a sam-
ple are labeled with one of the eight iTRAQ reagents. The labeled peptides from different
samples are then combined, separated by 2D-LC and subjected to MS/MS analysis. Iden-
tical peptides derived from different samples have the same mass. These peptides share
similar chromatographic properties, allowing both peptide identification and quantification
to be derived from the same MS/MS spectrum. Upon collision-induced dissociation (CID),
the iTRAQ-labeled peptides release reporter ions. The MS/MS spectra of the individual
peptides show signals reflecting amino acid sequences and also show reporter ions reflect-
ing the protein contents of the samples. A database search is then performed using frag-
mentation data to identify the labeled peptides and hence the corresponding proteins whilst
the iTRAQ mass reporter ion is used to relatively quantify the peptides. Quantification of
protein from multiple samples can be achieved in the same run.
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Figure 1.12: Chemical structure of the 8-plex iTRAQ reagent. The label consists of a reporter
group (N-methylpiperazine), a mass balance group (carbonyl group) and a peptide-reactive group
(N-hydroxy-succinimide (NHS) ester). The reporter group ranges in mass from m/z 113-121 Da
(skip 120); the balance group ranges in mass from 192 to 184 Da (skip 185) to ensure that the
combined mass remains constant (305 Da) for all eight reagents.
The major advantage of isobaric tagging over other stable isotope labeling techniques
is that it allows labeling up to eight different samples within a single experiment [72]. This
significantly increases the analytical throughput of the experiment and makes the iTRAQ
strategy ideal for comparative studies of multiple samples, such as time course studies [74],
assessment of technical and biological variation [75; 76], or simultaneous proteomic pro-
filing of samples representing several physiological states [77]. Unlike other stable isotope
labeling approaches that use MS spectra for quantification, iTRAQ quantifies the relative
peptide abundance from the MS/MS spectrum. This feature of iTRAQ provides several
advantages, such as reduced signal-to-noise ratio of reporter ions due to the removal of
chemical noise in the second stage of MS. Additionally, because of the isobaric nature of
these reagents, the same peptide from each sample appears as a single peak in the MS spec-
trum, thus reducing the complexity of the MS spectrum compared to ICAT. This results in
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increased signal intensity and higher confidence of peptide identification, which is partic-
ularly relevant for non-abundant proteins. All peptides in a sample are labeled and can be
used for identification as well as quantification, compared to ICAT, and in that way multi-
ple peptides per protein are identified and quantified. A disadvantage is the late pooling of
the samples, which may contribute to the experimental variation. This iTRAQ method is
utilized in the following chapters in part II.
Stable isotope labeling by amino acids in cell culture (SILAC)
A very straightforward method of metabolic labeling, proposed in 1999, labels cells by
making use of 15N isotopes [62]. Generally, proteins are labeled by growing cells in media
enriched for 15N. Complete incorporation of 15N to all amino acids within the cells or
organisms is achieved. All peptides obtained from tryptic digestion are then suitable for
quantification. However, the mass difference between the labeled and unlabeled peptide
depends on the number of nitrogen atoms within the amino acid sequence of the particular
peptide, which complicates data analysis enormously. In addition, highly enriched 15N
labeled sources are required to avoid complex isotopic distribution from partially labeled
peptides [72].
A more popular method of metabolic labeling is SILAC, first introduced by the M.
Mann group in 2002 [63]. Here, labeled essential amino acids (typically 13C or/and 15N
labeled lysine or arginine) are added to amino acid deficient cell culture media and are
therefore incorporated into all newly synthesized proteins, resulting in virtually 100% la-
beling efficiency. Subsequently the lysates can be combined, digested and further analyzed
by geLC-MS or 2D-LC MS. The quantification of proteins is then based on the relative
intensities of corresponding differentially labeled peptides.
The use of stable isotopes for quantitative proteomics has several advantages. One of
the most prominent advantages is that the tags are incorporated at the early stage of sam-
ple preparation, allowing to mix samples at a very early stage of analysis. This reduces
variation between samples and yields highly accurate quantification. Secondly, because the
extent of label incorporation into samples is essentially 100%, theoretically there should be
no difference in labeling efficiency between different samples. As proteins are uniformly
labeled, several peptides from the same protein can be compared to ensure that the extent
of change is the same. Lastly, SILAC allows quantification of a high variety of proteins,
including those not containing cysteine residues (which therefore cannot be covered by
ICAT), as well as small proteins. A minor disadvantage of SILAC is that it requires a rather
long time (i.e. five population doublings) to achieve complete incorporation. Moreover,
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although SILAC has recently been extended to include in vivo experiments in multicellu-
lar organisms, e.g. mouse [78] and fruit fly [79], the technique remains limited to tissue
labeling and cannot be applied to body fluids, which are of particular interest for medical
research. Finally, in contrast to for example iTRAQ, only a limited number of samples can
be compared.
Enzymatic 18O -labeling
Isotopic labels can also be incorporated during enzymatic proteolysis [65; 66]. Proteins
extracted from two different cell states are digested with trypsin in a buffer including either
regular H2O or H218O. In that way an 18O atom is introduced into the carboxyl group at the
C-terminus and a second 18O atom can be introduced by a slower oxygen exchange reaction
in the presence of H218O [80; 81]. This results in a mass shift of 4 Da between the labeled
(18O) and non-labeled (16O) peptides.
The main disadvantage of this method is the incorporation efficiency and that the in-
corporated 18O atoms can be exchanged back to a 16O atom in the presence of H216O,
especially at extreme pH values [81]. This process of back-exchange thus contributes to a
(small) fraction of peptides with zero or only one incorporated 18O isotopes in the labeled
sample. This in turn leads to imperfect ratios and complicates quantification. A second dis-
advantage is the introduced mass shift, either 2 Da (one 18O) or 4 Da (two 18O) is difficult to
handle especially with doubly and triply charged peptides because the isotopic envelopes of
the heavy labeled peptides will overlap with those of their unlabeled counterparts, creating
a serious issue when the signals need to be deconvoluted to calculate their intensities.
Absolute quantification (AQUA)
The AQUA method employs synthetic peptides to perform absolute quantification of pep-
tides and proteins [68]. These peptides are synthesized using one or more stable isotope
labeled amino acid as building blocks. These labeled peptides are added at a known concen-
tration to the biological sample after protein digestion. By calculating the relative peptide
abundance between the sample and the heavy labeled synthetic peptide, an absolute peptide
concentration can be derived. However, since absolute concentrations can only be calcu-
lated for the small set of peptides and proteins for which synthetic peptides are created, this
method is only applicable in hypothesis driven, targeted proteomics approaches.
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1.3.2 Label-free quantification
As an alternative, several methods of peptide and protein quantification that do not involve
labeling have been developed [82]. This is generally based on two categories of mea-
surements. The first approach involves spectral counting, where protein quantification is
achieved by comparing the number of identified MS/MS spectra from the same protein in
each of the multiple of LC-MS/MS data sets. This is possible as the increase in protein
abundance results in a higher number of proteolytic peptides, and vice versa. In its turn,
the increased number of proteolytic peptides leads to higher protein sequence coverage, in-
creased numbers of identified unique peptides and identified total MS/MS spectra (spectral
count) for each protein [70; 83; 20]. This approach thus makes direct use of the identi-
fication results from the MS/MS spectra. The second is a measurement of ion intensity
changes such as peptide peak areas, which became possible after it had been observed that
the signal intensity from ESI correlates linearly with ion concentration [84; 71]. Unlike the
chemical labeling techniques where quantification is performed in a single separation, this
technique relies on the comparison of mass spectrometry data, normally the different inten-
sities of peaks between runs. It is therefore entirely reliant on the reasonable reproducibility
of the mass chromatograms. Making high chromatographic resolution and reproducibility
essential, in order to avoid signal interference and signal suppression. This ion counting
technique is in most cases applied to data acquired on higher resolution mass spectrometers
(Q-TOF, FTICR, or orbitrap) [85]. The high-resolution power facilitates the extraction of
peptide signals on the MS level and thus uncouples the quantification from the identification
process.
Label-free mass spectrometry-based quantitative approaches provide powerful, fast and
low-cost tools for analyzing protein changes in complex biological samples, and have been
utilized in a number of large-scale biomarker discovery studies [86].
1.3.3 Conclusions
As explained in the above sections every method (label-free of different label techniques)
has its strengths as well as its weaknesses. Although isotopic labeling strategies are very at-
tractive, the commercially available labels are quite expensive, and the number of replicate
analyses or/and different conditions to be compared are restricted as they are limited by the
number of available labels. Furthermore, the introduction of chemical labels requires addi-
tional manipulations and is thus prone to technical variations [87]. Label-free approaches
provide powerful, fast and low-cost tools for analyzing protein changes in complex biolog-
ical samples, and allow for an unlimited number of samples to be compared. However, in
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order to avoid run-to-run variation, errors in performance of LC and MS need to be carefully
controlled. Another drawback of any label-free approach is the possibility of experimen-
tal variation. As all the samples to be compared are processed separately throughout the
hole experiment there is a greater risk of sample variation and experimental bias. This is
in contrast with labeling, where proteins or peptides are labeled and all subsequent sample
preparation and analysis is performed with the combined samples [88]. The risk for exper-
imental variation changes dependent on the strategy used (Figure 1.13).
Figure 1.13: Experimental workflows in MS-based quantitative proteomics. Depending on the stage
at which isotopes are incorporated, samples are pooled and subsequently analyzed together. After
pooling, all samples undergo the same technical variance. However, the more handling individual
samples undergo, the more variance will be detected during MS-based quantification. In metabolic
labeling strategies, such as SILAC, samples can already be pooled at the cellular level, excluding
all variance during sample handling and improving quantitative accuracy. Different colored boxes
represent different experimental conditions. Horizontal lines indicate when samples are combined.
Dashed lines indicate points at which experimental variation and thus quantification errors can occur.
Today the methods most often used are iTRAQ and SILAC for labeling, together with
the label-free approaches which are gaining more and more interest in proteomics over the
last years. In the following chapters the iTRAQ method is used.
1.4 Proteomics applications in the clinical field
Proteomic analysis in human disease is moving ahead rapidly. The majority of proteomic
studies in the clinical field focus on serum biomarker discovery and especially in cancer
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research. Biomarkers are biological molecules that are indicators of a physiological state.
The utility of a biomarker lies in its ability to provide an early indication of the disease,
to monitor disease progression, to provide ease of detection, and to provide a factor mea-
surable across populations. For such biomarker studies cohorts of dozens of patients are
required in order to minimize the effect of biological variation. In the rare disorders dis-
cussed throughout the following chapters of this thesis, both the number of patients and the
amount of tissue or cell material available is limited. The proteomics studies performed on
those samples are aimed at a more cellular level to explore the disease mechanisms.
iTRAQ as a quantification tool is an excellent choice in the light of analysis of clinical
samples. It has not the difficulty of the specific culture conditions with the stable isotopes
as in SILAC, and it makes comparison up to 8 samples possible, which is important to
compare different patients within the same experiment to minimize the biological varia-
tion. The combination of iTRAQ with a MALDI-TOFTOF mass spectrometer is obvious.
The iTRAQ method was originally developed for use on a MALDI-TOFTOF platform. As
described above, during peptide sequencing by tandem mass spectrometry, these iTRAQ
labels give rise to distinct low-mass peptide fragment ions from which quantification val-
ues are determined. Mass spectrometers such as quadrupoles and TOF instruments have the
inherent capability of detecting low m/z fragment ions whereas e.g. ion trap mass spectrom-
eters, the recovery of those low-mass fragment ions is very poor. Even though with some
adaptations it is now possible to more or less overcome this limitation, a MALDI-TOFTOF
mass spectrometer is still preferable.
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2.1 Fibroblasts as a diagnostic tool
Fibroblasts are the most important cell type of connective tissue and have many vital func-
tions both during development and in adult organisms. Fibroblasts are large, flat, elongated,
spindle-like cells. They have a branched cytoplasm with a lot of extensions, surrounding
an oval nucleus with 1 or 2 nucleoli (Figure 2.1A). Active fibroblasts can be recognized by
the large amount of rough endoplasmic reticulum (RER) and a prominent golgi apparatus.
Inactive fibroblasts (fibrocytes) are smaller and have less RER.
Connective tissue makes up a variety of physical structures including tendons and the
connective framework of fibers in muscles, capsules and ligaments around joints, cartilage,
bone, adipose tissue, blood and lymphatic tissue. It is composed of a relatively limited num-
ber of cells and a large amount of extracellular material (the extracellular matrix (ECM)),
consisting of fibers and a ground substance, the so-called matrix. Fibroblasts are responsi-
ble for synthesis and maintenance of all elements of the ECM: the collagens, reticular and
elastic fibers, as well as the glycosaminoglycans and the glycoproteins of the ground sub-
stance, ensuring the structural integrity of the tissue. Fibroblasts play an important role in
wound healing, and this activity is regulated by cells known as fibrocytes (inactive fibrob-
lasts) residing in the tissue stroma. Following tissue injury, fibroblasts migrate to the site of
damage, where they deposit new collagen and facilitate the healing process.
Figure 2.1: (A) Schematic overview of a fibroblast. (B) Fibroblasts in culture.
Fibroblasts are among the most accessible normal mammalian cell types and the most
amenable to culture in vitro (Figure 2.1B). A skin biopsy is a non-invasive procedure to
obtain patient tissue for analysis. Given that they provide the same or comparable results,
this method and cell type is preferred over e.g. muscle or brain biopsy, for obvious reasons.
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Fibroblasts begin to grow after 1-2 weeks. The cells migrate out of the biopsy onto the
culture dish/flask, forming a monolayer of cells attached to the bottom of the flask. Primary
human fibroblasts derived from skin biopsies provide a cell system that can be cultured over
quite a long period of time without the need to immortalize the cells. Even though, after
a certain number of passages (around 15 but culture dependent) the cells will start to grow
slower and will eventually die. The use of cultured skin fibroblasts for diagnostic purposes
is currently applied e.g. for diagnosis of oxidative phosphorylation defects [1].
Fibroblasts are associated with many diseases, either because they are implicated in
their etiology or due to fibrosis that accompanies damage to other cell types in tissues.
On occasion, patients with rare genetic disorders are presented at the Pediatric Neu-
rology department of the Ghent University Hospital. Due to the low prevalence of these
disorders, research of the underlying causes and mechanisms is limited, resulting in a se-
vere lack of treatment options. In this thesis, we will focus on three of these disorders,
Giant Axonal Neuropathy (GAN), Ullrich Congenital Muscular Dystrophy (UCMD), and
Pseuxantoma elasticum (PXE), which will be discussed below. Each of these disorders has
a clear connection with fibroblasts. In GAN, an aggregation of the intermediate filament
vimentin is found in the fibroblasts. In UCMD and PXE, fibroblasts are responsible for
the production of abnormal collagen and elastin fibers. Thus, skin fibroblast cultures are
particularly well suited for studying each of the three disorders under investigation.
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2.2 Giant axonal neuropathy (GAN)
2.2.1 Clinical signs
Giant axonal neuropathy (GAN, OMIM 256850) is a rare autosomal recessive disorder
characterized by progressive dysfunctioning of peripheral and central nervous system [2].
The disease generally becomes symptomatic in infancy or early childhood, and most chil-
dren are wheelchair dependent in the second decade of life. Degradation of the peripheral
nervous system results in gait disorders, loss of sensation, coordination, and muscle strength
and absent deep tendon reflexes. As the disorder progresses, the central nervous system also
becomes affected. Patients show a gradual decline in mental function and loss of control
of body movements. Additionally, tightly curled frizzled hair, unlike that of the parents, is
seen in almost all affected patients (Figure 2.2).
The diagnosis of GAN is established by the finding of the typical clinical characteristics
and by performing investigations such as measurement of nerve conduction velocity, brain
MRI, and skin/peripheral nerve biopsy. Molecular genetic testing of GAN is also available.
Figure 2.2: Patients with GAN.
2.2.2 Microscopic findings
Morphologically, GAN is characterized by the presence of giant axons filled with densely
packed accumulations of neurofilaments (NF). Affected axons have a thin myelin sheath, do
not transmit signals properly, and eventually perish. Large axons and NF accumulations can
also be seen in several other neurodegenerative disorders [3], but unique to GAN is that, in
addition to the aforementioned NF aggregates in neurons, other cell types are also affected,
e.g. astrocytes can be filled with glial filament bodies, fibroblasts with vimentin clusters and
muscle fibers with desmin accumulations. Abnormal aggregates of keratin in hair are likely
responsible for the characteristic curled hair [4–6]. The vimentin aggregates in fibroblasts
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are located in the perinuclear space close to the microtubule organizing center. Vimentin
proteins are densely packed and occupy a large area in the cytoplasm, pushing away all other
organelles. Since neurofilaments, vimentin, glial filaments, desmin, and keratin constitute
different types of intermediate filaments (IF), one can assume that GAN is associated with
a generalized disorganization of cytoplasmic IF (Figure 2.3).
Figure 2.3: Generalized disorganization of intermediate filaments (IF) in GAN. (A) IF staining of
vimentin (green) organization in normal cultured skin fibroblasts, showing a generalized network.
(B) IF staining of abnormal vimentin (green) organization in GAN cultured skin fibroblasts. (C)
Electron microscopic analysis of a GAN skin fibroblast, showing densely packed material devoid of
cell organelles. (D) Hair from a control (upper) and a GAN patient (lower). (E) Normal axon, with
a normal distribution of neurofilaments throughout the axoplasm. (F) Densely packed aggregation
of neurofilaments in an enlarged axon from a GAN patient and a thin myelin sheath. (Panel E and F
adopted from [7]).
2.2.3 Molecular findings
GAN is caused by mutations in the GAN gene [8] that codes for gigaxonin. Gigaxonin is an
ubiquitous protein which is highly expressed in brain, heart and skeletal muscle. Thus far,
over 35 mutations have been identified in GAN patients, including deletions, insertions, and
both missense and nonsense mutations, each of which leads to a loss of function [8–15].
The mutations are scattered over the whole gene (Figure 2.4) and clear correlations between
specific mutations and particular phenotypic characteristics have not been reported yet.
Gigaxonin contains an N-terminal BTB domain (BR-C, ttk and bab), a centrally lo-
cated conserved BACK domain, and six C-terminal kelch motifs. It was found to be a
substrate-specific adaptor for the BCR (BTB/Kelch protein-cullin-3-RING box protein1)
E3 ubiquitin ligase complex [16]. The major function of the adaptor protein in the BCR
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Figure 2.4: Overview of GAN associated mutations in the protein coding region of the gigaxonin
gene. (A) regions of protein-protein interaction and interacting proteins, (B) allocation of protein
regions to corresponding exons on genomic DNA level, (C) structure of the gigaxonin protein with
BTB- and kelch domains, (D) known GAN associated mutations in the protein coding region. (Fig-
ure adapted from [13]).
complex is to target specific proteins for ubiquitination and degradation by the proteasome.
Gigaxonin binds through its N-terminal BTB domain to ubiquitin activating enzyme E1
(UBA1), while its C-terminal kelch domains interact with specific substrates, such as the
microtubule-associated proteins MAP1B and MAP8, and the tubulin folding cofactor B
(TBCB) [17–19], proteins that are presumed to influence the stability of the microtubule
network [17; 20; 21] (Figure 2.4). In vitro accumulation of MAP1B and MAP8 leads to
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neuronal degeneration and cell death, and accumulation of MAP8 leads to impaired axonal
transport. MAP8 also plays a role in anchoring the microtubule-organizing center to the
centrosome.
In light of these observations, gigaxonin is considered to control the degradation of the
above-mentioned proteins by the proteasome. It has been postulated that loss of function
of gigaxonin results in impaired degradation of these MAPs. This hypothesis was partially
confirmed in vitro in GAN KO mice brain [18–20] but not in human cells [22]. Moreover,
the putative role of gigaxonin in the degradation of microtubule associated proteins does
not explain why aggregates of IF are found in GAN deficient cells (Figure 2.5).
Figure 2.5: Giant axonal neuropathy: current knowledge. (A) Normal gigaxonin (green) targets
MAP1B, MAP8 and TBCB to the proteasome which prevents an accumulation of these proteins.
(B) Mutant gigaxonin leads to increased intracellular amounts of MAP1B, MAP8 and TBCB which
is the cause of aggregation of IFs.
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2.2.4 Treatment
There is presently no cure available for GAN patients and thus treatment of GAN is primar-
ily symptomatic, usually involving a team of (pediatric) neurologists, orthopedic surgeons,
physiotherapists, psychologists, and speech and occupational therapists. The main goals are
to optimize the patient’s intellectual and physical development to improve communication,
to maximize independence in activities of daily living, and to preserve mobility as long as
possible. In some cases, orthopedic surgery may be needed when foot deformities occur, or
ophthalmologic treatment may be required in case of diplopia.
A possible gene therapies is currently under development. The correct GAN gene is
inserted into the central nervous system through the use of a viral carrier in order to replace
the mutated gene. The main challenge is to circumvent the body’s inherent defense mech-
anisms, e.g. the blood-brain barrier, against the entry of viruses. The preparatory research,
including the testing of injection on small and large animals takes place primarily in the
group of Dr. Steven Gray, headed by Prof. Dr. Jude Samulski at the Gene Therapy Centre
at Chapel Hill, USA. The first treatment of GAN patients is planned in 2013-2014. A small
harmless virus, Adeno Associated Virus (AAV9), containing the correct GAN gene, will
thereby be injected in the spinal cord in a first stage, and in a later stage in the brain as well.
These single doses should be sufficient to provide the patient with a functional gene for his
or her lifetime.
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2.3 Ullrich congenital muscular dystrophy (UCMD)
Collagen VI myopathies caused by mutations in the genes encoding collagen type VI
(ColVI) typically cover two disorders, initially described separately but now recognized
as two ends of a clinical spectrum, a severe form which is the Ullrich congenital muscu-
lar dystrophy (UCMD, OMIM 254090) and a milder form which is the Bethlem myopathy
(BM, OMIM 158810) [23–25]. Prevalence is estimated at 0.1:100,000 for UCMD and
0.5:100,000 for BM, but in all likelihood disorders are currently under-diagnosed.
2.3.1 Clinical signs
UCMD is one of the more common forms of congenital muscle dystrophy and was first de-
scribed in 1930 [26]. The hallmarks of the disease are early onset muscle weakness, prox-
imal joint contractures and a striking hyperlaxity of the distal joints [26; 27]. Orthopedic
deformities (joint contractures, scoliosis) and respiratory impairment with diaphragmatic
failure generally develop within the first decade of life, and may be life-threatening. Some
patients never achieve the ability to walk independently, although most are able to walk for
short periods of time and show later progression of muscle weakness with loss of ambula-
tion around age 10 and a requirement for mechanical ventilation in late childhood or young
adulthood [28; 29].
Patients display normal cognitive abilities, normal or only slightly raised serum crea-
tine kinase (CK) levels, and lack of cardiac phenotype. Skin features such as follicular
hyperkeratosis and hypertrophic scars or keloid formation, on the other hand, are common
[23; 25; 28; 29], as is respiratory failure, which requires regular follow up and support. In
the context of the differential diagnosis, the absence of raised CK levels and the lack of a
cardiac phenotype are strongly suggestive of a ColVI myopathy.
2.3.2 Molecular findings
UCMD is a genetic disorder caused by mutations in the COL6 genes. Collagens are major
constituents of the extracellular matrix (ECM) and are found in connective tissues. They
provide structural and mechanical stability to tissues, but also play crucial roles in cell-
ECM interactions through various receptors [30]. ColVI, an important component of skele-
tal muscle ECM, is involved in maintaining tissue integrity by providing a structural link
between different constituents of connective-tissue basement membranes (for example, col-
lagen types I and IV, biglycan, and decorin) and cells [31–39]. In addition to its structural
role, ColVI supports adhesion, spreading and migration of cells, and cell survival. Based
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on the clinical features seen in patients with ColVI defects, it must play an important role
in skeletal muscle, tendons and skin, and a more subtle role in other tissues. In different
tissues, ColVI is expressed and secreted by different types of fibroblasts: in skeletal mus-
cle by interstitial fibroblasts, in skin by skin fibroblasts, and in tendons mainly by resident
tendon fibroblasts [40; 41].
ColVI is a heterotrimeric molecule composed of three genetically distinct peptide chains,
α1(VI), α2(VI) and α3(VI), that display a similar structure, with a central triple heli-
cal domain characterized by repetition of the Gly-Xaa-Yaa amino acid sequence, flanked
by two globular domains [42]. The three chains assemble intracellularly as triple helical
monomers (1:1:1 ratio) that are stabilized by disulfide bonds between cysteine residues of
the three chains, and subsequently form dimers (two anti-parallel, overlapping monomers)
and tetramers (four monomers) (Figure 2.6 [43; 44]).
ColVI chains are subjected to post-translational modifications such as hydroxylation
of lysine and proline residues [45], and glycosylation of hydroxylysines, which have been
shown to be essential for the tetramerization and further secretion of ColVI [46; 47]. Upon
secretion, tetramers are further aligned end-to-end as microfibrils in the extracellular space
with a characteristic beaded appearance [48]. In addition to the three well-characterized
ColVI chains described above, three novel chains α4(VI), α5(VI) and α6(VI) have recently
been identified [49; 50], each of which bears high structural homology to the α3(VI) chain.
The question of whether and how these additional chains may fit in the pathogenesis of
ColVI myopathies remains unresolved to date.
In light of the clinical variability and the overlapping presentation with other muscular
disorders, a definite diagnosis can only be made after identification of pathogenic mutations
in one of the three COL6A genes. De novo dominant mutations account for more than
50% of the mutations in UCMD [25; 27; 51], aside from the initially described autosomal
recessive mutations [52; 53]. The most common types of mutations are point mutations,
and mutations leading to premature termination codons and exon skipping (Figure 2.7)
[24]. Among the former, missense changes affecting glycine residues in the triple helix of
the corresponding proteins are the most common, and are often dominant de novo. The
glycine residues govern the hydrogen bridges that stabilize the intermolecular interactions
and as such hamper triple-helix formation.
Specific mutations tend to be associated with either BM or UCMD phenotype. For
example, recessive mutations leading to premature termination codons have been associ-
ated with severe UCMD phenotypes [28]. Nevertheless, genotype-phenotype correlations
remain very difficult to identify.
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Figure 1 Schematic representation of the collagen type VI (ColVI) intracellular assembly process, and interactions with skeletal muscle
extracellular matrix (ECM) components. Individual a(VI) chains fold through their triple helical domains to form monomers (1:1:1 ratio) in the
endoplasmic reticulum (ER), which further align in an anti-parallel manner as dimers and tetramers that are stabilized by disulfide bonds
between cysteine residues (S = S links). Post-translational modifications (indicated in orange) take place in the ER and Golgi, followed by
secretion of tetramers that align non-covalently end to end, to form beaded microfibrils in the ECM. ColVI interacts with collagenous and non-
collagenous components of the basal lamina and interstitial matrix surrounding muscle fibers.
Allamand et al. Skeletal Muscle 2011, 1:30
http://www.skeletalmusclejournal.com/content/1/1/30
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Figure 2.6: Schematic representation of the collagen type VI (ColVI) intracellular assembly pro-
cess, and int ract ons with extracellular matrix (ECM) c mpon nts. Individua α(VI) chains fold
through their triple helical domains to for monomers (1:1:1 ratio) in the endoplasmic reticulum
(ER), which further align in an anti-parallel manner as dimers and tetramers that are stabilized by
disulfide bonds between cysteine residues (S = S links). Post-translational modifications take place
in the ER and Golgi, followed by secretion of tetramers that align non-covalently end to end, to form
beaded microfibrils in the ECM. ColVI interacts with collagenous and noncollagenous components
of the basal lamina and interstitial matrix surrounding muscle fibers (adopted from [24]).
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isometric tension generated by ColVI-deficient skinned
fibers from gastrocnemius was found to be reduced in a
recent report; however, using a protocol of eccentric
contractions in vivo, no muscle force drop was found,
indicating that the lack of ColVI does not impair myofi-
brillar function [99]. Importantly, mitochondrial dys-
function was also reported in cultured muscle cells from
patients and could be reversed by cyclosporin (Cs)A, an
immunosuppressive drug that prevents the opening of
the mitochondrial permeability transition pore through
binding to cyclophilin D, and also inhibits the phospha-
tase calcineurin [100,101]. Another in vitro study
showed that patients-derived skin fibroblasts behave dif-
ferently from myoblasts in that respect, and also ques-
tioned the specificity of this mitochondrial dysfunction
[102], warranting further studies on the matter.
A role for cell survival had previously been proposed
for ColVI because it was shown to prevent anti-a1
integrin-mediated apoptosis and trigger the downregula-
tion of bax, a pro-apoptotic molecule [103,104].
Recently, a study of the autophagic process in muscles
of Col6a1 knockout mice revealed that autophagy was
not induced efficiently [105]. The ensuing defective
autophagy provides the link between the previously
Figure 4 Repartition of the various types of mutations identified in the COL6A1, COL6A2 and COL6A3 genes. This schematic reflects, to
the best of our ability, the distribution of 258 allelic mutations (98 on COL6A1, 113 on COL6A2 and 47 on COL6A3). Dominant de novo mutations
represent 67% of the missense mutations, affecting glycine residues in the TH domains (Gly in TH), 57% of small deletions (< 5 amino acids) and
44% of splice-site mutations leading to in-frame exon skipping, whereas 97% of mutations leading to premature termination codons (PTCs) are
familial (recessive or dominant).
Allamand et al. Skeletal Muscle 2011, 1:30
http://www.skeletalmusclejournal.com/content/1/1/30
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Figure 2.7: Schematic overview of the various types of mutati ns i ntified in the COL6A1-3
genes, reflecting the distribution of the 258 mutations (98 on COL6A1, 113 on COL6A2 and 47
on COL6A3). Dominant de novo mutations represent 67% of the missense mutations, affecting
glycine residues in the TH domains (Gly in TH), 57% of small deletions (< 5 amino acids) and
44% of spli e-site mutations leading t in-frame ex skip ing, whereas 97% of muta ions leading
to premature termination codons (PTCs) are familial (recessive or dominant) (adopted from [24]).
2.3.3 Microsco ic findi gs
The results of immunohistochemical ColVI staining in a skeletal muscle biopsy specimen
may vary between different UCMD patients. When performed together with immunostain-
ing of a basement membrane marker (collagen IV), it enables detection of ColVI deficiency
in UCMD by showing either slight or marked reduction, total absence of the protein or
disturbed interaction with the basement membrane (Figure 2.8) [54].
Cultured skin fibroblasts can also be used for the diagnosis. Immunocytochemical de-
tection of the absence or alteration of ColVI secretion and intracellular presence of ColVI
(Figure 2.9), in combination with a typical clinical phenotype and followed by a proper
genetic analysis is a less invasive diagnostic method currently used in most cases. This
analysis, however, is available only in a limited number of laboratories [55].
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Figure 2.8: Immunohistochemistry of muscle sections (adopted from [54]). (A) Both collagen
VI (green) and collagen IV (red) are present in the sarcolemma of control muscle, as indicated in
merged images (yellow). (B) Collagen VI is only seen in the interstitium but not in the sarcolemma
in UCMD patients with normal or reduced secretion. (C) Complete deficiency of collagen VI in
UCMD patients (F).
Figure 2.9: Collagen type VI (ColVI) expression in cultured skin fibroblasts (by the protocol of
[55]). (A) UCMD fibroblasts clearly showing the intracellular retention of ColVI and the lack of
secretion or incorporation in the ECM. (B) Control displaying a normal extracellular network.
2.3.4 Pathophysiological mechanisms
Limited access to muscle tissue hinders extensive investigations of the specific cellular
mechanisms which lead to diseased muscle cells and ultimately muscle cell death.
Recent experiments demonstrated a latent mitochondrial defect in cultured myoblasts
from UCMD patients and in skeletal muscle from a ColVI-deficient mouse model. This de-
fect occurs at the mitochondrial permeability transition pore (PTP), a conductance pore that
spans the inner and outer mitochondrial membranes. Inappropriate opening of PTP plays
a role in several forms of cell death and may explain the altered mitochondrial membrane
potential (∆ψ) and increased apoptosis observed in UCMD patient and mouse cultured
muscle cells [56]. Recent work showed that patient-derived skin fibroblasts behave dif-
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ferently from myoblasts in that respect, and questions the specificity of this mitochondrial
dysfunction [57].
Another phenomenon that possibly contributes to the accumulation of defective mito-
chondria in muscle cells is the impairment of the autophagocytic flux in muscle cells as can
be seen in ColVI-deficient mice [58]. In addition, EM analysis shows ultrastructural defects
of mitochondria and sarcoplasmic reticulum in col6a1-/- mice muscles. Mitochondria dis-
play abnormal cristae that have a tubular shape and altered matrix density. Also dilatations
of sarcoplasmic reticulum and an increase of apoptotic fibers is seen [59].
2.3.5 Treatment
As is the case for GAN, a curative treatment does not exist for ColVI disorders. Most
patients rely on supportive treatment of complications, such as spinal deformations and
contractures, and respiratory insufficiency [60]. Usually extensive orthopedic care is needed
to promote mobility and independence.
The discovery of a mitochondrial dysfunction in ColVI deficient patients led to a poten-
tial treatment with cyclosporin A (CsA), an immunosuppressive drug that also inhibits the
phosphatase calcineurin [61; 62]. CsA is a desensitizer of PTP and prevents the inappro-
priate opening of the PTP by binding to cyclophilin D, leading to a decrease of apoptosis
in muscle cells. Pilot trials with CsA treatment showed normalization of the mitochondrial
function and a decrease of apoptosis of muscle cells following short-term treatment [63–
65]. Longer treatment had some beneficial effect on muscle function but did not prevent
progression of the disease [23]. Debio-025, a CsA analog that does not interfere with cal-
cineurin, was also shown to restore mitochondrial function in cultured muscle cells from
patients [61] and col6a1-/- mice [66].
Another anti-apoptotic agent investigated in the context of ColVI myopathies is Omi-
gapil, which has already been shown to reduce apoptosis in laminin α-2 chain deficiency
[67]. However, due to concerns about the possible harmful effect of anti-apoptotic treat-
ments (e.g. immunosuppression), none of these potential drugs has been approved yet for
use in children. Moreover, neither of these approaches address the primary defect in these
disorders, i.e. lack of ColVI in the connective tissue.
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2.4 Pseudoxantoma elasticum (PXE)
Pseuxantoma elasticum (PXE, OMIM 264800) was originally described as a connective
tissue disorder, more specifically an elastinopathy, However, research findings of the last
years changed the perspective to a metabolic disorder with secondary connective tissue
implications [68]. The reported prevalence of PXE is about 1:50000.
2.4.1 Clinical signs
PXE is characterized by a remarkable phenotypic variability [69–71]. While the organs
affected (skin, eye and cardiovascular system) are the same in all patients, the age of onset,
severity of organ involvement and natural course display much larger variation.
Usually, the skin is the first organ to be affected. Small, yellowish papular lesions
form and cutaneous laxity occurs, mainly around the flexural areas of the body such as
neck, armpits, groin and inside parts of elbows and knees. The skin may become lax and
redundant (Figure 2.10). Cutaneous lesions typically are first seen in childhood or early
adolescence. An accurate diagnosis is in many patients not made until after several years
when serious ocular or vascular complications develop.
Figure 2.10: Skin features in PXE including papular lesions in neck region and elbow (A), plaques
of papules (B), cutaneous ‘peau d’orange’ (C), increased skin laxity (D), and a crack in the Bruch
membrane with penetration of blood vessels (E).
PXE affects the retina through a dimpling of the Bruch membrane in almost all patients,
usually occuring a few years after the appearance of the cutaneous lesions. The fragmen-
tation of the elastic fibers in the Bruch membrane creates cracks (‘angioid streaks’) that
radiate out from the optic nerve, allowing small blood vessels that were originally held
back by Bruch’s membrane to penetrate the retina. These blood vessels may leak, and it are
these retinal hemorrhages that ultimately lead to loss of central vision.
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In the circulatory system, coronary artery disease may develop, which may lead to
angina and heart attacks. Another serious vascular complication is gastrointestinal bleed-
ing, usually from the stomach, although this occurs in a small number of patients only.
Adding to the clinical diagnostic difficulties is the observation that manifestations sim-
ilar to those in PXE can be found in a number of unrelated clinical conditions [71]. Partic-
ularly intriguing observations, with potential pathomechanistic implications for PXE, have
been recently made in families with PXE-like cutaneous findings, in association with vita-
min K-dependent multiple coagulation factor deficiency.
2.4.2 Microscopic findings
The primary histological alteration in PXE is degeneration of elastic fibers that undergo pro-
gressive mineralization (accumulation of calcium and other minerals) and fragmentation,
resulting in a histological image called ‘elastorrhexis’ (Figure 6) [72]. These alterations
can be observed by light and electron microscopy in the main organs affected by PXE
(skin, retina, blood vessels), and to a lesser extent in other tissues which contain elastin.
Figure 2.11: Histological alterations in PXE. (A) Normal thin elastic fibres (insert) and a lightmi-
croscopical Von Kossa stain revealing elastorrhexis (x400). (B) An electron microscopical image
of calcifications (arrowed) throughout the core of an elastic fibre (Bar = 1µm). (C) Illustrates the
presence of collagen flowers (arrowed) (Bar = 1µm). (Adopted from [73]).
Several studies also describe abnormalities in other ECM components, such as colla-
gens and proteoglycans. Collagen ‘flowers’, a sign of abnormal collagen fibrillogenesis,
are although commonly found in PXE also highly aspecific. Abnormal amounts of pro-
teoglycans are localized nearby and within mineralized elastic fibers as well as abnormal
amounts of glycosaminoglycans and also alterations in their synthesis and deposition have
been detected in PXE patients.
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2.4.3 Molecular findings
Causal mutations in the ABCC6 gene were identified in 2000. Eighty percent of the pa-
tients with PXE have detectable mutations in the ABCC6 gene [74–77]. So far, more than
150 mutations in almost all parts of the gene have been described, the majority of which
are missense mutations. Although there have been reports of autosomal dominant inheri-
tance, the inheritance is typically autosomal recessive [69]. The ABCC6 gene codes for the
ABCC6 protein, an ATP-dependent membrane transporter from the large ATP-binding cas-
sette (ABC) transporter family (Figure 2.12). This family involves 48 different transporters
divided into 7 subclasses. These proteins play a role in transport of amino acids, lipids,
anorganic ions, peptides, saccharides, metals, drugs and proteins, and are involved in sig-
nal transduction, drug resistance, protein secretion and antigen production. Several family
members have been shown to be correlated to genetic disorders, e.g. ABCC7, a chloride
ion channel involved in cystic fibrosis.
Figure 2.12: Schematic representation of the ABCC6/MRP6 protein and the positions of missense
mutations identified in patients with PXE. (Image adopted from [78]).
The transporter has no apparent relation with ECM proteins or homeostasis and the ex-
act mechanism by which this protein influences the disease course is still unknown. ABCC6
is expressed in most organs, mainly in liver and kidneys. It is unclear in which way protein
malfunction would lead to abnormalities in skin, eyes and blood vessels.
To date, no correlation has been established between the phenotype and the nature or po-
sition of the mutations and given the variations in severity and age of onset it is likely that
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other, so far unknown, risk factors (e.g. genetic or dietary) may be involved.
2.4.4 Pathophysiological mechanisms
Although the pathophysiological mechanisms of PXE remains largely unknown, two major
hypotheses, the ‘cell hypothesis’ and the ‘metabolic hypothesis’ have been proposed to
explain the processes leading to ectopic elastic fiber mineralization [73].
The ‘PXE cell hypothesis’ postulates that lack of expression of ABCC6 in fibroblasts or
smooth muscle cells may result in local mineralization as a result of cellular perturbation.
The hypothesis is based on experiments in fibroblast cultures established from skin lesions
of PXE patients which display abnormalities in cell-cell and cell-matrix adhesion proper-
ties, and in proliferative capacity of cells harboring the mutations [79; 80]. Specifically, af-
fected cultured skin fibroblasts display enhanced synthesis of connective tissue compounds,
such as elastin, collagen and glycosaminoglycans / proteoglycans [81], and show enhanced
degradative potential because of increased matrix metalloproteinase-2 activity and expres-
sion [79; 82]. The mechanisms by which such apparently permanent changes are elicited
in fibroblasts are currently unknown, and how such cell biological perturbations might con-
tribute to the clinical findings in PXE remain to be studied further. Nevertheless, cells in
peripheral organs may serve as target of metabolic alterations that facilitate mineralization
of adjacent connective tissues. In this context, it is important to note that ectopic miner-
alization is a complex process and that a number of modifiers involving soluble factors,
cellular elements, and the state and composition of the extracellular matrix can influence
the degree of mineralization.
ABCC6 is active in normal human dermal fibroblasts and deficiency may cause im-
paired transmembrane transport of physiologically important substrates and/or metabolites
[81]. In fibroblasts, ABCC6 shows a different sensitivity to inhibitors/competitors of the
multidrug resistent protein (MRP) systems and indicates that ABCC6 behaves differently.
This may suggest that ABCC6 has peculiar functions in fibroblasts, and its deficiency could
not be compensated by other transporters [81].
Another factor potentially modifying the phenotype of PXE may relate to tissue damage
by free radical oxygen. The cells have been shown to suffer from mild chronic oxidative
stress [82]. Whether the observed oxidative stress is an important primary pathogenetic
mechanism or merely a secondary end-stage result of ECM degradation in PXE remains to
be elucidated.
The ‘metabolic hypothesis’ is based on the clinical observation that PXE is a slowly
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progressing disorder caused by a defect in a transporter predominantly expressed in liver
and kidney, and at very low levels (if at all) in tissues clinically affected in PXE. It has
been postulated that, in the absence of functional ABCC6, the levels of certain metabolic
compounds in the circulation that are physiologically present to prevent aberrant mineral-
ization, are now altered [68; 83] (Figure 2.13). The disturbed levels of these compounds
may affect the connective tissue directly, may have an indirect effect through pathways in-
volved in ECM homeostasis, or they may alter the biosynthetic capacity of resident cells,
thus leading to pathologic mineralization and degradation. This hypothesis is supported by
studies in Abcc6 knockout mouse models [68].
Le Saux et al. addressed this hypothesis by incubating cultured fibroblasts from skin
of patients and age-matched unaffected individuals into medium supplemented with nor-
mal human serum or serum from patients with PXE [84]. Results indicated that in the
presence of normal human serum, PXE fibroblasts displayed increased synthesis of elastic
fibers in comparison with normal fibroblasts, but the fibers were structurally normal. When
maintained in the presence of serum from PXE patients, however, both PXE and normal
fibroblasts deposited abnormal aggregates of elastic fibers. Thus, it can be concluded that
certain metabolites in the PXE serum interfere with normal elastic fiber assembly in vitro
[84]. No data are available on the effects of sera on the mineralization process.
The nature of molecules potentially transported by ABCC6 from the liver into the blood
circulation is currently unknown. Studies however, have identified a number of proteins that
can act as powerful anti-mineralization factors in the circulation. These include fetuin-A
and matrix-gla protein [85]. The presence of many of these proteins has been demonstrated
in association with mineral deposits in the mouse knockout model of PXE [86].
An interesting observation with potential pathomechanistic implications is offered by
patients with mutations in the GGCX gene, with the development of skin findings reminis-
cent of PXE [87; 88]. The GGCX gene encodes a vitamin K-dependent enzyme, γ-glutamyl
carboxylase, which catalyzes γ-carboxylation of glutamyl residues in a number of proteins
(Gla proteins), including several coagulation factors and a number of extracellular matrix
proteins such as coagulation factors II, VII, IX and X, protein S, protein C, matrix gla pro-
tein and osteocalcin. The carboxylation reaction is required for activation of these proteins.
Based on the similarity of cutaneous findings in PXE and patients with GGCX mutations,
it has been suggested that the ABCC6 deficiency in PXE patients may result in reduced
concentrations of vitamin K or its derivatives in serum causing reduced activation of an-
timineralization proteins, such as MGP [89]
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Figure 2.13: Schematic illustration of the proposed ‘metabolic hypothesis’ of PXE. Under physi-
ologic conditions, the ABCC6 protein is expressed at high levels on the baso-lateral surface of the
liver where it facilitates the transport of currently uncharacterized molecule(s) from hepatocytes to
the circulation. These molecules are postulated to serve physiologically as potent anti-mineralization
factors which under normal Ca/P homeostasis prevent precipitation of metastable calcium/phosphate
complexes in the peripheral tissues. In the absence of ABCC6 transporter activity in the liver in PXE,
the concentration of the anti-mineralization factors in circulation and consequently in peripheral tis-
sues is reduced, allowing mineralization of connective tissues in a number of organs (middle panel).
The presence of mineral deposits in the eye, blood vessels, kidney, and skin (left panels) is demon-
strated by histopathological staining (Alizarin Red) of tissues from Abcc6-/- mice which recapitulate
features of PXE in humans (adopted from [83]).
2.4.5 Treatment
At present, there is no cure for PXE. A major obstacle is the lack of knowledge of the precise
pathophysiological mechanisms which lead to mineralization of peripheral tissues. Current
treatment focuses on prevention of complications and if necessary early intervention. For
excessive areas of skin, plastic surgery may be needed, and approaches have been adopted
from the treatment of other diseases, such as those affecting the eyes. For example, the
use of intra-ocular injection of antiangiogenic agents targeting vascular endothelial growth
factor has demonstrated significant improvement in visual acuity in patients with PXE [90],
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replacing the previous used laser photocoagulation and photodynamic therapy to treat the
growth of abnormal blood vessels in the retina. Cardiovascular disease is treated as in
individuals without PXE, although some studies recommend avoidance of nonsteroidal anti-
inflammatory drugs (NSAIDS) that increase bleeding risk, such as aspirin and ibuprofen.
Clinical manifestations in PXE are primarily, if not exclusively, related to ectopic miner-
alization of peripheral tissues. Thus, anti-mineralization approaches might provide a treat-
ment for PXE.
In this context, recent studies have been exploring the role of the mineral content of the
diet in modifying the severity of the disease in PXE. Studies have shown that the magne-
sium, but not calcium, content of the diet can influence the extent of ectopic mineralization
in peripheral tissues in Abcc6 -/- mice. This might be helpfull for treatment of patients with
PXE [91; 92].
The suggestion that PXE may result in reduced concentrations of vitamin K or its deriva-
tives in serum causing reduced activation of anti-meneralization proteins, has led to studies
with vitamin K injections in a mouse model. The results showed no effect on tissue miner-
alization and suggested that supplementation of the diet may not be effective.
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Project goals
Identification of the gene and its mutations responsible for a disease is not sufficient to
elucidate the disease mechanism. Knowledge about these mechanisms is very important
and can lead to the finding of better treatment of this diseases. It is clear that there is a
rising interest for the use of molecular techniques in order to help understand how the dis-
eases progress at the molecular level. Techniques such as proteomics, transcriptomics and
metabolomics are quickly gaining interest in clinical research. These high-throughput tech-
niques are readily applicable, as genetic information and annotation has become available
for many organisms, including human. The study of the cellular proteome, i.e. the entire
set of proteins expressed under specific physiological or pathological conditions, can reveal
interaction networks and regulatory dynamics that may escape investigations of individual
proteins. This allows for the identification of novel proteins or pathways, and thereby the
mechanisms involved in the pathogenesis of genetic diseases.
This PhD work was carried out in the context of a collaboration between the Division
of Pediatric neurology, in the Department of Pediatrics (Prof. Dr. Van Coster, University
Hospital, UGent) and the L-ProBE laboratory (Prof. Dr. Devreese, Faculty of Science,
UGent).
The aim of this study was to use cultured, non-transformed primary skin fibroblasts
derived from human skin biopsies as a model system for LC-MS based proteome analysis
in three different genetic disorders. While proteomic analysis is already widely applied in
cancer research, it has rarely been used for research in connective tissue and neurological
disorders.
Using the mass spectrometry based techniques described in chapter 1, we will try to
get a better understanding in the above described disorders.
In GAN, it is not clear how a defect in gigaxonin can lead to intracellular aggregations
in several cell types. In previous studies, MAP1B, MAP8 and TBCB were shown to bind
to gigaxonin which is a adaptor protein for ubiquitination of these proteins. The hypothe-
sis in earlier studies was that a defect in gigaxonin caused accumulation of these proteins
and subsequently aggregation of intermediate filaments. One of the weak points in this hy-
pothesis was that these proteins are associated with microtubules and not with intermediate
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filaments. In mice studies an increase of these proteins was found, but this has not been
confirmed in other studies. The first question we raised was whether these proteins were
increased in GAN fibroblasts when compared to controls. If not, are there other proteins
in GAN fibroblasts that might be increased or decreased. In chapter 3, a proteomics setup
is developed in order to try to answer these questions by a quantitative comparison of the
proteome in GAN patient fibroblasts and control fibroblasts. A second question is how the
gigaxonin deficient fibroblasts do react after transfection of the correct GAN gene. Will this
transfection be able to reduce the intracellular filament aggregations? And what about the
expression levels of proteins that were shown to be dysregulated by our first experiment?
Is there a trend towards normal levels? Will other pathways be ‘activated’ due to the trans-
fection? This is investigated in chapter 4. Fibroblast cultures from GAN patients will be
transfected with the correct GAN gene, or with GFP as a control. Following the transfec-
tion, protein expression profiles are analysed and compared for each patient (GAN/GFP).
In addition, the transfection will be tested in mice.
In UCMD, the mechanism by which aberrant synthesis and secretion of collagen VI by
fibroblasts leads to muscular dystrophy is poorly understood. In chapter 5, we will compare
patients fibroblast proteome to that of control fibroblasts in order to identify dysregulated
proteins and pathways that could help to get more insight into the disease mechanism.
For PXE there is no clear correlation between the mutated ABC transporter and the
fragmentation of elastin fibers into skin, eye, and cardiovascular system. A comparison of
the patients fibroblast proteome to that in controls will be performed in order to get more
insight in how this defect that lead to skin abnormalities. This is described in chapter 6 of
this thesis.
Part II
RESULTS
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When a thing was new, people said, ‘It is not true’.
Later, when the truth became obvious, people said,
‘Anyway, it is not important.’ And when its importance
could not be denied, people said, ‘Anyway, it is not new’.
William James (1842-1920)
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3.1 Abstract
Introduction: Giant axonal neuropathy (GAN) is a progressive hereditary disease that af-
fects the peripheral and central nervous systems. It is characterized morphologically by
aggregates of intermediate filaments in different tissues. Mutations have been reported in
the gene that codes for gigaxonin. Nevertheless, the underlying molecular mechanism re-
mains obscure.
Methods: Cell lines from four GAN patients and four controls were analyzed by iTRAQ.
Results: Among the dysregulated proteins were ribosomal protein L29, ribosomal protein
L37, galectin-1, glia-derived nexin and aminopeptidase N. Also, nuclear proteins linked to
formin-binding proteins were found to be dysregulated. Although the major role of gigax-
onin was reported to be in degradation of cytoskeleton-associated proteins, the amount of
76 structural cytoskeletal proteins was unaltered.
Discussion: Several of the dysregulated proteins play a role in cytoskeletal reorganization.
Based on these findings, we speculate that disturbed cytoskeletal regulation is responsible
for formation of aggregates of intermediate filaments.
3.2 Introduction
Giant axonal neuropathy (GAN) is a rare autosomal recessive disorder that affects the pe-
ripheral and central nervous systems [1]. The disease generally becomes symptomatic in in-
fancy or early childhood, and most children are wheelchair dependent in the second decade
of life. Degradation of the peripheral nervous system results in gait disorders, loss of sen-
sation, incoordination, loss of muscle strength and absent deep tendon reflexes. The central
nervous system becomes involved as the disorder progresses. Patients show a gradual de-
cline in mental function and loss of control of body movements. Tightly curled frizzled
hair, unlike that of the parents, is seen in almost all affected patients. Morphologically,
GAN is characterized by the presence of giant axons filled with densely packed accumu-
lations of neurofilaments (NF). Affected axons have a thin myelin sheath, do not transmit
signals properly, and eventually perish. Large axons and NF accumulations can also be seen
in several other neurodegenerative disorders [2], but unique to GAN is that, besides accu-
mulations of NF aggregates in neurons, astrocytes can be filled with glial filament bodies,
fibroblasts with vimentin clusters and muscle fibers with desmin accumulations. Abnormal
aggregates of keratin in hair are likely responsible for the typical curled hair [3–5]. The
vimentin aggregates in fibroblasts are located in the perinuclear space close to the micro-
tubule organizing center. Vimentin proteins are densely packed and occupy a large area
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in the cytoplasm, pushing away all other organelles. Since neurofilaments, vimentin, glial
filaments, desmin and keratin constitute different types of intermediate filaments (IF), one
can assume that GAN is associated with a generalized disorganization of cytoplasmic IF.
GAN is caused by mutations in the GAN gene [6] that encodes the protein gigaxonin.
This is a ubiquitous protein which is strongly expressed in brain, heart and skeletal mus-
cle. More than 40 mutations have been identified in GAN patients, including deletions,
insertions, missense and nonsense mutations, which lead to loss of function of gigaxonin
[6–13].
Although the discovery of the GAN gene in 2000 represented an important step forward
in the elucidation of the pathogenesis of GAN, the underlying mechanism still remains
poorly understood. Gigaxonin contains an N-terminal BTB domain (BR-C, ttk and bab),
a centrally located conserved BACK domain, and six kelch motifs in the C-terminal part.
It was found to be a substrate-specific adaptor for the BCR (BTB/Kelch protein-cullin-3-
RING box protein1) E3 ubiquitin ligase complex [14]. The BTB-containing protein in the
BCR complex functions as an adaptor protein between cullin-3 and other substrate pro-
teins. The major function of the adaptor protein in the BCR complex is to target specific
proteins for ubiquitination and degradation by the proteasome. Gigaxonin binds through its
N-terminal BTB domain to ubiquitin activating enzyme E1 (UBA1), while its C-terminal
kelch domains interact with specific substrates. Using yeast two hybrid screens, pulldown
assays and/or co-localization experiments, the kelch domains in gigaxonin were shown to
bind the microtubule-associated proteins MAP1B and MAP8, and to tubulin folding cofac-
tor B (TBCB) [15–17]. Gigaxonin is thus considered to control the degradation of these
proteins by the proteasome. It has been postulated that loss of function of gigaxonin re-
sults in impaired degradation of these MAPs. This hypothesis was partly confirmed in
GAN KO mice [16–18] but not in human cells [19]. Moreover, the fact that gigaxonin
plays a role in degradation of microtubule associated proteins does not explain why aggre-
gates of intermediate filaments are found in GAN deficient cells. Gigaxonin is a member
of a BTB/kelch repeat super family (Kelch-like genes, KLHL). In addition to gigaxonin
(also named KLHL16) several other KLHL proteins can form a BCR complex. The BCR-
containing KLHL9 or KLHL13, for example, target auroraB for degradation by the pro-
teasome. AuroraB is one of the kinases responsible for phosphorylation of vimentin. The
polymerization of vimentin is regulated by phosphorylation/dephosphorylation at several
sites by different kinases and phosphorylases.
In this study cultured skin fibroblasts were used as a cell model for GAN in order
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to obtain additional insight into the cellular impact of the gigaxonin defect. The pro-
teome of these cells was analyzed, measuring the relative abundance of proteins. A dif-
ferential proteomics method was used based on the iTRAQ strategy in combination with
two-dimensional liquid chromatography mass spectrometry (2D-LC-MS) on a MALDI
TOFTOF MS platform.
3.3 Methods
3.3.1 Patients and fibroblast cultures
GAN patients from four unrelated families were included in this study (Table 3.1). Skin
biopsies were received from Belgium, Serbia, Italy and the USA. All families gave informed
consent. The patients were diagnosed based on clinical neurological characteristics. All
patients had the typical frizzy hair, the presence of giant axons, aggregation of IF in skin
and nerve biopsy samples, distal limb weakness, areflexia (patient 4 unknown) and initial
symptoms were walking problems. In all patients, pathogenic mutations were detected. The
clinical data of patients 1 and 2 have been reported previously [20; 11]. In addition, four
age and gender matched control fibroblast cell cultures from skin biopsies were used.
Table 3.1: Clinical data of the patients.
Patient No. 1 2 3 4
Gender M M F F
Age at onset 2y 2y 2.5y 3y
Mutations in the
gigaxonin gene
57-131 kb
microdeletion
encompass-
ing at least
exons 3-11 /
p.Glu486Lys
(c.1456G>A;
exon 9)
p.Tyr89Cys
(c.266A>G;
exon 2) /
p.Gly368Arg
(c.1102G>A;
exon 7)
Homozygous
deletion:
c.1647-
8680∗258del
p.Ser52Gly
(c.154A>G;
exon 1) /
p.Cys393X
(c.1179T>A;
exon 7)
Scoliosis No Yes No Yes
Fibroblasts from skin biopsies were cultured in Medium 199 with Earle salts and L-
glutamine (PAA Laboratories, Linz, Austria) supplemented with fetal bovine serum (10%),
kanamycine (1%) and penicillin-streptomycin (1%, Gibco, Carlsbad, California) and were
maintained at 37◦C, 5% CO2. All fibroblast samples were grown until 90% confluence
before harvesting the cells. Cells were washed with 3.5 mM tris, 140 mM NaCl, 0.02%
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EDTA, centrifuged at 1200 rpm for 20 min at 4◦C, and dry pellets were stored (-80◦C) until
use.
3.3.2 iTRAQ reagent labeling and peptide separation
Proteins were extracted by re-suspending each cell pellet in 300 µl lysis buffer, contain-
ing 0.5 M triethyl ammonium bicarbonate (TEAB) and protease inhibitor cocktail (Roche,
Vilvoorde, Belgium). The cell lysates were sonicated, and the supernatant was collected
after centrifugation at 13000 g for 20 min at 4◦C. A summary of the experimental work-
flow is shown in Figure 3.1. Protein concentrations were measured by the BCA protein
assay (Thermo Scientific, San Jose, California). Equal amounts of protein (50 µg) from
each cell lysate were used. iTRAQ labeling was performed according to the manufacturer’s
protocol using solvents included in the kit (AB SCIEX, Foster City, California). Proteins
were denatured with 1 µl of 2% sodium dodecyl sulfate (SDS), reduced with 2 µl 50 mM
tris(2-carboxyethyl)phosphine and incubated at 60◦C for 1h. Cysteines were blocked with 1
µl 200 mM S-methyl methanethiosulfonate (MMTS) followed by incubation at room tem-
perature for 10 min. Digestion of the protein samples with trypsin (Promega, Madison,
Wisconsin) was performed overnight at 37◦C at a ratio of 1:50. Peptide samples were vac-
uum dried in a speedvac (Thermo Savant, Holbrook, New York) and re-suspended in 40
µl of isopropanol (80%) and 10 µl of 1 M TEAB pH 8.5. This 50 µl of the eight peptide
samples was added to the eight labels of the 8-plex iTRAQ kit (AB SCIEX) as follows: con-
trol samples were labeled with iTRAQ tags 113-116, and GAN samples were labeled with
iTRAQ tags 117-119 and 121. The labels were added in excess to acquire full labeling.
Labeling was confirmed for all samples before combining the samples. After combining
the eight iTRAQ-labeled samples, the mixture was vacuum dried and dissolved in 20 mM
HCOONH4, 2% ACN at pH 10.
The labeled peptide mixture was separated on an Ettan liquid chromatography system
(GE Healthcare, Diegem, Belgium), using a Luna C18 column (2.0 mm i.d. x 150 mm
length x 5 µm, 100 A˚ column) (Phenomenex, Torrance, California). The buffer composi-
tions were 20 mM HCOONH4, 2% acetonitrile (ACN) at pH 10 for buffer A and 20 mM
HCOONH4, 80% ACN at pH 10 for buffer B. The flow rate was 0.2 ml/min, and the elution
gradient was as follows: 7 min 100% A, 60 min 0-50% B, 15 min 50-100% B, 10 min 100%
B, and 3 min 100% A. Fractions were collected every minute. After drying, the fractions
were re-dissolved in 0.1% formic acid for nano-LC/mass spectrometric analysis.
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Figure 3.1: iTRAQ experimental workflow for comparing the proteome of GAN fibroblasts and
control fibroblasts.
3.3.3 Nano-liquid chromatography and mass spectrometry analysis
Analytical reversed phase separation of the labeled peptide mixture was performed on an
Ultimate Plus Dual-gradient Capillary/Nano-LC system (Dionex-LC Packings, Hercules,
California) using a C18 column (75 µm i.d. x 150 mm length, 3 µm, 100 A˚)( Dionex) at a
flow rate of 250 nl/min. The mobile phases were 5% ACN/0.05% trifluoroacetic acid (TFA),
pH 3 for buffer A and 80% ACN/0.05% TFA, pH 3 for buffer B. Peptides were resolved
by gradient elution using a gradient of 0-50% buffer B over 25 min, 50-100% buffer B
over 10 min, 5 min of 100% buffer B and 10 min of 100% buffer A. Column effluent was
monitored using a 3 nl UV flow cell (240 nm). The nano-LC system was connected to a
Probot fraction collector (Dionex). Column effluent was mixed in a 1:4 ratio with MALDI
matrix (4 mg/ml α-cyano-4-hydroxycinnamic acid, 70% ACN, 10 mM dibasic ammonium
citrate, 1% TFA, 10 fm/µl Glu-fibrinopeptide) by a T-junction. Fractions were collected
every 30 seconds directly on a MALDI target plate. The MALDI plates were analyzed
by a 4800+ MALDI-TOFTOF Proteomics Analyzer (AB SCIEX). This mass spectrometer
uses a 200-Hz frequency tripled Nd:YAG laser operating at a wavelength of 355 nm. A
plate calibration was performed using the 4700 calibration mixture with a mass tolerance
of 0.5 m/z. The MSMS mode was calibrated with a mass tolerance of 0.1 m/z. Additionally,
MS spectra were internally calibrated with Glu-fibrinopeptide (1552.62 m/z). MS data were
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acquired in the reflector positive mode over a mass range of 900-3500 m/z, by accumulation
of 1000 laser shots per spectrum. The eight highest precursor masses in each MS spectrum
with an S/N threshold of minimum 50, were selected for fragmentation, and the fraction-
to-fraction mass tolerance was set to 200 ppm. MS/MS data were acquired with 2000 laser
shots per spectrum, using 1keV collision energy and air as the collision gas. The timed-
ion-selector window was set to 400 resolution (fwhm). Each plate was analyzed twice by
reinterpretation of the MS spectra with a method containing an exclusion list from initial
MS/MS data to avoid analyzing peptides more than once. All fibroblasts protein extracts
were labeled a second time and analyzed by 2D-LCMS, giving two technical replicates of
the experiment (referred to as experiment 1 and 2).
3.3.4 Database searching and data analysis
Data analysis was performed with the software package ProteinPilot 2.0.1 (AB SCIEX).
All MS/MS spectra were processed by a ‘thorough’ search against the Swissprot Homo
sapiens database. The tolerance used for matching was based on information about the
accuracy of the instrument, 0.1 m/z. The Paragon algorithm in ProteinPilot was used for
peptide identification, and results were subsequently processed by the Pro Group algorithm.
Search parameters included iTRAQ labeling at the N-terminus and lysine residues, cysteine
modification by MMTS, digestion by trypsin (including two missed cleavages allowed) and
methionine oxidation as a variable modification. For quantification with iTRAQ isotope
labeling, the corresponding ‘correction factors’ were considered. Data were normalized
for loading error by bias corrections. Isoform specific identification and quantification was
carried out by selecting unique peptides and excluding all shared peptides from quantifi-
cation. Proteins identified with >95% confidence (Protscore >1.3) were used for further
analysis. Searching a concatenated database containing both forward and shuffled decoy
sequences allowed estimation of the false discovery level [21]. Control 113 was used as
denominator, and data were exported to excel for further analysis. A student t-test was
performed at the 95% confidence level (p<0.05) to indicate significant protein abundance
differences between control and patient groups. The function, interactions and localization
of the differential regulated proteins were studied based on information in databases such
as Swiss-Prot, STRING [22] and the Human Protein Reference Database.
3.3.5 Western blotting
For validation of the proteins found by iTRAQ, fibroblast protein extracts of each sample
described above (proteins sonicated in lysis buffer) were separated by SDS-PAGE (150V)
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on a 12.5% polyacrylamide gel. Proteins were transferred by electroblotting (3h at 60V)
onto a nitrocellulose membrane (Amersham Biosciences, Uppsala, Sweden). Non-specific
antibody binding was blocked with 5% non fat dry milk (Bio-Rad, Nazareth, Belgium)
in PBS-T (phosphate-buffered saline + 0.1% Tween 20) for 2h at room temperature. Im-
munoblotting was carried out with primary antibodies against the 60S ribosomal protein
L29 (RPL29) (Abcam, Cambridge, UK), vimentin (Invitrogen, Carlsbad, California) and
β-actin (Abcam) at 4◦C overnight. Blots were subsequently washed twice in PBS-T and
incubated with a secondary antibody (HRP anti-mouse IgG, GE Healthcare). Bound anti-
bodies were visualized using SuperSignal® West Femto Maximum Sensitivity Substrate kit
(Thermo Scientific) and exposure to CL-XPOSURE FILM (Thermo Scientific). The inten-
sity of the protein bands was quantified using the Quantity One imaging software (Bio-Rad).
For western blotting analysis of vimentin in the pellets remaining after isolation of the
soluble protein fraction, proteins were resolubilized in lysis buffer (1% SDS, 8 M guanidine
hydrochloride, 50 mM Tris, 50 mM dithiothreitol. Acetone precipitation was performed by
mixing 6 volumes of acetone with the sample, followed by 2h incubation at -20◦C and cen-
trifugation at 13000 x g for 10 min. SDS-PAGE and blotting was performed as described
above; immunoblotting was carried out with primary anti-vimentin and anti-β-actin anti-
bodies.
3.3.6 Immuno fluorescence Staining
Fibroblasts grown on glass chamber slides were washed with phosphate buffered saline
(PBS) and fixed in ice-cold acetone for 2 min. Slides were blocked with 2.5% bovine
serum albumin (Sigma, St Louis, Missouri) in PBS for 30 min, and incubated with mouse
monoclonal antibodies directed against vimentin (0.7 µg/ml, Invitrogen), and alpha-tubulin
(10 µg/ml, Invitrogen) for 2 hours at room temperature. An anti-mouse secondary anti-
body labeled with AlexaFluor488 (1 µg/ml, Invitrogen) was added for 30 min. Slides were
washed with PBS between incubations. Slides were mounted with Vectashield containing
Dapi (Vector Laboratories, Burlingame, California).
3.4 Results
Cultured fibroblasts were used as a cell model for GAN, and clusters of vimentin were
observed using immunofluorescence staining and EM (Figure 3.2).
Protein extracts from eight cultured fibroblast cell lines (four controls and four pa-
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Figure 3.2: (A) IF staining of vimentin (green) organization in normal cultured skin fibroblasts
(control 1), showing a generalized network. (B) IF staining of abnormal vimentin (green) organiza-
tion in GAN cultured skin fibroblasts (patient 2). (C) Electron microscopic image of a GAN skin
fibroblast (patient 1) showing densely packed material devoid of cell organelles. (D) Immunfluo-
rescent staining of α-tubulin (green) showing a normal distribution in the GAN fibroblasts (patient
2).
tient cultures) were trypsinized and iTRAQ-labeled, followed by RP-RP LC and MALDI-
TOFTOF MS/MS analysis for identification and quantification. All RP-LC MALDI-TOF-
TOF runs were analyzed using the ProteinPilot software (ABSCIEX), resulting in 29314
and 16192 spectra in experiments 1 and 2 respectively, and searched against 40763 proteins
in the database. An identity confidence cut-off of 95% (Protscore >1.3) was employed, re-
sulting in identification of 8640 peptides leading to 845 proteins in experiment 1, and 6410
peptides leading to 685 proteins in experiment 2. Searching a decoy database containing
both forward and shuffled sequences allowed estimation of a false positive rate of 4.8% at
the protein level. Contaminant proteins, decoy hits, proteins without all eight iTRAQ® la-
bels and peptides with an identification confidence <65% were removed from the final list.
The iTRAQ protein ratios reported here are the average ratios calculated from the ratios of
the individual peptides determined for each protein.
In the two experiments, a total of 743 or 618 proteins, respectively, were identified with
>95% confidence and quantified from the total cell lysate. Of those proteins, 464 were
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identified in both experiments. Eight proteins were found to be significantly regulated (p-
value<0.05) in both experiments (Table 3.2), and 22 proteins were significantly regulated
in only one experiment (not detected in the other experiment) (Table 3.3). The number
of peptides identified and quantified per protein was much higher in the proteins detected
in both experiments (Table 3.2). In particular, a high number of peptides was found for
galectin-1 (n=55 and 56), aminopeptidase N (n=13 and 11), glia-derived nexin (n=11 and
8), ribosomal protein L29 (n=9 and 13) and ribosomal protein L37 (n=9 and 6). A higher
number of peptides per protein increases the reliability of the findings in these proteins.
Differential regulated proteins were further analyzed according to their function, interaction
and localization. A large number of cytoskeletal proteins were identified and quantified
(supplementary data). 76 of the 78 cytoskeletal proteins quantified were not dysregulated.
Only lamin-B1 and WD repeat-containing protein 1 were downregulated in experiment
1 (both not detected in experiment 2 and only one peptide for each protein detected in
experiment 1).
Table 3.2: Proteins differentially expressed in both experiments.
Experiment 1 Experiment 2
Acc. No.a Name RatiobpValc Peptd%Cove Ratio pVal Pept %Cov
P07093 Glia-derived nexin 0.53 0.0139 11 27.8 0.45 0.008 8 24.3
Q14108 Lysosome membrane
protein 2
0.55 0.0469 2 11 0.65 0.0337 1 6
P15144 Aminopeptidase N 0.58 0.0237 13 11.6 0.71 0.0245 11 14.4
O43670 Zinc finger protein 207 1.19 0.0356 3 7.9 1.37 0.0299 2 5
O95881 Thioredoxin domain-
containing protein 12
1.25 0.013 4 48.2 1.45 0.035 1 15.5
P47914 60S ribosomal protein
L29
1.64 0.0131 9 46.5 1.69 0.0121 13 62.2
P61927 60S ribosomal protein
L37
1.66 0.0021 9 52.5 1.47 0.0216 6 41.2
P09382 Galectin-1 1.68 0.0036 55 64.4 1.42 0.003 56 70.3
a SwissProt accession number.
b Ratio of the patients group to the control group.
c Statistical significance of the change in abundance as determined by student t-test (p<0.05 to be significant).
d Number of peptides (with identification threshold >65%) used for quantification.
e % Protein coverage.
Western blot analysis was performed to validate results obtained from the proteome
analysis. RPL29 was selected for western blotting, as according to the iTRAQ results it was
one of the most significantly overexpressed proteins in patient samples. Western blotting
confirmed significant upregulation of RPL29 protein levels in GAN patients as compared
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Table 3.3: Proteins differentially expressed but detected in one experiment only.
Acc. No.a Name Ratiob pValc Peptd %Cove
Experiment 1
Q8TET4 Neutral alpha-glucosidase C 0.35 0.0166 1 4.2
Q9HCU0 Endosialin 0.43 0.0019 3 9.6
Q9P2P1 Integrase catalytic domain-containing protein
KIAA1305
0.45 0.0255 1 8.3
O75083 WD repeat-containing protein 1 0.47 0.0488 1 4.6
Q00341 Vigilin 0.49 0.05 1 7
Q96PU8 Protein quaking 0.61 0.015 1 9.9
P20700 Lamin-B1 0.62 0.0102 1 17
O94979 Protein transport protein Sec31A 0.64 0.023 2 3
Q15459 Splicing factor 3 subunit 1 0.65 0.0041 1 7
Q92841 Probable ATP-dependent RNA helicase DDX17 0.7 0.0467 4 18.7
Q08211 ATP-dependent RNA helicase A 0.73 0.0109 2 16.6
P53803 DNA-directed RNA polymerase II subunit K 0.84 0.0473 2 13.7
O75400 Formin binding protein 3 0.86 0.0379 2 15.7
Q13243 Splicing factor, arginine/serine-rich 5 1.43 0.043 1 38.6
Q6TFL3 Uncharacterized protein C9orf93 1.54 0.0208 1 9.2
Q9Y520 BAT2 domain-containing protein 1 2.04 0.0374 1 10.8
Experiment 2
Q9C0B7 Transmembrane and coiled-coil domain-
containing protein 7
0.32 0.0491 2 6.3
O60237 Protein phosphatase 1 regulatory subunit 12B 0.53 0.0432 1 11.7
P0C0S5 Histone H2A.Z 0.65 0.0019 2 37.5
P00167 Cytochrome b5 0.69 0.0492 2 44.7
O95302 FK506-binding protein 9 0.74 0.0321 3 12.5
Q96CT7 Coiled-coil domain-containing protein 124 1.34 0.0343 1 13.9
a SwissProt accession number.
b Ratio of the patients group to the control group.
c Statistical significance of the change in abundance as determined by student t-test (p<0.05 to be significant).
d Number of peptides (with identification threshold >65%) used for quantification.
e % Protein coverage.
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to controls (Figure 3.3A). Western blotting showed that the amount of vimentin in the cells
from GAN patients was not different from that in control cells, further confirming the results
obtained with iTRAQ. The validity of actin as a loading-control was justified by its stable
undifferential expression in GAN patients [3; 4].
Figure 3.3: (A) Western blot analysis for RPL29 of the soluble fraction, normalized against β-actin.
The mean control value was set to 1. Note the significant upregulation of RPL29 in patients. (B)
Western blot for vimentin of the insoluble fraction normalized against β-actin. No significant change
was found between control and patient samples.
To exclude the possibility that vimentin in the aggregates had not been solubilized com-
pletely, western blots were also performed on the insoluble fraction, after solubilization
with a stronger chaotrope/detergent solution. Again, no significant difference in abundance
between GAN patients and controls was found (Figure 3.3B).
3.5 Discussion
GAN is a rare genetic disease characterized clinically by progressive dysfunctioning of
the peripheral and central nervous system. Morphologically, large aggregates of IF can
be observed in different tissues [3; 5]. GAN is caused by mutations in the GAN gene
encoding gigaxonin, a substrate-specific adaptor for a Cul3-dependent E3 ubiquitin ligase
complex [14]. It binds with specific microtubule-associated proteins: MAP1B [15], MAP8
[16] and TBCB [17]. Accumulation of these three proteins was demonstrated in vitro in
GAN KO mice brain [16–18]. These proteins are proposed to influence the stability of
the microtubule network [15; 18; 23]. Accumulation of MAP1B and MAP8 in vitro leads
to neuronal degeneration and cell death, and MAP8 leads to impaired axonal transport.
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MAP8 also plays a role in anchoring the microtubule-organizing center to the centrosome.
In human GAN cells, little is known about the abundance of MAP1B, MAP8 and TBCB.
In one study, TBCB amounts were found to be unaltered in human GAN cultured skin
fibroblasts [19]. Data on the amounts of MAP1B and MAP8 in cultured skin fibroblasts or
other cell types from GAN patients are not yet available in the literature.
In the differential proteomics experiment reported here, MAP1B was identified and
quantified, and a change in abundance of MAP1B was not found. TBCB and MAP8 could
not be detected, possibly because of their low expression in cultured skin fibroblasts (mostly
expressed in the brain). Three other MAPs (MAP1A, MAP4, MAPRE1) were found to not
be differentially regulated. In addition, 74 other structural cytoskeletal proteins, including
vimentin, were detected and quantified (supplementary data). Significant differences in
protein abundance could not be detected in 72 proteins. Only two cytoskeletal proteins
(lamin-B1 and WD repeat-containing protein 1) were found to be downregulated, but only
one peptide had been identified and quantified in each of these proteins. From these findings
we conclude that the abundance of the great majority of the structural cytoskeletal proteins
in GAN cultured skin fibroblasts is not different from controls. Other mechanisms must
therefore be responsible for the formation of the vimentin aggregates.
In the GAN cells studied here, 30 proteins were found to be either significantly up-
regulated or downregulated (Tables 3.2 and 3.3). Looking at their function, it is clear that
several proteins are linked to pathways involved in modulation and regulation of the cy-
toskeleton (Figure 3.4). The cytoskeleton is not simply a static structure. Reorganization of
the cytoskeletal network is required for resistance to mechanical stress, cell differentiation,
cell division and cell migration [24]. Reorganization of the cytoskeletal protein network
is also needed for the epithelial-mesenchymal transition, a phenomenon seen in normal
development and in cancer metastasis, initiated by altered cell-cell and cell-extracellular
matrix interactions [25]. Interestingly, two of the dysregulated proteins are heparin binding
proteins localized in the plasma membrane. Heparin is a constituent of the extracellular
matrix, either as free chains or as proteoglycans. In cultured endothelial cells, heparin was
shown to influence the organization of the cytoskeleton, especially of actin and intermediate
filaments [26]. Numerous growth factors, but also coagulation factors and some proteins
in the extracellular matrix, are heparin binding proteins. The heparin-binding EGF-like
growth factor (HB-EGF) is the best known. This growth factor is synthesized as a single
pass membrane-anchored precursor that undergoes cleavage of the entire ectodomain by
metalloproteinases (ADAMs) to yield the mature soluble growth factor.
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In the GAN cells studied here, two ribosomal proteins were found to be upregulated, the
ribosomal proteins RPL29 and RPL37. This is unusual, as the higher demands placed upon
the protein translation system in patients should be accompanied by general upregulation of
a wide range of ribosomal proteins. Selective upregulation of individual ribosomal proteins
can be explained by the fact that these ribosomal proteins display an alternative function
outside the ribosome. This is the case for RPL29 that, in addition to its cytoplasmic local-
ization, is also localized in the plasma membrane. RPL29 is a heparin binding protein. Its
exact role in the plasma membrane is not known.
Glia-derived nexin is also a heparin binding protein located at the external side of the
plasma membrane, and it was found to be downregulated in the GAN cells (Table 3.2). It is a
serine protease inhibitor with activity toward thrombin, trypsin, and urokinase. Glia-derived
nexin promotes neurite extension by inhibiting thrombin. It plays a role in cell migration
and astrocyte differentiation. It also functions as an inhibitor of plasminogen activator. The
latter cleaves plasminogen to form the active plasmin, which is a serine protease involved in
several processes, including degradation of fibrin clots, tissue remodeling and degradation,
cell migration and many other pathophysiological events. Downregulation of glia-derived
nexin leads to increased plasmin production. In a transcriptome study reported earlier [13]
an upregulation of plasminogen activator was found.
Surprisingly, a peptidase was found among the dysregulated proteins in the GAN cells.
Aminopeptidase N was downregulated. It is a transmembrane zinc-binding metallo ec-
topeptidase that preferentially removes neutral or basic amino acids from unblocked N-
termini of bioactive peptides or proteins. It is localized in the plasma membrane, the ER-
Golgi membranes and the cytosol. Besides its role in the gamma-glutamyl pathway it is
involved in the metabolism of regulatory peptides. Aminopeptidase N participates in cell
migration and invasion of extracellular matrix and is important in both angiogenesis and
tumor progression. Aminopeptidase N, together with the ADAMs and MMP14 (membrane
type matrix metalloproteinase-1), is considered to be the most important cell surface asso-
ciated zinc-dependent metalloprotease with a function in regulation of extrinsic regulatory
factors of tumor growth [27].
Galectin-1, a galactose binding lectin, was found to be upregulated in the GAN cells
(Figure 3.4). In the cytoplasm, galectin-1 binds to H-Ras, and the galectin-1/H-Ras complex
then migrates to the plasma membrane, where it activates Raf-1 [28]. Raf-1 [29] activates
Rho kinase, which influences the cytoskeletal organization by three different routes: (i) di-
rect phosphorylation of vimentin causing disassembly of vimentin filaments, (ii) phospho-
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rylation of myosin, and (iii) inhibition of myosin phosphatase, also resulting in increased
phosphorylation of myosin. Protein phosphatase 1 regulatory subunit 12B was found to be
downregulated, which reinforces the expected hyperphosphorylation of myosin. The over-
all result of overexpression of galectin-1 is hyperphosphorylation of vimentin. Increased
phosphorylation of vimentin and myosin occurs when the cytoskeletal network needs to be
thoroughly reorganized. Earlier studies have shown that excessive hyperphosphorylation of
vimentin can cause collapse of the vimentin network [29; 30].
Galectin-1 is also present in the extracellular matrix where it binds to the galactosyl
residues of integrin α5β1 [31] (Figure 3.4). Integrins are major receptors for cell adhesion
to the extracellular matrix. After formation of the integrin α5β1/galectin-1 complex in
the plasma membrane it can activate RhoA. The latter activates the formin protein family.
Formins play an important role in remodeling of the cytoskeleton necessary for adhesion,
intracellular trafficking and maintenance of the shape of the cells and in cytokinesis by
promoting the assembly of actin filaments [32]. Galectin-1 in the extracellular matrix can
also bind to protein tyrosine phosphatase receptor type C causing its inhibition, and to
leukosialin, another plasma membrane protein. An increase of galectin-1 results via this
route in decreased lyn and fyn activity [33]. Fyn is involved in transcription, regulation
and stabilization of myelin associated proteins, probably via quaking protein that stabilizes
pre-mRNA of myelin associated proteins and is of importance for the myelinization process
[34; 35]. It is interesting to note that the protein quaking was found to be downregulated.
These protein alterations could explain the thin myelin sheaths found in axons from GAN
patients. Leukosialin also links intracellularly to ERM proteins (ezrin, radixin, moesin)
[36] that have a role in cell motility. Finally, galectin-1 is also present in the nucleus, where
it can bind to gemin-4, a member of the survival of motor neuron (SMN) complex. The
latter is thought to recycle and resupply snRNPs to the spliceosome assembly [37].
Endosialin was significantly downregulated (experiment 1). It is an integral membrane
receptor exhibiting a high degree of O-linked glycosylation. The expression of endosialin is
induced in cells associated with endothelium and stromal fibroblasts in actively remodeling
tissues such as invasive tumor [38]. Expression of endosialin in cells increases their abil-
ity to adhere to the extracellular matrix, increases cell migration through the extracellular
matrix, and enhances the activity of matrix metalloproteinase 9 (MMP-9). Fibronectin and
collagen types I and IV are specific ligands for endosialin.
Thioredoxin domain containing protein 12 is a glutathion-mediated protein thiol disul-
fide oxidase which was found to be upregulated. The significance of this upregulation is
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not clear. Lysosome membrane protein 2 (LIMPII) was downregulated. Mice with deficient
lysosome membrane protein 2 suffer from demyelinating peripheral neuropathy [39].
Several nuclear proteins were found to be dysregulated in the GAN cells. As can be
seen in (Figure 3.5, most of these dysregulated nuclear proteins are in some way connected
to each other or have a link to the formin binding protein 3. The latter was found to be
downregulated. Formin binding protein 3 plays a central role in cytoskeletal reorganization
by binding to pre-mRNA and to three proteins that shuttle between the nucleus and the
cytoplasm: (i) the WW domain binding protein 11, (ii) WASL/N-WASP and (iii) formin-1.
A decreased amount of formin binding protein 3 in the nucleus leads to decreased seques-
tration of these proteins in the nucleus and hence to increased presence in the cytoplasm
where they can participate in the remodeling of the cytoskeleton.
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We conclude that in cultured skin fibroblasts, used as a cell model for GAN, expression
of cytoskeletal structural proteins was not altered significantly. However, several proteins
linked to regulation of the cytoskeletal network were found to be upregulated or down-
regulated. Our hypothesis is that in GAN, dysregulation of the cytoskeletal network leads
to a hyperphosphorylation state of vimentin that results in massive depolymerization of
vimentin filaments and finally in collapse of the vimentin network. The unpolymerized
filaments are collected in the aggresome near the nucleus where they form the typical ag-
gregates.
It remains to be elucidated how a defect in gigaxonin can induce dysregulation of the
cytoskeletal organization before any significant increase of MAP1B can be detected. At this
moment, we can only speculate regarding the underlying mechanism. One of the possibili-
ties is that in the absence of gigaxonin, the free position in the BCR complex might be oc-
cupied by another KLHL protein, for example, KLHL 9 or KLHL 13. In that case, another
protein (e.g. aurora B) will be ubiquitinated instead of the substrate proteins of gigaxonin.
This inappropriate targeting could disturb the equilibrium upheld by tight regulation of the
cytoskeleton by specific kinases and phosphatases. Future research should be directed at
determining the phosphorylation state of vimentin in the aggregates using different spe-
cific antibodies against phosphorylated vimentin (different kinases phosphorylate vimentin
at the multiple phosphorylation sites). Also, it would be of interest to document whether
changes in the extracellular matrix can trigger the formation of IF aggregates. Finally, a
basic understanding of the disease mechanisms could lead to new treatment strategies in
patients with GAN.
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4.1 Abstract
Giant axonal neuropathy (GAN) is caused by loss of function of the gigaxonin protein. On
a cellular level GAN is characterized by intermediate filament (IF) aggregation, leading to
a progressive and fatal peripheral neuropathy in humans. This study sought to determine if
re-introduction of the GAN gene into GAN-deficient cells and mice would restore proper
cytoskeleton IF homeostasis. Treatment of primary skin fibroblast cultures from three dif-
ferent GAN patients with an adeno-associated virus type 2 (AAV2) vector containing a nor-
mal human GAN transgene significantly reduced the number of cells displaying vimentin
IF aggregates. A proteomic analysis of these treated cells was also performed, wherein
32 proteins were identified whose abundance changed in response to gigaxonin gene trans-
fer. Three of these were previously identified as being disregulated in GAN and were now
shifted toward normal levels. To assess the potential application of this approach in vivo
and eventually in humans, GAN mice received an intracisternal injection of an AAV9/GAN
vector to globally deliver the GAN gene to the brainstem and spinal cord. The treated mice
showed a nearly complete clearance of peripherin IF accumulations at three weeks post-
injection. These studies demonstrate that gigaxonin gene transfer can reverse the cellular
IF aggregate pathology associated with GAN.
4.2 Introduction
Giant Axonal Neuropathy (GAN, OMIM #256850) is a rare chronic neurodegenerative
disease characterized by enlarged axons with disordered microtubules and intermediate fil-
aments, which is fatal by the third decade of life [1]. The disease pathology is due to
homozygous loss-of-function mutations in the GAN gene, which encodes the protein gi-
gaxonin. Onset of symptoms is usually 3-4 years of age, with a slightly awkward gait.
By the end of the 2nd decade of life, patients normally are wheelchair bound with limited
use of the arms and little to no use of their legs. Death normally occurs in the 2nd or 3rd
decade of life. Peripheral nerve biopsies from humans show enlarged axons with densely
packed and disorganized microtubules and IFs [2; 3]. The dysfunction and degeneration of
peripheral nerves is attributed to this pathology. These same studies showed white matter
abnormalities in the brain by MRI, indicating an involvement of the central nervous system.
This peripheral nerve pathology (enlarged axons densely filled with neurofilaments) serves
as a basis for diagnosis, which is then confirmed by sequencing the GAN gene. There are
no statistics on the incidence of the disease, but it is considered extremely rare.
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Giant axonal neuropathy was characterized over 25 years ago as an inborn error in in-
termediate filament organization [4], which was later found to be from mutations in the
gigaxonin gene and resulting loss of functional gigaxonin protein [5]. More than 40 mu-
tations have been identified in GAN patients, including deletions, insertions, missense and
nonsense mutations, which lead to loss of function of gigaxonin [2; 5–10]. Gigaxonin is a
broadly expressed Cul3 ubiquitin ligase adaptor protein, normally present at extremely low
levels throughout the brain [11]. Known direct targets of gigaxonin are MAP8, MAP1B,
and TCBC, which are involved with intermediate filament (IF) regulation [12–15]. In the
absence of gigaxonin, the regulation of IFs is disrupted, leading to increased IFs which
can form inclusion bodies. The composition of these inclusions varies based on the spe-
cific IF composition in any given cell type. Vimentin, peripherin, neurofilaments (NF-H,
NF-M, NF-L), alpha-internexin, GFAP, nestin, desmin, and keratin are IFs known to be
accumulated in mice and/or humans lacking gigaxonin [1; 4; 16]. Abnormal aggregates of
keratin in hair are likely responsible for the typical curled hair observed in most patients
[4; 17; 18]. The vimentin aggregates in fibroblasts are located in the perinuclear space
close to the microtubule organizing center [17]. Gigaxonin is also a substrate for ubiq-
uitination and degradation by its own Cul3 ubiquitin ligase complex, providing a level of
self-regulation at the protein level [19].
Unfortunately, the underlying function(s) of gigaxonin and the mechanism by which the
protein regulates IFs is poorly understood. The structural/functional domains of gigaxonin
include: an N-terminal BTB domain (BR-C, ttk and bab), a centrally located conserved
BACK domain, and six kelch motifs in the C-terminal part. Gigaxonin has a suspected
role as a substrate-specific adaptor for the BCR (BTB/Kelch protein-cullin-3-RING box
protein1) E3 ubiquitin ligase complex [20]. As such an adaptor, it may facilitate proteasome
targeting and degradation of various substrate proteins such as MAP1B, MAP8, and TBCB
via interactions with its C-terminal kelch domains [12–14]. It has been postulated that
these substrates are accumulated in the absence of gigaxonin, and this hypothesis was partly
confirmed in GAN-KO mice [13–15] but not in human cells [11]. However, no direct link
has been established to explain how this leads to disregulation of IFs.
Conceptually, the unbalanced regulation of IFs could be corrected by re-introducing
gigaxonin. In such a scenario, it is also conceivable that restoring normal IF regulation
could allow cells to resolve IF inclusions and reverse existing pathology. Carriers of mutant
gigaxonin alleles (humans and mice) express approximately 50% levels of gigaxonin and
are phenotypically and pathologically normal, suggesting that restoration of lower-than-
normal gigaxonin levels could still be efficacious. While gross overexpression of gigaxonin
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has a conceptual risk for toxicity, the protein-level auto-regulation of gigaxonin abundance
should correct for mild overexpression. Therefore, a broad therapeutic index of gigaxonin
expression levels is expected. For these reasons, we propose that GAN is an excellent can-
didate for a gene replacement therapy. This study sought to determine if re-introduction
of gigaxonin into GAN-deficient cells would restore proper cytoskeleton IF homeostasis,
reversing the cellular disease phenotype of IF aggregation. In this study, skin fibroblast
cultures from 3 different GAN patients were transduced with an AAV2 vector containing
a normal human GAN transgene or a GFP transgene as a control. Reduction in vimentin
aggregation following viral delivery was scored microscopically. To further characterize
the global intracellular changes associated with gigaxonin re-introduction, the proteome of
these cells was analyzed after viral delivery, identifying and measuring the relative abun-
dance of proteins using a differential proteomics method based on the iTRAQ strategy in
combination with two-dimensional liquid chromatography mass spectrometry (2D-LC-MS)
on a MALDI TOFTOF MS platform. Finally, to assess the potential application of this ap-
proach in vivo and eventually in humans, GAN KO mice were injected with an AAV9/GAN
vector and scored for reduction of the neuronal IF peripherin in the brainstem and spinal
cord. This study sought to understand intracellular changes that occur in response to the
re-introduction of gigaxonin into GAN-null cells, both in vitro and in vivo.
4.3 Methods
4.3.1 Patients fibroblast cultures
Primary skin fibroblasts were maintained in MEM-alpha (Gibco #12561) containing peni-
cillin and streptomycin with 10% FBS, at 5% CO2 and 37◦C. P1 has a homozygous mis-
sense mutation (p. Ala49Glu), P2 has heterozygous mutations (p. S52G and C393X),
and P3 has a homozygous deletion (c.1647-8680 ∗258del, encompassing exons 10 and 11).
These patients were all clinically verified to be GAN patients with typical symptoms. P2
was described previously [5], and an Ala49Thr (similar to P1) has been described [6]. The
normal human fibroblast line was transformed with hTERT.
4.3.2 Vector preparation
rAAV vectors were produced using a triple-transfection method in HEK293 cells as de-
scribed [21]. Highly pure recombinant virus were recovered using sequential step and con-
tinuous CsCl gradients, then the peak fractions were dialyzed in phosphate-buffered saline
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(PBS) containing 5% D-sorbitol. Viral titers were determined by dot blot or qPCR as de-
scribed [21]. The recombinant vectors in these studies were single-stranded AAV using
AAV2 ITRs, packaged in either an AAV2 or AAV9 capsid. The CMV-GAN construct used
a CMV enhancer/promoter, myc-tagged gigaxonin coding sequence, and SV40 polyA. The
GFP construct used the same CMV enhancer/promoter, enhanced GFP coding sequence,
and SV40 polyA.
4.3.3 Vector treatments in vitro, immunocytochemistry, and vimetin
aggregate scoring
For proteomic analysis, cells were grown in 10 cm plates. 2.5x105 cells were seeded per
plate, in triplicate to 3 plates. After 1 day, 5x1010 vg of either ssAAV2/CMV-GAN or
ssAAV2/CMV-GFP were added to each plate. Three days post-infection, cells were har-
vested with trypsin, washed with PBS, and cell pellets were frozen at -80◦C until use.
For immunocytochemistry (ICC), 10,000 cells per well were seeded onto poly-L-lysine
coated coverslips (BD #354085) in 24 well plates on day 0. On day 1, 5x109 vg of AAV2
vector, or a corresponding amount of PBS containing 5% sorbitol, was added per well. On
day 2 the media was changed. On day 4-5 (3-4 days post-infection), cells were washed with
PBS and fixed with 4% paraformaldehyde for 10 minutes at room temperature (RT). Cells
were then washed with PBS and incubated twice for 10 minutes at RT with PBS containing
0.1% Triton-X100. Blocking was done for 1 hr at RT with PBS containing 3% goat serum
and 0.1% Triton-X100. Primary antibody incubation was for 1 hr at RT with PBS contain-
ing 3% goat serum, 0.1% Triton-X100, 1:1000 dilution of mouse anti-vimentin (Millipore
#CBL202), and 1:500 dilution of rabbit anti-GFP (Millipore #3080). After washing 3 times
with PBS containing 0.1% Triton-X100, secondary antibody incubation was for 1 hr in
PBS containing 3% goat serum, 0.1% Triton-X100, goat anti-mouse Alexa594 (Invitrogen
#A11032), and goat anti-rabbit Alexa488 (Invitrogen #A11008). After washing twice with
PBS, coverslips were mounted onto slides using ProLong Gold Antifade mounting media
with DAPI (Invitrogen #P-36931). The presence of vimentin aggregates were scored visu-
ally, with >500 cells typically assessed per coverslip.
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4.3.4 Quantitative PCR analysis of vector genomes and gigaxonin m-
RNA expression
RNA was recovered from the cells using the RNA Mini Plus kit (Qiagen); tissue lysis was
performed with the TissueLyser (Qiagen), and automated purification was carried out on a
Qiacube (Qiagen). RNA was treated to remove any residual genomic DNA as follows: RNA
was incubated for 10 minutes at 37◦C with 20 units Protector RNase Inhibitor (Roche), 1x
DNase I reaction buffer (NEB) and 2 units of DNase I (NEB). This was followed by an
additional incubation of 10 minutes at 75◦C with EDTA added to a final concentration
of 2.5mM for DNaseI inactivation. cDNA was synthesized from the purified RNA using
the Transcriptor First Strand cDNA Synthesis kit (Roche), following the manufacturers
instructions, then used directly as template for RT-qPCR. RT-qPCR reactions and analysis
were carried out on a Roche Lightcycler 480, following the manufacturers instructions and
as described [22]. All primer sets used SyBR green for quantitation except for the GAPDH
primer, which used a primer and hydrolysis probe combination.
To quantify the myc-tagged gigaxonin transgene separate from the endogenous gigax-
onin, primers were designed so that the upstream primer annealed to the myc tag. An
internal set of gigaxonin primers were also used that would equally recognize the endoge-
nous and transgene gigaxonin. qPCR of cDNA samples was used to determine the abso-
lute numbers of mycgigaxonin, total gigaxonin, and GAPDH transcripts per unit volume
in each sample. Transcript quantification is reported as the absolute number of gigaxonin
transcripts/Pl divided by the absolute number of actin transcripts/Pl in the sample. Primers
for myc-tagged human gigaxonin were as follows: FORWARD: 5-tgatcagcgaggaggacctgg-
3; REVERSE: 5-gttgatccatcatcttttggagg-3. Internal gigaxonin primers recognizing the en-
dogenous and transgene gigaxonin were as follows: FORWARD: 5-ggttatgagagagatcctgga-
3; REVERSE: 5-cgtgatggaggcagtaatgta -3. The human GAPDH reactions use the following
primers and probe: FORWARD: 5-agccacatcgctcagacac-3; REVERSE: 5-gcccaatacgaccaaatcc-
3; PROBE: UPL#60 (Roche cat# 04688589001). A melting curve analysis was performed
at the end of each SyBR green qPCR run, following the manufacturers instructions, to verify
the purity of the PCR product.
4.3.5 iTRAQ reagent labeling and peptide separation
Proteins were extracted by re-suspending each cell pellet in 200 µl lysis buffer, containing
0.05 M triethyl ammonium bicarbonate (TEAB), 7 M urea, 2 M thiourea and protease in-
hibitor cocktail (Roche, Vilvoorde, Belgium). The cells were sonicated, and the supernatant
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was collected after centrifugation at 13000 g for 20 min at 4◦C. An aceton precipitation was
performed prior to the protein concentrations measurement by the Bradford protein assay
(Thermo Scientific, San Jose, California). (A summary of the experimental workflow is
shown in Supplementary Figure 4.5, p113). Equal amounts of protein (25 µg) from each
cell lysate were used. The iTRAQ labeling was performed according to the manufacturer’s
protocol using solvents included in the kit (AB SCIEX, Foster City, California). The six
peptide samples were added to the different labels of the 8-plex iTRAQ kit (AB SCIEX)
as follows: Patient 1: 113 (GAN) and 114 (GFP), patient 2: 115 (GAN) and 116 (GFP),
patient 3: 117 (GAN) and 118 (GFP). The labels are added in excess to obtain full labeling.
Labeling was confirmed for all samples before combining the samples. After combining
the six iTRAQ-labeled samples, the mixture was vacuum dried and dissolved in 20 mM
HCOONH4, 2% ACN at pH 10.
The labeled peptide mixture was separated on an Ettan liquid chromatography system
(GE Healthcare, Diegem, Belgium), using a Luna C18 column (2.0 mm i.d. x 150 mm
length x 5 µm, 100 A˚ column) (Phenomenex, Torrance, California), as described by Muss-
che et al [23]. The buffer compositions were 20 mM HCOONH4, 2% acetonitrile (ACN) at
pH 10 for buffer A and 20 mM HCOONH4, 80% ACN at pH 10 for buffer B. The flow rate
was 0.2 ml/min, and the elution gradient was as follows: 7 min 100% A, 60 min 0-50% B,
15 min 50-100% B, 10 min 100% B, and 3 min 100% A. Fractions were collected every
minute. After drying, the fractions were re-dissolved in 0.1% formic acid for nano-LC/mass
spectrometric analysis.
4.3.6 Nano-liquid chromatography and mass spectrometry analysis
Off-line LC-MS was done as described by Mussche et al [23]. Briefly, analytical reversed
phase separation of the labeled peptide mixture was performed on an Ultimate Plus Dual-
gradient Capillary/Nano-LC system (Dionex-LC Packings, Hercules, California) using a
C18 column (75 µm i.d. x 150 mm length, 3 µm, 100A˚) (Dionex) at a flow rate of 250
nl/min. The mobile phases were 5% ACN/0.05% trifluoroacetic acid (TFA), pH 3 for buffer
A and 80% ACN/0.05% TFA, pH 3 for buffer B. Peptides were resolved by gradient elution
using a gradient of 0-50% buffer B over 25 min, 50-100% buffer B over 10 min, 5 min of
100% buffer B and 10 min of 100% buffer A. Fractions were collected every 30 seconds
directly on a MALDI target plate. The MALDI plates were analyzed by a 4800+ MALDI-
TOFTOF Proteomics Analyzer (AB SCIEX). A plate calibration was performed using the
4700 calibration mixture with a mass tolerance of 0.5 m/z. The MSMS mode was calibrated
with a mass tolerance of 0.1 m/z. Additionally, MS spectra were internally calibrated with
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Glu-fibrinopeptide (1552.62 m/z). MS data were acquired in the reflector positive mode
over a mass range of 900-3500 m/z, by accumulation of 1000 laser shots per spectrum. The
eight highest precursor masses in each MS spectrum with an S/N threshold of minimum 50,
were selected for fragmentation, and the fraction-to-fraction mass tolerance was set to 200
ppm. MS/MS data were acquired with 2000 laser shots per spectrum, using 1keV collision
energy and air as the collision gas. Each plate was analyzed twice by reinterpretation of the
MS spectra with a method containing an exclusion list from initial MS/MS data to avoid
analyzing peptides more than once.
4.3.7 Database searching and data analysis
Data analysis was performed with the software package Mascot Daemon [24] (version 2.3,
Matrix science). All MS/MS spectra were processed against the UniProtKB/SwissProt
Homo sapiens database. Search parameters included iTRAQ labeling at the N-terminus
and lysine residues, cysteine modification by MMTS, digestion by trypsin (including two
missed cleavages allowed) and methionine oxidation as a variable modification. Normal-
ization of the ratios was performed by the median ratio. A significance threshold of p<0,05
was used for peptide identification and an ion score cut off of 30. Only unique peptides
were selected for quantification and protein ratios were calculated by the weighted average
of the peptide ratios. Using the build in decoy function, searching a concatenated database
containing both forward and shuffled decoy sequences, allowed estimation of the false dis-
covery rate [25]. The ratio of GAN/GFP was considered in the 3 patients, and accepted as
significant regulated when the ratios of all 3 patients samples showed a significant value at
the 95% confidence level (p<0.05). The function, interactions and localization of the dif-
ferential regulated proteins were studied based on information in databases such as Uniprot,
neXtProt, STRING [26], only considering experimentally confirmed interactions.
4.3.8 Western blotting of fibroblast samples
For validation of the proteins found by iTRAQ, fibroblast protein extracts of each sample
described above (proteins sonicated in lysis buffer) were separated by tricine-SDS-PAGE
on a 16.5% polyacrylamide gel. Proteins were transferred by electroblotting (3h at 60V)
onto a nitrocellulose membrane (Invitrogen, Carlsbad, California). Immunoblotting was
carried out with primary antibodies against the galectin-1 (ab25138, Abcam, Cambridge,
UK), PARK7/DJ1 (Abcam ab18257) and β-actin (Abcam). The intensity of the protein
bands was quantified using the Quantity One imaging software (Bio-Rad).
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4.3.9 Mouse Studies
All investigations were approved by the University of North Carolina-Chapel Hill Insti-
tutional Animal Care and Use Committee. Ten microliters (µL) of scAAV9/CMV-GFP
(8x1010 vg) or ssAAV9/CMV-GAN (7.2x1010 vg) vector were injected into the cisterna
magna. The AAV9/GFP injections were done in adult C57B1/6J mice purchased from Jack-
son Laboratory (Bar Harbor, ME), and the ssAAV9/GAN injections were done in knock-out
GAN∆ex1 [16] or GAN∆ex3−5 [14] mice. 3-4 weeks following vector injection, each mouse
was sacrificed and transcardially perfused with PBS or PBS containing 1U/mL heparin
(Abraxis, Schaumburg, IL).
4.3.10 Immunohistochemistry to detect peripherin aggregates
After 48 hours of fixation in freshly made PBS with 4% paraformaldehyde, the entire brain
and portions of the cervical and lumbar spinal cords were sectioned at 40 microns using
a Leica vibrating microtome. Every 5th section was processed for immunohistochemistry
(IHC). Samples were incubated for 1 hour at room temperature in blocking solution (10%
goat serum, 0.1% triton X-100, 1X PBS), then incubated 48-72 hours at 4◦C in primary
antibody solution (3% goat serum, 0.1% triton X-100, 1X PBS, and primary antibody).
Primary antibodies were as follows: rabbit anti-GFP (Millipore #AB3080, 1:500), rabbit
anti-peripherin (Millipore #AB1530, 1:500), mouse anti-neurofilament heavy chain (NF-
H, Covance #SMI-32P, 1:1000). After washing 3 times in PBS, secondary amplification
was performed using a VectaStain ABC Elite Kit (Vector Labs, #PK-6101 for rabbit and
PK-6102 for mouse, as appropriate) with 3,3’-diaminobenzidine tetrachloride (DAB; Poly-
sciences, Inc. #04008) substrate and nickel-cobalt intensification of the reaction product.
DAB-processed brain sections were digitized using a Scan-Scope slide scanner (Aperio
Technologies, Vista, CA). Virtual slides were viewed using ImageScope software package
(v. 10.0; Aperio Technologies), which allowed sections to be viewed at equivalent magnifi-
cations.
4.3.11 Western blot of mouse tissue
To validate expression of the gigaxonin transgene following intracisternal vector delivery,
a small portion of the caudal brainstem was homogenized and subjected to SDS-PAGE,
then blotted. The myc-tagged gigaxonin band was detected with a goat anti-gigaxonin
antibody (N-18, Santa Cruz #49688, 1:300) or a mouse anti-myc antibody (Millipore #05-
724, 1:1000).
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4.4 Results
4.4.1 Reduction of vimentin aggregates following gigaxonin gene trans-
fer
The first part of this study sought to investigate the effects of AAV/gigaxonin gene transfer
into GAN patient fibroblasts, in terms of the IF organization and potentially broader effects
on the proteome (Figure 4.1).
Figure 4.1: Study Design. (A) Diagram of the packaged single-stranded rAAV genomes used in
these studies. (B) Workflow for in vitro experiments using normal (NHF) or GAN patient (GAN)
fibroblasts.
Dermal fibroblasts taken from human GAN patients show cytoskeletal disorganization
and aggregation of the IF vimentin when grown in culture, and these accumulations may be
enhanced by culturing them in low serum media (0.1% FBS) or growing cells to confluence
for 3 days [17]. We have observed that when grown on poly-L-lysine coated coverslips
these accumulations are enhanced even in 10% FBS-containing media. Untransformed
fibroblasts from 3 GAN patients and a normal human fibroblast line were seeded, then in-
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fected the next day with AAV2 vectors (CMV-GFP, CMV-GAN, or PBS ‘mock’) at an MOI
of 5x104 vg/cell. The media was changed 24 hours after infection and then the cells were
grown in complete media (10% FBS) for an additional 2-3 days (3-4 days post-infection).
Cells were then fixed and immunolabeled for vimentin, and the percentage of vimentin
aggregate-containing cells were scored.
Approximately 53% of the fibroblasts were transduced (average of 9 trials, range 30%
to 71%), as gauged by the number of cells GFP-positive in the AAV2/GFP control group.
No suitable anti-gigaxonin antibodies were available to immuno-label for cells expressing
the gigaxonin transgene, and ICC against the myc tag also failed to detect the gigaxonin
protein. Treatment with the AAV2/GAN vector resulted in a significant reduction in the
percentage of cells containing vimentin aggregates, as compared to the mock-infected and
AAV2/GFP-infected cells (Figure 4.2).
Analysis of the mRNA from the cells by RT-qPCR indicated a 3.8-, 1.1-, and 12.4-
fold (P1, P2, and P3 respectively) average increase in gigaxonin mRNA in GAN-treated
patient cells versus mock-treated patient cells. The amount of gigaxonin mRNA seen in
mock-treated patient cells was equivalent when comparing P1 and P2 to normal human
fibroblasts, but the P3 mRNA levels were lower. This is understandable since P1 and P2
have missense mutations that are unlikely to affect the mRNA expression and stability,
whereas P3 has a homozygous deletion at the 3 end of the gene. The overall average amount
of gigaxonin mRNA in GAN-treated cells increased was 6.2-, 2.6-, and 5.7-fold (P1, P2, and
P3 respectively) above that detected in normal human fibroblasts. These results indicated
that gigaxonin is being mildly overexpressed at 3 days post-infection in this experiment.
There was a small decrease in the overall number of fibroblasts following the AAV2/
GAN treatment, suggesting the possibility of overexpression-related toxicity, but it isn’t
clear if this was due to the gigaxonin gene or high doses of AAV used (P = 0.03 compared
to mock treatment and 0.69 compared to GFP treatment (Suppl Figure 4.6 (p114)). No
vimentin aggregates were observed in any of the normal human fibroblasts, and no obvious
change in vimentin was observed in the normal human fibroblasts following AAV2/GAN
treatment. These results indicate that gigaxonin can function to reduce vimentin IF aggre-
gations and restore normal vimentin organization within 3-4 days of infection.
4.4.2 Proteome analysis
Currently, there is an incomplete understanding of the cellular function of gigaxonin, and
gaps of knowledge exist regarding both its direct binding partners and its downstream tar-
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Figure 2.  Reduction of vimentin aggregates after AAV/gigaxonin gene transfer.  Cultured GAN patient 
fibroblasts were treated with in parallel with vehicle buffer (mock), AAV2/GAN vector (GAN), or AAV/GFP 
vector (GFP), then fixed and immunostained for vimentin after 3-4 days.  (A) Representative images of 
cells with (right) or without (left) the vimentin aggregate phenotype.  Vimentin is red and DAPI is blue.  
(B) Vimentin aggregates were manually scored, and the average percent of cells containing vimentin 
aggregates plotted.  Three different lines were used: P1 (n=5, blue bars), P3 (n=4, red bars), and P2 (n=2, 
green bars).  (C) An additional set of cells was collected to assess the relative level of gigaxonin 
expression  by  mRNA  analysis  after  3  days.  In  panel  C,  “GAN  (total)”  used  primers  that  will  recognize  
endogenous  and  exogenous  gigaxonin,  and  “myc-GAN”  used  primers  that  only  recognize  the  exogenously  
delivered gigaxonin.  Error bars  =  S.E.M.    P  values  calculated  using  a  Student’s  T  test,  one-tailed, unequal 
variance.  
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Figure 4.2: Reduction of vimentin aggregates after AAV/gigaxonin gene transfer. Cultured GAN
patient fibroblasts w re tre ted with in parallel with vehicle buffer (mock), AAV2/GAN vector
(GAN), or AAV/GFP vector (GFP), then fixed and immunostained for vimentin after 3-4 days.
(A) Represent tive images of cells with (right) or without (left) the vim ntin aggregate phenotype.
Vimentin is red and D PI is blue. (B) Vimentin aggregates were manually scored, and the average
percent of cells containing vimentin aggregates plotted. Three different lines were used: P1 (n=5,
blue bars), P3 (n=4, red ba s), nd P2 (n=2, green b rs). (C) An additional s t of cells was collected
to assess relative level of gigaxonin expression by mRNA analysis after 3 days. In panel C, ‘GAN
(total)’ used primers that will recognize endogenous and exogenous gigaxonin, and ‘myc-GAN’
used primers that only recognize the exogenously delivered gigaxonin. Error bars = S.E.M. P values
calculated using a Student’s T test, one-tailed, unequal variance.
gets. To assess the more global consequence of gigaxonin re-introduction into GAN pa-
tient fibroblasts, we undertook a proteomic analysis of the cells following AAV2/GAN or
AAV2/GFP gene transfer. Protein extracts from the total cell lysate from six cultured fibrob-
last cell line samples (three GAN-infected and three GFP-infected patient cultures) were
trypsinized and iTRAQ-labeled, followed by RP-RP LC and MALDI-TOFTOF MS/MS
analysis for identification and quantitation. All RP-LC MALDI-TOFTOF runs were searched
against the UniProtKB homo sapiens database, resulting in identification of 14460 peptides
leading to 780 proteins. Proteins with all six iTRAQ labels were considered in the final
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list. The iTRAQ protein ratios reported here are weighted averages calculated from the
ratios of the individual peptides determined for each protein with the accompanying SD
and p-value. From the total of 780 proteins identified with >95% confidence, 31 proteins
were found to be significantly regulated (p<0.05) between GAN- and GFP-transfected cells
in all three patients (Table 4.1). Changes seen between different samples will not be due
to any AAV-specific effects since each AAV2/GAN-treated culture was compared with an
AAV2/GFP-treated culture from the same patient.
The differentially-regulated proteins were further analyzed according to their function,
interaction and localization, based on information in databases such as UniProt, neXtProt,
STRING. Some possible interesting interactions with components of the ubiquitin proteo-
some system are listed in Supplemental Table 4.2 (p117). A set of proteins previously
described to be differentially regulated in GAN patients vs controls was found not altered
in response to the AAV2/GAN treatment (Supplemental Table 4.3 p118). Interestingly, we
found no change in the overall levels of vimentin in response to the AAV2/GAN treatment.
Western blot analysis was performed to validate results obtained from the proteome
analysis. Galectin-1 and DJ-1 were selected, as according to the iTRAQ results these were
significantly down-regulated following gigaxonin gene transfer, and galectin-1 was previ-
ously shown to be overexpressed in GAN patients compared to controls [23]. This means
that this is probably an important player in GAN. Even though the degree of reduction
detected in the proteomic analysis was modest (0.65-0.88 fold compared to the GFP treat-
ment), the western blot results confirmed the down regulation of galectin-1 and DJ-1 in the
transduced fibroblasts (Figure 4.3).
4.4.3 In vivo rescue of peripherin IF aggregates following CNS AAV9
/ GAN gene transfer
To assess the possible translational potential of an AAV/GAN vector, a similar experiment
to the in vitro vimentin IF rescue was undertaken in vivo. There are 3 knock-out mouse
models described for GAN [16; 14; 27]. The first was described as recapitulating many
of the human disease symptoms, but subsequent rigorous analysis of all 3 mouse models
have shown that the mice do not develop any behavioral, motor, or sensory deficits until
>12 months of age, and these affects are fairly modest [27]. However, these mouse models
do display IF aggregates that are a hallmark of the underlying disease pathology, including
aggregations of neurofilaments, alpha-internexin, and peripherin in the CNS that are visible
as early as 3 months of age [16].
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Table 4.1: Differentially regulated proteins between GAN-transfected and GFP-transfected GAN
patients.
Acc. No.a Protein name %Covb nc P1d P2e P3f Localizationg
O15145 Actin-related protein 2/3 complex subunit
3
19,1 6 1,29 1,61 1,33 cytoskeleton
P60981 Destrin∗ 47,3 6 0,85 0,47 0,51 cytoskeleton
Q14315 Filamin-C∗ 24 26 1,30 1,44 1,12 cytoskeleton
P60660 Myosin light polypeptide 6∗ 66,9 11 0,77 0,83 0,61 cytoskeleton
Q01995 Transgelin∗ 84,6 30 0,81 0,47 0,65 cytoskeleton
O75347 Tubulin-specific chaperone A∗ 45,4 4 0,63 0,82 0,49 cytoskeleton
P63104 14-3-3 protein zeta/delta∗ 60 7 0,76 0,63 0,76 cytoplasm
P15880 40S ribosomal protein S2 29,7 4 1,24 1,23 1,21 cytoplasm
P36578 60S ribosomal protein L4 42,9 10 1,18 1,28 1,54 cytoplasm
P23588 Eukaryotic translation initiation factor 4B∗ 27,3 6 0,55 0,80 0,72 cytoplasm
Q15056 Eukaryotic translation initiation factor 4H∗ 16,1 4 0,52 0,80 0,61 perinuclear
P09211 Glutathione S-transferase P∗ 30 10 0,74 0,67 0,89 cytoplasm
O43795 Myosin-Ib 16,5 6 1,18 1,61 1,31 cytoplasm
Q99497 Protein DJ-1∗ 32,8 7 0,74 0,62 0,65 cytoplasm
P52565 Rho GDP-dissociation inhibitor 1∗ 43,1 5 0,75 0,41 0,66 cytoplasm
P39656 Dolichyl-diphosphooligosaccharide–
protein glycosyltransferase 48 kDa
subunit∗
15,7 5 1,48 1,66 1,70 ER
P04843 Dolichyl-diphosphooligosaccharide–
protein glycosyltransferase subunit 1∗
12,4 6 1,57 1,79 1,26 ER
O95302 FK506-binding protein 9 20 7 1,37 1,24 1,15 ER
P55072 Transitional endoplasmic reticulum
ATPase∗
41,2 20 1,42 1,25 1,17 ER
P23284 Peptidyl-prolyl cis-trans isomerase B∗ 68,5 18 1,45 1,52 1,17 ER
P09382 Galectin-1 63 28 0,88 0,82 0,65 Extracellular,
cytoplasm
P15144 Aminopeptidase N 11,3 9 1,63 1,41 1,16 Extracellular,
membrane
P16070 CD44 antigen∗ 7,5 6 1,36 1,47 1,30 membrane
Q00610 Clathrin heavy chain 1∗ 21,9 24 1,31 1,10 1,43 membrane
Q9NZM1 Myoferlin 14,3 8 1,36 1,45 1,27 membrane
O00469 Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2
17,5 4 1,41 1,50 1,33 membrane,
RER-
membrane
O60568 Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3
19,4 4 1,50 1,64 1,17 membrane,
RER-
membrane
Q6NUK1 Calcium-binding mitochondrial carrier
protein SCaMC-1
6,9 5 1,08 1,41 1,60 Mitochondrial
inner mem-
brane
Q9H1E3 Nuclear ubiquitous casein and cyclin-
dependent kinases substrate
15,6 6 0,68 0,80 0,81 nucleus
P22392 Nucleoside diphosphate kinase B∗ 50 7 0,89 0,71 0,74 nucleus
Q9H299 SH3 domain-binding glutamic acid-rich-
like protein 3∗
53,8 5 0,67 0,84 0,77 nucleus
a Uniprot accession number.
b Percent protein coverage.
c Number of peptides.
d Patient 1, ratio of GAN transfected to GFP transfected cells (p<0,05).
e Patient 2, ratio of GAN transfected to GFP transfected cells (p<0,05).
f Patient 3, ratio of GAN transfected to GFP transfected cells (p<0,05).
∗Proteins identified in this study but not altered between GAN patients and controls [].[25]
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Figure 4.3: Western blot experiments were performed on protein extracts of fibroblasts after treat-
ment with AAV vectors. (A) Representative Western blot analysis for proteins DJ-1 and galectin-1.
(B and C) Densities of the bands were first measured and normalized against actin for each lane.
Then ratios were calculated by dividing the actin-normalized GAN value by the actin-normalized
GFP value for each patient. The values in panels B and C are the average from 3 Western blots.
A pvalue was calculated based on the ratios of the 3 patients in the 3 western blots. For both DJ-
1 and galectin-1 the changes were significant (p<0.05). DJ-1 and galectin-1 were downregulated
in GAN-transduced cells compared to GFP-transduced cells, consistent with the itraq proteomics
results (Table 4.1). The validity of actin as a loading-control was justified by its unchanged ex-
pression in GAN patients [17; 4; 23]. GAN = treated with AAV2/CMV-GAN, GFP = treated with
AAV2/CMV-GFP. Error bars are SD.
In this experiment, we introduced the GFP or GAN gene into two of the GAN knock-out
mouse models (GAN∆ex1 and GAN∆ex3−5) when these mice were 17-21 months old (see
Supplemental Table 4.4 (p 118) for a list of subjects and results summary). Under anesthe-
sia, mice received a single injection into the cerebrospinal fluid of the cisterna magna. Ten
microliters (7.2x1010 total vg) of AAV9/CMV-GAN were injected into KO mice or 10 (µL)
108 RESULTS
(8x1010 vg) of AAV9/CMV-GFP were injected into age-matched heterozygous mice, then
the mice were allowed to recover. When injected into the cisterna magna in mice, AAV9
efficiently transduces large areas of the brainstem, dorsal spinal cord, motor neurons in the
ventral horn, and to a much lesser extent other areas of the brain as visualized with GFP
(Figure 4.4A-C). In the absence of a good behavioral readout in these mice for a phenotypic
rescue of function, a histological evaluation of IF aggregate resolution was pursued. Three
weeks post-injection with the AAV9/CMV-GAN vector, mice were sacrificed for immuno-
histochemical (IHC) evaluation of the IF aggregates in the brain. No IHC was done against
gigaxonin, because no suitable antibodies are available and IHC against the myc epitope
failed. We observed nearly complete clearance of peripherin aggregates in the brainstem
and dorsal lumbar spinal cord, in both the GAN∆ex1 and GAN∆ex3−5 knock-out mice (Fig-
ure 4.4D-F, Supplemental Figures 4.7 and 4.8, (p115)). As expected, heterozygous mice did
not show any abnormal peripherin staining and homozygous knock-out mice showed con-
sistent and extensive aggregates of peripherin, at ages ranging from 8 months to 24 months
old (Supplemental Table 4.4, p118). Expression of exogenous myc-tagged human gigax-
onin in the brainstem was verified by western blot analysis of brainstem tissue from treated
mice, compared to heterozygous or untreated knock-out mice of similar age (Figure 4.4G).
The amount of gigaxonin in treated mice compared to heterozygous controls indicates a
higher degree of overexpression in the mice at 3 weeks post-infection compared to the mild
overexpression seen in fibroblasts at 3 days post-infection (compare WB in Figure 4.4G to
Figure 4.2). Although the study investigated peripherin aggregates in age-matched knock-
out mice, and in some cases littermates, we wanted to verify to the best extent possible that
the treated mice had IF aggregates pre-injection and that these were resolved as a result
of the AAV9/GAN treatment. As areas of the midbrain and forebrain were not efficiently
targeted by AAV9 via this route of administration, they were stained for peripherin (mid-
brain, dorsal raphe nucleus) and neurofilament-heavy chain (NF-H, cortex and striatum) to
investigate the presence if IF aggregates in these areas. Despite the absence of peripherin
aggregates in the brainstem and dorsal spinal cord, the treated mice still had peripherin
aggregates in the dorsal raphe nucleus and NF-H aggregates in the cortex and striatum
(Supplemental Figure 4.9, p116). Although a comprehensive histopathological evaluation
was not done on these mice, they did not display any adverse behavior phenotypes or gross
brain pathology as a result of the treatment. These data provide strong evidence that the
AAV9/GAN vector was capable of resolving long-standing peripherin IF aggregates in the
CNS.
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Figure 4.4: Resolution of peripherin aggregates in GAN mice. WT C57B1/6J mice were injected
with 8x1010 vg scAAV9/CMV-GFP into the CSF of the cisterna magna, then GFP expression was
assessed in the forebrain (A), brainstem (B), and lumbar spinal cord (C) by IHC against GFP. (C-F)
17-21 month-old GAN∆ex1 (n=2) or GAN∆ex3−5 (n=2) mice were injected with 7.2x1010 vg of
ssAAV2/CMV-GANv2 vector into the CSF of the cisterna magna. Three weeks post-injection the
mice were sacrificed and sections of their brain and spinal cord assayed for peripherin accumulations
by IHC. Results shown are indicative of all mice per group (see Supplemental Table 4.4 (p118) for
summary of all mice examined). Columns D-F: top panel shows the spinal trigeminal nucleus of
the brainstem and the bottom set of panels show the dorsal lumbar spinal cord. Column D shows
the IHC against peripherin in a normal mouse. Column E shows the pattern in a knock-out GAN
mouse, and Column F shows mice of the same age treated with the vector. Panel G is a Western
blot brainstem tissue from a knock-out GAN mouse (showing no gigaxonin), a heterozygous GAN
mouse showing the low level of endogenous gigaxonin expression, and a treated knock-out GAN
mouse expressing the myc-tagged gigaxonin transgene. The top row of bands are blotted with an
anti-gigaxonin antibody, and the bottom row is a blot done in parallel with an anti-myc tag antibody.
Samples are run in duplicate. Scale bars indicate microns. Larger annotated images are available as
supplemental Figures 4.7 and 4.8 (p115).
4.5 Discussion
As a whole, these experiments provide critical proof-of-concept data that re-introduction of
gigaxonin into affected GAN-null cells resolves IF aggregates, which are a major hallmark
of the underlying disease pathology in mice and humans. This was demonstrated in vitro
in cultured GAN-null fibroblasts with the IF vimentin, and in vivo in GAN-null mice with
the IF peripherin. Moreover, the proteomic analysis of treated GAN primary fibroblasts
provides important information with regards to more global changes (besides IFs) that occur
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in treated cells, which provides further insights into both the mechanism of the rescue and
the basic biology of gigaxonin’s function. While several reasonable conclusions can be
drawn from these studies, the results should be considered within the appropriate context;
namely that gigaxonin was overexpressed using the CMV promoter. Also, for the proteomic
analysis, it is important to consider that this analysis was restricted to a single time point
of 3 days post-infection. The timing was restricted to allow enough time for gigaxonin
expression without prolonged maintenance of the dividing fibroblast culture (which would
dilute transgene-expressing cells). Our results indicated that gigaxonin may play a role
in multiple pathways affecting cytoskeleton regulation, and thus it may take longer than
practical for an in vitro experiment to observe all proteome-level changes, especially for
proteins with long half-lives. Therefore we can only interpret the presence of proteome-
level changes, but not the absence of change.
4.5.1 Proteome analysis
Mussche et al. had previously done a proteomic analysis of GAN patient fibroblasts com-
pared to normal control fibroblasts [23]. One interesting finding is that three proteins that
were previously found to be disregulated in GAN patients compared to healthy controls
again showed altered expression levels in the AAV2/GAN-treated cells, only the regula-
tion was seen in the other direction towards normal levels. This is the case for galectin-1,
aminopeptidase N (APN), and FK506-binding protein 9. Interestingly, a set of proteins pre-
viously found to be differentially regulated in GAN patients versus controls was found not
altered in response to the AAV2/GAN treatment (Supplemental Table 4.3, p118). Those
results would suggest that while some of the disregulated proteins in GAN can rapidly
return to homeostatic levels in response to gigaxonin reintroduction, other changes may
take longer to correct or may represent irreversible changes. However, since the proteomic
changes in our experiment can be correlated to resolution of IF aggregates within the 3-4
day experimental timeframe, we can speculate that the proteins that modulated in response
to gigaxonin reintroduction are important in the GAN disease mechanism. Especially a
role for galectin-1 was previously proposed for GAN, as a regulator of cytoskeleton reor-
ganization [23]. The FK506BP9 belongs to the FK506BP family, which are peptidyl prolyl
isomerases that function as protein folding chaperones and are also involved in the aggrega-
tion process of alpha-synuclein clusters in Parkinson disease [28]. APN is a transmembrane
zinc-binding metallo-ectopeptidase that removes amino acids from unblocked N-termini of
bioactive peptides or proteins. It plays a role in cell migration and invasion of extracellular
matrix, angiogenesis and regulation of extrinsic regulatory factors of tumor growth, all con-
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ditions where remodeling of the cytoskeleton is required. The introduction of the correct
GAN gene will activate several processes in reaction to this new gene which reflects in up or
down regulation of a set of proteins (Table 4.1). The majority of the differentially regulated
proteins in the present study were previously identified in the proteomic analysis done by
Mussche et al., but were not found to be disregulated in GAN fibroblasts (indicated (∗) in
Table 4.1) [23]. This may indicate that they are associated with GAN overexpression, rather
than a return to a normal state. Some of these proteins were found to be associated with
several ubiquitin specific peptidases [29], and the ubiquitin-proteasome system, as listed in
Supplemental Table 4.2. Ubiquitin-specific peptidases are a class of deubiquitinating en-
zymes that help to regulate many cellular processes by controlling the amount of the protein
ubiquitin, through removing ubiquitin from a large variety of substrates [30; 31]. But tar-
gets, interactions and specific functions of deubiquitinating enzymes are poorly understood.
However it is possible that in response to GAN overexpression they play a compensatory
role by deubiquitination of targeted proteins.
Since GAN fibroblasts don’t display a rise in the overall abundance of vimentin [23]
and there was no change in overall vimentin levels following AAV2/GAN treatment (Sup-
plemental Table 4.4), we can speculate that the absence (and reintroduction) of gigaxonin
is affecting the cytoskeletal organization of vimentin, rather than its total intracellular lev-
els. The reduction of vimentin aggregates seen in transduced GAN fibroblasts indicates that
there is a fairly rapid reorganization of the cytoskeleton. Several disregulated proteins were
found associated with cytoskeleton reorganization (Table 4.1). Actin-related protein 2/3
complex subunit 3 functions as a component of the Arp2/3 complex, which is involved in
the regulation of actin polymerization and, together with an activating nucleation-promoting
factor (NPF), mediates the formation of new branched actin networks. This is important
during centrosome reorientation before cytokinesis, and cytoskeletal organization. Destrin
is an actin-depolymerizing protein, which severs actin filaments (F-actin) and binds to actin
monomers (G-actin) and profilin4. Transgelin is an actin-crosslinking protein found in fi-
broblasts and muscle. The abundance of cytoskeleton proteins that were found changed in
response to gigaxonin re-expression in this study reinforces gigaxonin’s role in cytoskele-
ton organization, but a full model for all the interactions and pathways still remains elusive.
Another pertinent observation is the upregulation of several ER resident proteins in GAN-
treated fibroblasts, in particular enzymes involved in protein synthesis, maturation and post-
translational modification, in addition to enzymes involved in endocytosis and recycling.
This reflects a general return to a functional state of the fibroblast.
112 RESULTS
4.5.2 Potential for GAN gene therapy
GAN is a progressively fatal sensory and motor neuropathy. It begins with the loss of distal
motor and sensory function, and as the disease progresses into the teenage years individuals
will gradually lose the ability to walk and use their arms. The disease is normally fatal in
the 3rd decade of life, often due to respiratory dysfunction or other complications normally
associated with a motor neuron disease. While GAN patients will display IF cytoskeletal
disorganization in many cell types in their body, successful treatment of the spinal cord and
brainstem would be hypothesized to treat the most serious disease phenotypes.
AAV9 vector administration into the vein, lumbar intrathecal space, and cisterna magna
have all been validated as ways to achieve broad CNS transgene delivery in large animal
models [32–34]. In the present study, cisterna magna injections were modeled in mice to
investigate a potential therapeutic approach for GAN that might be translatable to humans.
Although the behavioral phenotype of these mice is very mild and therefore not amenable to
assess a phenotypic rescue, they do display extensive IF aggregates. Encouragingly, there
was widespread resolution of peripherin aggregates throughout the brainstem and spinal
cord at 3 weeks following vector delivery. Considering that IF accumulations (including
peripherin) are present as early as 3 months of age in GAN mice [16], this result demon-
strates the ability of the gigaxonin gene to resolve long-standing IF aggregates that are a
hallmark of the disease pathology, in vivo.
While the present studies implicate gigaxonin for a role in cytoskeleton organization,
future studies are still needed to understand the exact cellular pathways affected by gigax-
onin. In terms of a future gene therapy for GAN, the present study indicates the potential
of gigaxonin gene replacement as a therapeutic approach for GAN. However, the use of
a strong promoter and a single-stranded AAV genome are not ideal. Since gigaxonin is
normally expressed at very low levels [11], overexpression-related toxicity is a concern and
our studies suggest this possibility (See indicated changes in Table 4.1 and Supplemental
Figure 4.6), so a weak promoter may be sufficient and preferred. Self-complementary (sc)
AAV vectors would greatly increase the transduction efficiency with AAV [35; 36] which
could be critical for human translation, although the 1.9 kb size of the gigaxonin gene may
be challenging to fit in a ˜2.2 kb scAAV genome with the appropriate transcriptional con-
trol elements. We speculate that these improvements would play an important role in the
translation of these findings to future human application.
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Supplemental data
Figure 4.5: iTRAQ experimental workflow for comparing the proteome of AAV-GAN transfected
fibroblasts and AAV-GFP fibroblasts.
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Figure 4.6: Cell counts post-treatment. Three to four days post infection with either vehicle (mock),
AAV2/GAN (GAN), or AAV2/GFP (GFP) vector, cells were fixed and immunostained for GFP and
vimentin, then counterstained with DAPI. Each color bar represents a separated experiment, where
mock, GAN, and GFP treatments were done in parallel. The black bar is a normal human fibroblast
cell line, the 3 blue bars are the P1 cell line, and the 2 red bars are the P3 cell line. DAPI-positive
nuclei were counted in 4 random fields per treatment at 5x magnification, and values are expressed
relative to the mock treatment in each experiment. P values were calculated by a Student’s T Test,
comparing the average fold change in cell number across the 5 GAN fibroblast treatments (2 tails,
equal variance).
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Supplemental Figure 3.  Peripherin aggregates in the brainstem of knock-out GAN mice.   Higher 
magnification representative images of (A) KO untreated GAN mouse, (B) heterozygous mouse, (C) KO GANJ 
mouse treated with an AAV9/GAN vector, and (D) KO GANJ mouse treated with an AAV9/GAN vector. Scale 
bar is 100 microns.  Examples of peripherin aggregates, which are densely stained punctate foci, are circled.   
A B 
C D 
Figure 4.7: Peripherin aggr gates in the brainstem of knock-out N mice. Higher magnification
representative images of (A) KO untreated GAN mouse, (B) heterozygous mouse, (C) KO GANJ
mouse treated with an AAV9/GAN vector, and (D) KO GANJ mouse treated with an AAV9/GAN
vector. Scale bar is 100 microns. Examples of peripherin aggregates, which are densely stained
punctate foci, are circled.
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Supplemental Figure 4.  Peripherin aggregates in the dorsal spinal cord of knock-out GAN mice. Higher 
magnification representative images of (A) KO untreated GAN mouse, (B) heterozygous mouse, (C) KO 
GANJ mouse treated with an AAV9/GAN vector, and (D) KO GANJ mouse treated with an AAV9/GAN vector. 
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Figure 4.8: Peripherin aggregates in the dorsal spinal cord of knock-out GAN mice. Higher mag-
nification representative images of (A) KO untreated GAN mouse, (B) heterozygous mouse, (C)
KO GANJ mouse treated with an AAV9/GAN vector, and (D) KO GANJ mouse treated with an
AAV9/GAN vector. Scale bar is 100 microns. Examples of peripherin aggregates, which are densely
stained punctate foci, are circled in panel A.
116 RESULTS
Figure 4.9: IF aggregate in non-transduced areas of treated mice. For the GAN mice shown in
Figure 4.4, peripherin aggregates were still visible in the dorsal raphe nucleus (row A). NF-H aggre-
gates were also visible in the cortex (row B) and striatum (row C) of treated and untreated knock-out
mice, but not heterozygous controls. Two examples of aggregates are circled in each panel. Scale
bar for all panels is shown in the lower left panel and is 100 microns.
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Table 4.2: Differentially regulated proteins associated with ubiquitin specific peptidases (USP) and
the proteasome system (UPS), according to [29] or protein interaction database STRING.
Acc. No.a Protein name Interacting proteins Function
Q99497 Protein DJ-1 USP19 Deubiquitination that regulates the
degradation of various proteins.
Parkin E3 ubiquitin ligase.
P23284 Peptidyl-prolyl
cis-trans isomerase B
USP16 Deubiquitinates histone H2A.
USP21 Regulates gene expression via histone
H2A deubiquitination.
USP-1 association factor 1 Regulator of deubiquitinating com-
plexes.
Q14315 Filamin-C USP25 Deubiquitination.
USP53 No peptidase activity (inactive).
P60660 Myosin light
polypeptide 6
USP46 Deubiquitination, and interaction
with USP-1 association factor 1.
USP45 Deubiquitination.
USP18 Deubiquitination.
P23588 Eukaryotic transla-
tion initiation factor
4B
USP7 Deubiquitination of several proteins.
USP11 Deubiquitination, and role in the reg-
ulation of pathways leading to NF-
kappa-B activation.
P55072 Transitional endo-
plasmic reticulum
ATPase (VCP)
USP13 Deubiquitination.
USP50 No peptidase activity (inactive).
ataxin-3 Deubiquitination.
Ubiquitin fusion degrada-
tion 1 like
Essential component of the
UPS,regulates spindle disassem-
bly at the end of mitosis.
UBXN1, 4 and 6. Involved in the UPS.
Ubiquitination factor E4B. Binds ubiquitin, catalyzes ubiquitin
chain assembly in conjunction with
E1, E2, and E3.
VCP interacting protein 1 Deubiquitination.
a Uniprot accession number.
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Table 4.3: Proteins not differentially regulated in response of gigaxonin gene transfer, though
previously found disregulated in GAN fibroblasts.
Acc.
No.a
Protein name Ratio
AAV2/GAN
vs AAV2/GFP
(p>0,05)
Ratio GAN pa-
tients vs controls
(p<0,05) [23]
O95881 Thioredoxin domain-containing protein
12
1,07 1,35
P47914 60S ribosomal protein L29 1,00 1,66
P61927 60S ribosomal protein L37 1,16 1,56
Q00341 Vigilin 1,10 0,49
P20700 Lamin-B1 0,75 0,62
O94979 Protein transport protein Sec31A 1,15 0,64
Q15459 Splicing factor 3 subunit 1 1,09 0,65
Q08211 ATP-dependent RNA helicase A 1,12 0,73
Q96CT7 Coiled-coil domain-containing protein
124
1,44 1,34
O75083 WD repeat-containing protein 1 1,07 0,47
a Uniprot accession number.
Table 4.4: Summary of all mice examined.
Straina Genotype Agea Treatedb N Peripherinc NF-Hd
GAN∆1 +/- 17-18 no 3 no no
GAN∆1 -/- 16-17 no 4 yes yes
GAN∆1 -/- 17 yes 2 no yes
GAN∆3−5 +/- 18-20 no 5 no no
GAN∆3−5 +/- 24 no 1 no no
GAN∆3−5 -/- 8 no 3 yes NTe
GAN∆3−5 -/- 18-20 no 6 yes yes
GAN∆3−5 -/- 24 no 1 yes yes
GAN∆3−5 -/- 21 yes 2 no yes
a in months
b 7.2x1010 vg of ssAAV9/CMV-GAN vector injected into the cisterna magna, assessed 3 weeks
post-injection
c peripherin aggregates present in the spinal trigeminal nucleus of the brainstem
d NF-H aggregates present in the cortex and striatum
e NT = not tested
GAN - gene transfection 119
References
[1] B.O. Berg, S.H. Rosenberg, and A.K. Asbury. Giant axonal neuropathy. Pediatrics, 49(6):894–
899, June 1972.
[2] E. Demir, P. Bomont, S. Erdem, L. Cavalier, M. Demirci, G. Kose, S. Muftuoglu, A.N. Cakar,
E. Tan, S. Aysun, M. Topcu, P. Guicheney, M. Koenig, and H. Topaloglu. Giant axonal neu-
ropathy: clinical and genetic study in six cases. Journal of Neurology Neurosurgery and Psy-
chiatry, 76(6):825–832, 2005.
[3] A. Nalini, N. Gayathri, T. C. Yasha, S. Ravishankar, A. Urtizberea, Kathrin Huehne, and Bernd
Rautenstrauss. Clinical, pathological and molecular findings in two siblings with giant axonal
neuropathy (gan): report from india. Eur J Med Genet, 51(5):426–435, 2008.
[4] S.D.J. Pena, M. Opas, K. Turksen, V.I. Kalnins, and S. Carpenter. Immunocytochemical stud-
ies of intermediate filament aggregates and their relationship to microtubules in cultured skin
fibroblasts from patients with giant axonal neuropathy. Eur.J.Cell Biol., 31(2):227–234, 1983.
[5] P. Bomont, L. Cavalier, F. Blondeau, C.B. Hamida, S. Belal, M. Tazir, E. Demir, H. Topaloglu,
R. Korinthenberg, B. Tuysuz, P. Landrieu, F. Hentati, and M. Koenig. The gene encoding
gigaxonin, a new member of the cytoskeletal btb/kelch repeat family, is mutated in giant axonal
neuropathy. Nat.Genet., 26(3):370–374, 2000.
[6] C. Bruno, E. Bertini, A. Federico, E. Tonoli, M.L. Lispi, D. Cassandrini, M. Pedemonte, F.M.
Santorelli, M. Filocamo, M.T. Dotti, A. Schenone, A. Malandrini, and C. Minetti. Clinical and
molecular findings in patients with giant axonal neuropathy (gan). Neurology, 62(1):13–16,
2004.
[7] H. Houlden, M. Groves, Z. Miedzybrodzka, H. Roper, T. Willis, J. Winer, G. Cole, and M.M.
Reilly. New mutations, genotype phenotype studies and manifesting carriers in giant axonal
neuropathy. Journal of Neurology Neurosurgery and Psychiatry, 78(11):1267–1270, 2007.
[8] O. Koop, A. Schirmacher, E. Nelis, V. Timmerman, P. De Jonghe, B. Ringelstein, V.M. Ra-
sic, P. Evrard, J. Gdrtner, K.G. Claeys, S. Appenzeller, B. Rautenstrauss, K. Hiffine, M.A.
Ramos-Arroyo, H. Wrle, J.S. Moilanen, S. HammanS, G. Kuhlenbdumer, and scipline: Clin-
ical Neurology; Neurosciences. Genotype-phenotype analysis in patients with giant axonal
neuropathy (gan). Neuromuscul.Disord., 17(8):624–630, 2007.
[9] G. Kuhlenbaumer, P. Young, C. Oberwittler, G. Hunermund, A. Schirmacher, K. Domschke,
B. Ringelstein, and F. Stogbauer. Giant axonal neuropathy (gan): Case report and two novel
mutations in the gigaxonin gene. Neurology, 58(8):1273–1276, 2002.
[10] C.L. Leung, Y. Pang, C. Shu, D. Goryunov, and R.K. Liem. Alterations in lipid metabolism
gene expression and abnormal lipid accumulation in fibroblast explants from giant axonal neu-
ropathy patients. BMC.Genet, 8:6–, 2007.
[11] D.W. Cleveland, K. Yamanaka, and P. Bomont. Gigaxonin controls vimentin organization
through a tubulin chaperone-independent pathway. Human Molecular Genetics, 18(8):1384–
1394, 2009.
[12] J.Q. Ding, J.J. Liu, A.S. Kowal, T. Nardine, P. Bhattacharya, A. Lee, and Y.M. Yang.
Microtubule-associated protein 1b: a neuronal binding partner for gigaxonin. J.Cell Biol.,
158(3):427–433, 2002.
[13] W. Wang, J.Q. Ding, E. Allen, P. Zhu, L. Zhang, H. Vogel, and Y.M. Yang. Gigaxonin interacts
with tubulin folding cofactor b and controls its degradation through the ubiquitin-proteasome
pathway. Curr.Biol., 15(22):2050–2055, 2005.
[14] J.Q. Ding, E. Allen, W. Wang, A. Valle, C.B. Wu, T. Nardine, B.X. Cui, J. Yi, A. Taylor, N.L.
Jeon, S. Chu, Y. So, H. Vogel, R. Tolwani, W. Mobley, and Y.M. Yang. Gene targeting of
120 RESULTS
gan in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired
retrograde axonal transport. Human Molecular Genetics, 15(9):1451–1463, 2006.
[15] E. Allen, J.Q. Ding, W. Wang, S. Pramanik, J. Chou, V. Yau, and Y.M. Yang. Gigaxonin-
controlled degradation of map1b light chain is critical to neuronal survival. Nature,
438(7065):224–228, 2005.
[16] Florence Dequen, Pascale Bomont, Genevie`ve Gowing, Don W. Cleveland, and Jean-Pierre
Julien. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in
mice with targeted deletion of gigaxonin exon 1. J Neurochem, 107(1):253–264, Oct 2008.
[17] P. Bomont and M. Koenig. Intermediate filament aggregation in fibroblasts of giant axonal
neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
Human Molecular Genetics, 12(8):813–822, 2003.
[18] J.W. Prineas, R.A. Ouvrier, R.G. Wright, J.C. Walsh, and J.G. Mcleod. Giant axonal neuropa-
thy - generalized disorder of cytoplasmic microfilament formation. J.Neuropathol.Exp.Neurol.,
35(4):458–470, 1976.
[19] D.D. Zhang, S.C. Lo, Z. Sun, G.M. Habib, M.W. Lieberman, and M. Hannink. Ubiquitination
of keap1, a btb-kelch substrate adaptor protein for cul3, targets keap1 for degradation by a
proteasome-independent pathway. J.Biol.Chem., 280(34):30091–30099, 2005.
[20] M. Furukawa, Y.Z.J. He, C. Borchers, and Y. Xiong. Targeting of protein ubiquitination by
btb-cullin 3-roc1 ubiquitin ligases. Nat.Cell Biol., 5(11):1001–1007, 2003.
[21] Steven J. Gray, Vivian W. Choi, Aravind Asokan, Rebecca A. Haberman, Thomas J. McCown,
and Richard Jude Samulski. Production of recombinant adeno-associated viral vectors and use
in in vitro and in vivo administration. Curr Protoc Neurosci, Chapter 4:Unit 4.17, Oct 2011.
[22] Steven J. Gray, Bonita L. Blake, Hugh E. Criswell, Sarah C. Nicolson, R Jude Samul-
ski, Thomas J. McCown, and Wuping Li. Directed evolution of a novel adeno-associated
virus (aav) vector that crosses the seizure-compromised blood-brain barrier (bbb). Mol Ther,
18(3):570–578, Mar 2010.
[23] Silke Mussche, Boel De Paepe, Joel Smet, Katrien Devreese, Willy Lissens, Vedrana Milic
Rasic, Matthew Murnane, Bart Devreese, and Rudy Van Coster. Proteomic analysis in gi-
ant axonal neuropathy: New insights into disease mechanisms. Muscle & Nerve, pages
10.1002/mus.23306–, 2012.
[24] D.N. Perkins, D.J.C. Pappin, D.M. Creasy, and J.S. Cottrell. Probability-based protein iden-
tification by searching sequence databases using mass spectrometry data. Electrophoresis,
20(18):3551–3567, 1999.
[25] K.A. Reidegeld, M. Eisenacher, M. Kohl, D. Chamrad, G. Korting, M. Blueggel, H.E. Meyer,
and C. Stephan. An easy-to-use decoy database builder software tool, implementing different
decoy strategies for false discovery rate calculation in automated ms/ms protein identifications.
Proteomics, 8(6):1129–1137, 2008.
[26] B. Snel, G. Lehmann, P. Bork, and M.A. Huynen. String: a web-server to retrieve and display
the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res., 28(18):3442–3444,
2000.
[27] Thibault Ganay, Alexia Boizot, Renaud Burrer, Jean Paul Chauvin, and Pascale Bomont.
Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice. Mol Neu-
rodegener, 6:25, 2011.
[28] M. Gerard, A. Deleersnijder, V. Daniels, S. Schreurs, S. Munck, V. Reumers, H. Pottel, Y. En-
gelborghs, C. Van den Haute, J.M. Taymans, Z. Debyser, and V. Baekelandt. Inhibition
of fk506 binding proteins reduces alpha-synuclein aggregation and parkinson’s disease-like
pathology. J.Neurosci., 30(7):2454–2463, 2010.
GAN - gene transfection 121
[29] M.E. Sowa, E.J. Bennett, S.P. Gygi, and J.W. Harper. Defining the human deubiquitinating
enzyme interaction landscape. Cell, 138(2):389–403, July 2009.
[30] A. D’Andrea and D. Pellman. Deubiquitinating enzymes: a new class of biological regulators.
Crit Rev.Biochem.Mol.Biol., 33(5):337–352, 1998.
[31] K.D. Wilkinson. Ubiquitination and deubiquitination: targeting of proteins for degradation by
the proteasome. Semin.Cell Dev.Biol., 11(3):141–148, June 2000.
[32] Sandra Duque, Be´atrice Joussemet, Christel Riviere, Thibaut Marais, Laurence Dubreil, Anne-
Marie Douar, John Fyfe, Philippe Moullier, Marie-Anne Colle, and Martine Barkats. Intra-
venous administration of self-complementary aav9 enables transgene delivery to adult motor
neurons. Mol Ther, 17(7):1187–1196, Jul 2009.
[33] T. Federici, J. S. Taub, G. R. Baum, S. J. Gray, J. C. Grieger, K. A. Matthews, C. R. Handy,
M. A. Passini, R. J. Samulski, and N. M. Boulis. Robust spinal motor neuron transduction
following intrathecal delivery of aav9 in pigs. Gene Ther, Sep 2011.
[34] Lluis Samaranch, Ernesto A. Salegio, Waldy San Sebastian, Adrian P. Kells, Kevin D. Foust,
John R. Bringas, Clementine Lamarre, John Forsayeth, Brian K. Kaspar, and Krystof S.
Bankiewicz. Adeno-associated virus serotype 9 transduction in the central nervous system
of nonhuman primates. Hum Gene Ther, 23(4):382–389, Apr 2012.
[35] Steven J. Gray, Valerie Matagne, Lavanya Bachaboina, Swati Yadav, Sergio R. Ojeda, and
R Jude Samulski. Preclinical differences of intravascular aav9 delivery to neurons and glia:
a comparative study of adult mice and nonhuman primates. Mol Ther, 19(6):1058–1069, Jun
2011.
[36] D. M. McCarty, H. Fu, P. E. Monahan, C. E. Toulson, P. Naik, and R. J. Samulski. Adeno-
associated virus terminal repeat (tr) mutant generates self-complementary vectors to overcome
the rate-limiting step to transduction in vivo. Gene Ther, 10(26):2112–2118, Dec 2003.

5
Proteomic analysis in cultured skin
fibroblasts from UCMD patients reveals
disturbed collagen I chaperone function
and increased formation of focal adhesions
Silke Mussche1, Nicolas Deconinck2, Arnaud Vanlander1, Boel De Paepe1,2, Corine
Gartioux3−5, Vale´rie Allamand3−5, Pascale Richard6, Joe´l Smet1, Bart Devreese7, Rudy
Van Coster1,2∗
1 Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium
2 Neuromuscular Reference Center, Ghent University Hospital, Ghent, Belgium
3 UPMC Univ Paris 06, UM 76, Institut de Myologie, IFR14, Paris F-75013, France
4 Inserm, U974, Paris F-75013, France
5 CNRS, UMR7215, Paris F-75013, France
6 AP-HP, Groupe Hospitalier Pitie´-Salpeˆtrie`re, UF Cardioge´ne´tique et Myoge´ne´tique, Service de Biochimie Me´tabolique, Paris, France
7 Laboratory for Protein Biochemistry and Biomolecular Engineering, Ghent University, Ghent, Belgium
∗Corresponding author: Rudy.VanCoster@UGent.be
This chapter is in preparation for submission to Neuromuscular Disorders
123
124 RESULTS
5.1 Abstract
Ullrich congenital muscular dystrophy (UCMD) is a severe neuromuscular disorder caused
by mutations in genes that code for collagen VI chains. The mutations result in a reduced
incorporation of collagen VI into the extracellular matrix of fibroblasts, the main collagen
VI secreting cells. The pathophysiological molecular mechanisms resulting from the de-
fective interaction of the cells with the extracellular matrix are not fully elucidated. It is
not clear how these mechanisms can lead to a mitochondrial dysfunction and ultimately
to cell death. Here, we present the results of a proteomic comparison between cultured
skin fibroblasts from patients with the G284R mutation in the COL6A1 gene and controls.
Altered expressions of twenty five proteins located in different cellular pathways were de-
tected. Changes were detected in (i) proteins that function as ER chaperone for pro-collagen
I, (ii) in proteins involved in the formation of focal adhesions, and (iii) in proteins involved
in calcium fluxes. Among the ER proteins that were upregulated in UCMD fibroblasts were
HSP47, cyclophilin B and calreticulin. The dysregulation of the proteins involved in cell-
matrix adhesions coincided with the increased number of focal adhesions detected in the
UCMD fibroblasts. These results provide information on downstream events that follow
from the collagen VI defect, and give more insight in the pathophysiological mechanisms
of this disease.
5.2 Introduction
Ullrich congenital muscular dystrophy (UCMD, OMIM ID:254090) is one of the more
common forms of congenital muscle dystrophy. The hallmarks of the disease are early on-
set muscle weakness, joint contractures affecting the proximal joints which contrast with
the striking hyperlaxity in the distal joints [1]. The muscle weakness is severe and children
typically either never achieve the ability to walk independently, or, walk independently for
short periods only. It is a genetic disorder with de novo dominant mutations accounting for
more than 50% of the mutations [1–3], aside from the initially described autosomal reces-
sive pattern [4; 5]. Together with Bethlem myopathy (BM), a milder myopathy displaying
autosomal dominant, as well as autosomal recessive and de novo mutations, they form the
opposite end points of a spectrum termed collagen VI-related myopathies [6–8].
Collagen VI (ColVI) is a ubiquitous extracellular matrix (ECM) protein that forms a
microfibrillar network in close association with the basement membrane in most tissues. It
is composed of three genetically distinct subunits: α1(VI), α2(VI) and α3(VI). All three
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chains have a central short triple helical domain, containing the repeating Gly-Xaa-Yaa
sequences, flanked by two large N- and C-terminal globular domains. Over 200 mutations
in all three genes have now been identified in both BM and UCMD [3; 9; 10]. The assembly
of ColVI is a complex multistep process. Equimolar association of the three subunits form
a triple helix that assembles further into disulphide bonded antiparallel overlapping dimers,
which in turn align to form tetramers, also stabilised by disulphide bonds [11–13]. These
tetramers are then secreted into the ECM where they form microfibrils.
The major function proposed for ColVI is to form an anchoring meshwork connecting
collagen fibres and other structures such as nerves and blood vessels to the surrounding
matrix [14; 15]. Other roles of ColVI include the promotion of adhesion, proliferation,
migration and survival of the cell [10]. Based on the clinical features seen in patients with
ColVI defects, it must play an important role in skeletal muscle, tendons and skin, and a
more subtle role in other tissues. In different tissues, ColVI is expressed by different types
of fibroblasts: in skeletal muscle by interstitial fibroblasts, in skin by skin fibroblasts, and
in tendons mainly by resident tendon fibroblasts [16; 17].
Although the identity of the molecular partners of ColVI in skeletal muscle basement
membrane is not fully described, ColVI was shown to interact with several ECM compo-
nents such as collagen I, II and IV, fibronectin, biglycan, fibulin2, decorin, microfibril as-
sociated glycoprotein-1, chondroitin sulfate proteoglycan 4, heparin and hyaluran (Bonne-
mann, 2011). Via interaction with ColIV and biglycan that both interact with the sarcogly-
can and dystroglycan complex [18] ColVI is indirectly linked to the dystrophin-associated
protein complex in the cell membrane of muscle fibers. ColVI was also shown to bind to
other cell surface receptors such as integrins [19–21], most likely forming an essential link
between cell surface receptors and several ECM components.
A relationship between the expression of ColVI and the pattern of organization of fi-
bronectin was reported in cultured fibroblasts [22]. Fibronectin is also an ECM protein that
interacts with several proteins including thrombospondin, ColVI, collagen I and integrins
[23–25]. It was consistently shown that fibronectin fibrils and ColVI microfilaments con-
nect to each other at discrete sites in the ECM [22]. In the absence of ColVI (COL6A1 null
mouse fibroblasts) an abnormal linear arrangement of fibronectin fibrils is seen, suggesting
a regulatory role for ColVI on the overall fibronectin matrix organization mainly when cell
cultures are confluent. Thus, in ColVI mutated fibroblasts two highly interconnected de-
fects may affect intracellular signaling: (i) the absence of ColVI itself, and (ii) the altered
organization of fibronectin fibrils.
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Immunohistochemical staining for ColVI in skeletal muscle from UCMD patients shows
either slight or marked reduction, total absence of the protein or disturbed interaction with
the basement membrane [26]. Today, the immuocytochemical detection of the absence or
alteration of ColVI secretion and intracellular presence in cultured skin fibroblasts [27] is a
very useful diagnostic method in combination with clinical symptoms and genetic analysis.
Recent experiments have demonstrated a latent defect of the mitochondrial permeabil-
ity transition pore (PTP), a conductance pore that spans the inner and outer mitochondrial
membranes, in cultured myoblasts from UCMD patients and in skeletal muscle from a
ColVI-deficient mouse model. Inappropriate opening of PTP plays a role in several forms
of cell death and may explain the apoptosis observed in UCMD patient and mouse cultured
muscle cells [28]. Recent work showed that patient-derived skin fibroblasts behave differ-
ently from myoblasts in that respect [29]. Subsequent work using the UCMD mouse model
suggests an impairment of autophagocytic flux in muscle cells from ColVI-deficient mice.
This phenomenon possibly contributes to the accumulation of defective mitochondria in
muscle cells [30].
The detection of pathogenic mutations in the COL6 genes in patients with UCMD and
BM represented an important step forward toward the elucidation of the pathogenesis of
both diseases. Nevertheless the underlying disease mechanisms remain poorly understood.
The objective of our study was to provide additional proteomics-based insight into the cel-
lular impact of the defective ColVI in cultured skin fibroblasts. To reach this objective, a
quantitative iTRAQ based LC-MALDI method [31] was used to compare the proteome in
cultured skin fibroblasts derived from UCMD patients with the proteome in control fibrob-
lasts.
5.3 Materials and methods
5.3.1 Patients and fibroblast cultures
Fibroblasts from four unrelated UCMD patients (one of which previously reported [32])
all carrying the heterozygous de novo p.G284R mutation in the COL6A1 gene were used.
All four patients presented a quite similar clinical UCMD picture: an early onset muscle
weakness, proximal joint contractures (in elbows, shoulders and knees), a distal joint hy-
perlaxity and an early onset scoliosis. In addition, 4 control fibroblast cell cultures were
used. Fibroblasts from skin biopsies were cultured in Medium 199 with Earle’s salts and L-
glutamine (PAA Laboratories, Linz, Austria) supplemented with fetal bovine serum (10%),
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kanamycin (1%) and penicillin-streptomycin (1%, Gibco, Carlsbad, California) and were
maintained at 37◦C 5% CO2. All fibroblast samples were grown until 90% confluence be-
fore harvesting the cells. Cells were scraped from the culture flask and subsequently washed
with 3.5 mM tris, 140 mM NaCl, 0.02% EDTA, centrifuged at 1200 rpm for 20 min at 4◦C,
and dry pellets were stored (-80◦C) until use.
5.3.2 iTRAQ reagent labeling and peptide separation
This was done according to [33] with some modifications. Briefly, proteins were extracted
by re-suspending each cell pellet in 400 µl lysis buffer, containing 0.5 M triethyl ammonium
bicarbonate (TEAB) and protease inhibitor cocktail (Roche, Vilvoorde, Belgium). The cell
lysates were sonicated and the supernatant was collected after centrifugation at 13000 g for
20 min at 4◦C. Protein concentrations were measured by the BCA protein assay (Thermo
Scientific, San Jose, California). Equal amounts of protein (50 µg) from each cell lysate
were used. Reduction, alkylation and iTRAQ labeling was performed according to the
manufacturer’s protocol using solvents included in the kit (AB SCIEX, Foster City, Cali-
fornia). Digestion of the protein samples with trypsin (Promega, Madison, Wisconsin) was
performed overnight at 37◦C, at a ratio of 1:50. Peptide samples were vacuum dried in a
speedvac (Thermo Savant, Holbrook, New York) and re-suspended in 40 µl of isopropanol
(80%) and 10 µl of 1 M TEAB pH 8.5. This 50 µl of the eight peptide samples was added
to the eight labels of the 8-plex iTRAQ kit as follows: control samples were pooled and
labelled with tags 117 and 119 and UCMD samples were labeled with tags 113-116 and a
pool with 118 and 121. This gives besides the biological replicates two technical replicates
of the sample and control group in the same experiment. After combining the eight iTRAQ-
labeled samples, the mixture was vacuum dried and dissolved in 20 mM HCOONH4, 2%
ACN at pH 10.
The labeled peptide mixture was separated on an Ettan liquid chromatography system
(GE Healthcare, Diegem, Belgium), using a Luna C18 column (2.0 mm i.d. x 150 mm
length x 5 µm, 100 A˚ column) (Phenomenex, Torrance, California). The buffer composi-
tions were 20 mM HCOONH4, 2% acetonitrile (ACN) at pH 10 for buffer A and 20 mM
HCOONH4, 80% ACN at pH 10 for buffer B. The used flow rate was 0.2 ml/min and the
elution gradient was as follows: 7 min 100% A, 60 min 0-50% B, 15 min 50-100% B, 10
min 100% B and 3 min 100% A. Fractions were collected every minute. After drying, the
fractions were re-dissolved in 0.1% formic acid for nano-LC/mass spectrometric analysis.
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5.3.3 Nano-liquid chromatography and mass spectrometry analysis
Analytical reversed phase (RP) separation of the labeled peptide mixture was performed
on an Ultimate Plus Dual-gradient Capillary/Nano-LC system (Dionex-LC Packings, Her-
cules, California) using a C18 column (75 µm i.d. x 150 mm length, 3 µm, 100A˚)( Dionex)
at a flow rate of 250 nl/min. The mobile phases were 5% ACN/0.05% trifluoroacetic acid
(TFA), pH 3 for buffer A and 80% ACN/0.05% TFA, pH 3 for buffer B. Peptides were re-
solved by gradient elution using a gradient of 0-50% buffer B over 25 min, 50-100% buffer
B over 10 min, 5 min of 100% of buffer B and 10 min of 100% buffer A. Column effluent
was monitored using a 3 nl UV flow cell (240 nm). The nano-LC system was connected to a
Probot fraction collector (Dionex). Column effluent was mixed in a 1:4 ratio with MALDI
matrix (4 mg/ml α-cyano-4-hydroxycinnamic acid, 70% ACN, 10 mM dibasic ammonium
citrate, 1% TFA, 10 fm/µl Glu-fibrinopeptide) by a T-junction. Fractions were collected
every 30 seconds directly on a MALDI target plate. The MALDI plates were analyzed by a
4800+ MALDI-TOFTOF Proteomics Analyzer (AB SCIEX). This mass spectrometer uses
a 200-Hz frequency tripled Nd:YAG laser operating at a wavelength of 355 nm. A plate
calibration was performed using the 4700 calibration mixture with a mass tolerance of 0.5
m/z. The MSMS mode was calibrated with a mass tolerance of 0.1 m/z. Additionally, MS
spectra were internally calibrated with Glu-fibrinopeptide (1552.62 m/z). MS data were ac-
quired in the reflector positive mode over a mass range of 900-3500 m/z, by accumulation
of 1000 laser shots per spectrum. The eight highest precursor masses in each MS spectrum
with a S/N threshold of minimum 50, were selected for fragmentation and the fraction-to-
fraction mass tolerance was set to 200 ppm. MS/MS data were acquired with 2000 laser
shots per spectrum, using 1keV collision energy and air as the collision gas. Each plate was
analyzed twice by reinterpretation of the MS spectra with a method containing an exclusion
list from initial MS/MS data to avoid analyzing peptides more than once.
5.3.4 Database searching and data analysis
Data analysis was performed with the software package ProteinPilot 4 (AB SCIEX). All
MS/MS spectra were searched against the Swissprot Homo sapiens database. The toler-
ance used for matching was 0.1 amu. The Paragon algorithm in ProteinPilot was used for
peptide identification and results were subsequently processed by the Pro Group algorithm.
Search parameters included iTRAQ labeling at the N-terminus and lysine residues, cysteine
modification by MMTS, digestion by trypsin (including two missed cleavages allowed) and
methionine oxidation as a variable modification. In addition the biological modification list
included in ProteinPilot was included also containing hydroxylation of lysine and proline,
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common modifications in collagens. For quantification with iTRAQ isotope labeling, the
corresponding ‘correction factors’ were considered. Normalization of the ratios was per-
formed by the median ratio. Isoform specific identification and quantitation was carried out
by selecting unique peptides and excluding all shared peptides from quantitation. Proteins
identified with >95% confidence (Protscore >1.3) were used for further analysis. Search-
ing a concatenated database containing both forward and shuffled decoy sequences allowed
estimation of the false discovery level [34]. The 95% confidence level (p<0.05) was used
to indicate significant protein abundance differences between control and patient groups.
The function, interactions and localization of the differential regulated proteins were stud-
ied based on information in databases such as Nextprot, Swiss-Prot, STRING [35] and the
Human Protein Reference Database.
5.3.5 Western blot
For validation of the proteins found by iTRAQ, fibroblast protein extracts of each sample
described above were separated by SDS-PAGE on a 10% polyacrylamide gel. Proteins were
transferred by electroblotting onto a nitrocellulose membrane (Amersham Biosciences, Up-
psala, Sweden). Non-specific antibody binding was blocked using 5% non fat dry milk
(Bio-Rad, Nazareth, Belgium) in PBS-T (phosphate-buffered saline + 0.1% Tween 20). Im-
munoblotting was carried out with primary antibodies against serpin H1 (HSP47) (Abcam,
Cambridge, UK) and β-actin (Abcam) overnight at 4◦C. Blots were subsequently washed in
PBS-T and incubated with a secondary antibody (HRP anti-mouse IgG and HRP anti-rabbit,
GE Healthcare). Bound antibodies were visualized using SuperSignal® West Femto Max-
imum Sensitivity Substrate kit (Thermo Scientific) and exposure to CL-XPOSURE FILM
(Thermo Scientific). The intensity of the protein bands was quantified using the Quantity
One imaging software (Bio-Rad).
5.3.6 Immunofluorescent staining of focal adhesion points
Fibroblast cultured on glass chamber slides till a confluence of approximately 60%, were
fixed in ice-cold acetone for 2 minutes. Slides were blocked with 2.5% BSA in PBS
for 30 min. Slides were incubated with 1.6 µg/ml rabbit monoclonal anti-vinculin (clone
42H89L44, Invitrogen) for 3.5 hours at room temperature and subsequently with 4 µg/ml
AlexaFluor488-labeled donkey anti-rabbit (Invitrogen) for 30 minutes. Slides were mounted
with vectashield containing dapi (Vector) and visualized with a fluorescence microscope
(Carl Zeiss). In four cells per patient, focal adhesion points were quantified by converting
images to brightfield and the touch count tool in the CellF software (Olympus), and mean
130 RESULTS
values and standard deviation were calculated. Differences were considered statistically
significant when student t-tests gave p-values below 0.05.
5.3.7 ColVI immunolabeling
Fibroblasts were cultured at confluence in DMEM (Gibco) supplemented with 10% FBS
and 0.25mM ascorbic acid for 5 days, as described by Demir et al [36]. Cells were then
fixed with 4% PFA and immunolabeling against COLVI and fibronectine was subsequently
performed as described by Hicks et al. [27]. Slides were observed with an Axioplan 2
microscope (Zeiss) equipped with a HBO 100 mercury lamp (Zeiss) and representative
images were obtained using the Metaview software (Roper Scientific).
5.3.8 Apoptosis stain
To identify apoptotic cells in the fibroblast cultures, cells were stained using the ApoTarget
kit (Invitrogen) according to the manufacturer’s instructions. Live fibroblasts were visu-
alized under a fluorescence microscope (Carl Zeiss), identifying early apoptotic cells as
annexin V-FITC positive, and late apoptotic or necrotic cells as annexin V-FITC and pro-
pidium iodide double positive. A minimum of 75 cells was scored per patient, and mean
values and standard deviation were calculated. Differences were considered statistically
significant when student t-tests gave p-values below 0.05.
5.3.9 JC-1 fluorescent stain
Skin fibroblasts (below 9 passages) cultured on glass chamber slides were incubated with
5 µg/ml of 5,5’,6,6’-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) in the culture
medium for 30 min at 37. After three successive washes with PBS for 5 min each, life
fibroblasts were visualized under a fluorescence microscope (Olympus), detecting red and
green fluorescent emission separately using optical filters. JC-1 is a cationic dye that in-
dicates mitochondrial polarization by shifting its fluorescence emission from green to red,
through the formation of red fluorescent J-aggregates. Red over green fluorescence ratios
were quantified by converting images to brightfield and measuring the average grey scale
(CellF software, Olympus). Ten 400x microscopic fields were measured per chamber and
mean values and standard deviation were calculated. Differences were considered statisti-
cally significant when student t-tests gave p-values below 0.05.
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5.4 Results
Immunolabeling with a polyclonal antibody against ColVI revealed clear intracellular label-
ing as frequently observed in UCMD fibroblasts and reduced incorporation of ColVI into
the extracellular matrix around the cultured skin fibroblasts cells from all patients when
compared to fibroblasts from control individuals (Figure 5.1). The fibronectin network was
also affected in all patients, to variable degrees.
Protein extracts from eight cultured fibroblast cell lines (four controls and four pa-
tient cultures) were digested with trypsin and iTRAQ-labeled followed by RP-RP LC and
MALDI-TOFTOF MS/MS analysis for identification and quantitation. All RP-LC MALDI-
TOFTOF runs were analyzed using the ProteinPilot software (ABSCIEX), resulting in
28696 spectra, searched against 40763 proteins in the database. An identity confidence
cut-off of 95% (Protscore >1.3) was employed resulting in identification of 9315 peptides
leading to 663 proteins. Searching a decoy database containing both forward and shuffled
sequences allowed estimation of a false positive rate of 0.5% at the protein level. Contam-
inant proteins, decoy hits, proteins without all eight iTRAQ were removed from the final
list. The iTRAQ protein ratios reported here are the average ratios calculated from the ratios
of the individual peptides determined for each protein. A total of 663 proteins were identi-
fied with >95% confidence, and quantified from the total cell lysate. Twenty-five proteins
were found significantly regulated (p<0.05) (Table 5.1). These differential regulated pro-
teins were further analyzed according to their function, interaction and localization. Based
on those findings we were able to detect the molecular changes in some important cellular
pathways associated with UCMD: upregulation of ER chaperones, protein changes in cell-
matrix adhesion structures and dysregulation of proteins involved in calcium regulation.
Western blot analysis using antibodies against HSP47 and performed on the four UCMD
cell cultures showed an average 2.5 fold upregulation compared to controls, confirming the
proteomics experiments (Figure 5.2).
Immunofluorescent staining for vinculin showed a significant increase of focal adhe-
sions in UCMD fibroblasts compared to the four control cell cultures (Table 5.2 and Figure
5.3).
Differences in the number of apoptotic cells were not observed in the UCMD fibroblast
cultures when compared to controls (Table 5.3). The mitochondrial membrane potential
(∆ψ) was slightly but significantly reduced in UCMD fibroblasts (Table 5.3).
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Figure 5.1: Immunolabelling of ColVI and fibronectin in cultured skin fibroblasts from a control
individual (top panels) compared to patients. A polyclonal antibody against ColVI (red, left panels)
revealed clear intracellular labeling and reduced incorporation of ColVI into the extracellular matrix
around the cultured skin fibroblasts cells from all patients. A higher magnification of these ColVI
images is given (red, right panels). A monoclonal antibody against fibronectin (green, right panels)
showed a slightly altered organization of the protein in ColVI-deficient fibroblasts in all patients, to
variable degrees. Insets show staining of nuclei with DAPI. Bar = 100 µm.
Ullrich congenital muscular dystrophy 133
Table 5.1: Proteins differentially expressed between UCMD patients and controls.
IDa Protein name nb %Covc P/Cd pVale
Endoplasmic reticulum (ER) and collagen related proteins
P50454 HSP47 (Serpin H1) 14 53.4 1.37 0.0109
P23284 Cyclophilin B (Peptidyl-prolyl cis-trans iso-
merase B)
23 89.4 1.65 0.0017
P27797 Calreticulin 23 45.1 1.40 0.0304
P14174 Macrophage migration inhibitory factor (Mif) 8 43.5 0.53 0.0196
P02452 Collagen alpha-1(I) chain 91 70.6 1.65 0.0000
P08123 Collagen alpha-2(I) chain 58 68.2 1.53 0.0000
Focal adhesion (FA) associated proteins
P07996 Thrombospondin-1 7 18.2 0.66 0.0077
Q15149 Plectin-1 6 28.5 1.54 0.0019
Q13813 Spectrin alpha chain, brain 21 2.7 1.26 0.0061
P26038 Moesin 15 67.1 1.59 0.0001
Other cytoskeleton related proteins
P27816 Microtubule-associated protein 4 22 49.1 0.78 0.0179
O75347 Tubulin-specific chaperone A 5 73.2 0.63 0.0315
P16949 Stathmin 10 88.6 0.62 0.0022
Annexin and Ca2+ associated protiens
P07355 Annexin A2 37 84.1 1.69 0.0020
P08758 Annexin A5 16 55 1.26 0.0134
Q09666 Neuroblast differentiation-associated protein
AHNAK
252 85.7 1.22 0.0000
Others
P04179 Superoxide dismutase [Mn], mitochondrial 7 35.6 0.39 0.0001
P53999 Activated RNA polymerase II transcriptional
coactivator p15
4 61.4 0.57 0.0421
Q00839 Heterogeneous nuclear ribonucleoprotein U 5 34.3 1.37 0.0076
P09936 Ubiquitin carboxyl-terminal hydrolase
isozyme L1
4 43.1 0.32 0.0020
P06733 Alpha-enolase 20 65.2 1.30 0.0206
P24534 Elongation factor 1-beta 11 42.2 0.76 0.0367
P29401 Transketolase 17 39 0.55 0.0000
P14618 Pyruvate kinase isozymes M1/M2 13 47.3 1.27 0.0302
P05387 60S acidic ribosomal protein P2 6 84.4 1.75 0.0228
a Uniprot accession number.
b Number of peptides.
c Percent protein coverage.
d Ratio patients over controls;
e p-value (<0.05 to be significant)
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Figure 5.2: Western blot and qPCR analysis for HSP47. (A) Western blot analysis for HSP47 in
fibroblasts from 4 UCMD patients and 4 controls. (B) Densities of the bands were first measured
and normalized against β-actin for each lane. Then ratios were calculated for each patient by di-
viding each actin-normalized patient value by the actin-normalized control-group value. Note the
upregulation of HSP47 in the 4 patients and the patient pool. SD = 0.92, p = 0.01.
Table 5.2: Focal adhesion points in fibroblast cell cultures
Sample Focal adhesion pointsa
Control 1 65±21
Control 2 41±7
Control 3 35±6
Control 4 46±13
Controls 47±13
UCMD1 77±16
UCMD2 85±12
UCMD3 80±22
UCMD4 84±18
UCMD 82±7∗
a Mean number of focal adhesion points per cell ± standard deviation are
given, measured as vinculin positive structures. Number of focal adhe-
sion points was found significantly increased in the patients (∗p=0.01).
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Figure 5.3: The focal adhesion point visualized as vinculin positive structures were significantly
increased in the UCMD patients (see Table 5.2). A representative cell from an UCMD patient (A)
and a control (B) are shown. Bar = 50 µm. The focal adhesion structures are visible as thin green
lines/spots at the cell membrane.
Table 5.3: Viability of fibroblast cell cultures
Apotosis Mitochondrial ∆ψ
Sample early apoptotic
cells
late apoptotic or
necrotic cellsa
JC-1 ratio
Control 1 6/77 4/77 2.06±0.01
Control 2 5/104 15/104 2.12±0.66
Control 3 6/159 10/159 2.11±0.12
Control 4 2/136 6/136 NA
Controls 5±3% 7±5% 2.10±0.03
UCMD 1 5/87 9/87 1.81±0.25
UCMD 2 2/102 8/102 1.56±0.24
UCMD 3 9/207 6/207 NA
UCMD 4 2/75 1/75 1.45±0.25
UCMD 4±2% 6±4% 1.61±0.18∗
No differences were observed in the number of apoptotic cells in fibroblast cultures from controls
and from UCMD patients. The mitochondrial membrane potential (∆ψ), quantified as the relative
JC-1 red over green fluorescence ratio, was significantly reduced in patients (∗p=0.04).
5.5 Discussion
Fibroblasts are the main cell type of connective tissues and are the most important ColVI
secreting cells [17]. In addition to muscular dystrophy, defects in ColVI also cause typical
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abnormalities in other tissues, such as skin and tendons. Patients frequently show abnor-
mal scar formation, poor wound healing, striae distensae and abnormal texture of the skin
[38; 39]. That makes fibroblasts a very convenient cell type for studying UCMD patho-
physiology.
In the proteome analysis presented here, the intracellular protein fraction was extracted
from the scraped cultured cells after removing the culture medium. The three ColVI chains
(α1, α2 and α3) could be identified and quantified in all samples, representing the intra-
cellular pool of ColVI. We observed no change in the relative amount of protein for these
three subunits when compared to the control samples. The intracellular presence of ColVI
was also clearly observed by the imunocytochemical detection of ColVI in the UCMD fi-
broblasts (Figure 5.1).
Twenty five proteins showed different abundance in all four UCMD fibroblast samples
as compared to control samples. According to their function and localization, the majority
of these proteins could be grouped into specific cellular pathways linked to UCMD (Figure
5.4). Most important are the formation of focal adhesions and the increased collagen I
chaperone function.
Figure 5.4: Overview of the dysregulated proteins in several pathways in UCMD fibroblasts.
Three endoplasmic reticulum (ER) proteins were significantly upregulated: (i) ser-
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pinH1, also known as heat shock protein 47 (HSP47) or collagen binding protein 1, (ii)
peptidyl-prolyl cis-trans isomerase B, also known as cyclophilin B (cypB) and (iii) calreti-
culin (CRT).
Heat shock proteins were shown earlier to be involved in neuromuscular conditions
[40]. Moreover, overexpression of HSP47 has already been discribed in UCMD patients
[45]. HSP47 is a collagen-specific glycoprotein residing in the ER of the fibroblast and
acts as a molecular chaperone stabilizing the triple-helix of procollagen [41]. It also has
a role in secretion of collagen [42; 43]. Enhanced expression of HSP47 is seen in stress
conditions such as heat shock and in liver fibrosis and keloid formation [44]. Keloid is
excessive scar tissue often seen in patients with UCMD. Our results confirm the findings of
Higuchi et al. who showed overexpression of HSP47 in connective tissue but not in skeletal
muscle cells from UCMD patients [45]. They demonstrated that HSP47 is synthesized
in the collagen secreting cells and that its expression paralleled the collagen production
and secretion. In another study, the association between increased collagen deposition and
increased expression of both HSP47 and collagen I was documented in fibrotic diseases
[46]. Silencing of HSP47 leads to reduced collagen synthesis [47]. This could explain why
in our proteomics study also collagen I (α1 and α2) was found significantly upregulated.
The increased level of HSP47 was confirmed by western blot and qPCR (Figure 5.2), further
implicating HSP47 in the collagen production in UCMD fibroblasts.
CypB is a cyclosporin A-binding protein and a peptidyl prolyl cis-trans isomerase. To-
gether with two other proteins cypB forms an intracellular collagen-modifying complex
that 3-hydroxylates proline at position 986 in the α1 chains of collagen I. It facilitates the
folding of pro-collagen I following stabilization by HSP47. CypB is important for transport
of collagen I from the ER to the Golgi [48] and for its secretion into the extracellular space.
Mutations in cypB were reported in patients with osteogenesis imperfecta, a disease caused
in most patients by a defect in collagen I. CypB protects cells against ER-stress [49] and
interacts with proteins that regulate Ca2+ homeostasis such as CRT [50]. CypB is involved
in reduction of Ca2+ release from the ER, in ROS production and in bax translocation
into the mitochondria. It resembles cypD that resides in the mitochondria. Merlini et al.
showed that when cyclosporin A binds to cypD, the PTP closes and apoptosis decreases in
UCMD [51]. Cyclosporin A can also bind to cypB, but the effect is unknown. We could not
demonstrate an increase in the number of apoptotic cells in our UCMD fibroblast cultures
(supplementary data). However the study mentioned above utilized muscle cells, a tissue in
which mitochondria play a more prominent role.
A third ER protein, calreticulin (CRT), was also found upregulated. CRT is an impor-
tant protein with multiple functions at several subcellular locations (ER, cytoplasm, cell
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surface, ECM). In the ER, it functions as a chaperone for monoglucosylated glycoproteins
and also as a calcium storage protein as it has several calcium-binding domains. Calcium
fluxes are important for a variety of cellular functions including those involved in cell sig-
naling through integrins. Total CRT expression is up-regulated by many forms of cellular
stress, among which depletion of the Ca2+ stores. Upregulation of CRT in fibrotic tissues
was reported earlier [52]. CRT also plays a role in collagen I expression, as it regulates
its transcription, translation and transit from the ER into the ECM. CRT at the cell surface
controls remodeling of the ECM through direct binding to cell adhesion receptors, throm-
bospondin (TSP1), α2β1integrin and glycoprotein VI [53; 54]. From the cell surface, CRT
regulates multiple cellular processes such as apoptotic clearance of cells, focal adhesion
turnover, proliferation and migration. In addition, CRT has an indirect effect on the colla-
gen matrix by regulating the fibronectin expression [55]. As already mentioned fibronectin
plays an important role in the organization of the ECM proteins and defects in ColVI were
associated with a reorganization of fibronectin in fibroblasts [22]. We were not able to de-
tect a dysregulation in the expression of fibronectin. An alteration in the organization of
the fibronectin network was observed by the fibronectin staining in our UCMD fibroblasts
(Figure 5.1).
Upregulation of the various collagen chaperone proteins in the ER in UCMD fibroblasts
can be considered as a rescue mechanism to compensate for the defect in ColVI. This could
also indicate a general ER-stress in these cells, but no upregulation of 78kDa glucose-
regulated protein (GRP78 or HSPA5) was seen, a protein typically increased in ER-stress.
This may imply that a more specific defect, rather than just the result of ER stress, arises
from the ColVI defect in these cells.
In addition to the dysregulation of the above mentioned ER proteins, the macrophage
migration inhibitory factor (Mif) was found downregulated. Mif activates prostaglandin
synthesis which induces an increase of cAMP concentration that causes decreased expres-
sion of collagen in keloid fibroblasts [56]. The decrease of mif may correlate with the
collagen level.
Thrombospondin 1 (TSP1) was found downregulated in our study. TSP1 is an extracel-
lular adhesive glycoprotein mediating cell-cell and cell-matrix interactions by interaction
with several ECM proteins (fibronectin, integrins, laminin and type V collagen). TSP1 can
bind to its receptor CRT at the cell membrane where they play a role in regulation of colla-
gen synthesis through the Akt signaling pathway [64; 65]. After interaction of TSP1 with
CRT, the latter binds to the co-receptor complex LRP1/CD91/α-2-macroglobulin [53; 54].
This large complex activates a signaling pathway downstream in the fibroblasts via ac-
tivation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK),
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resulting in down-regulation of Rho activity and alteration of the cytoskeletal reorganiza-
tion which finally leads to disassembly of focal adhesions. Thus, down regulation of TSP1
could lead to restructuring of focal adhesions. This is of interest as focal adhesions were
previously found to be increased in number in UCMD epithelial cells [66]. Interestingly, we
could also demonstrate an increase in number of focal adhesion points per cell in UCMD
fibroblasts (Figure 5.3 and Table 5.2).
Focal adhesions are specialized dynamic protein structures at the contact point between
the cell and the ECM [67–69]. They are formed around transmembrane integrins which
interact at the extracellular site to the ECM and associate with the actin microfilaments at the
cytoplasmic site. They play an important role in the regulation of actin organization, thereby
affecting cell spreading, morphogenesis and migration. They participate in the structural
link between membrane receptors and the actin cytoskeleton providing mechanical strength,
and are important for transmission of regulatory signals. The integrins themselves exhibit
no actin-binding capacity, and this is achieved by a dense heterogeneous network of adaptor
proteins at the cytoplasmic face of the integrins. Currently, more than 50 proteins have been
reported to be associated with focal adhesions.
In our proteomic data, upregulation of three actin-binding proteins which play a role
in focal adhesions was detected in UCMD fibroblasts: moesin, plectin-1, spectrin-alpha.
Moesin, a member of the ezrin/radixin/moesin protein family, is also involved in focal ad-
hesions as an adaptor protein by linking integrins to the actin cytoskeleton [68]. Plectin-1
links the cytoskeleton to the membrane proteins and is a constituent [70] of junctional
complexes (e.g. focal adhesions in fibroblasts, desmosomes in epithelial cells and stri-
ated muscle cells [70–72]). In fibroblasts, plectin molecules may mechanically enforce
the attachment of the actin filament network to the focal adhesions via their amino-terminal
actin-binding domains. Plectin also creates links between the intermediate filament network
and focal adhesions, and between the intermediate filaments and microtubules [73]. Thus,
plectin is an important adaptor protein between integrins and the cytoskeleton at the focal
adhesions. Analysis of plectin (-/-) mouse fibroblasts showed an increase in the number
of focal adhesions [73]. The apparently reduced mechanical resistance of the sarcolemma
observed in some regions of skeletal muscle in plectin (-/-) mice could be a consequence
of the unstable actin filament attachment and could explain the observed necrosis of my-
ofibrils. Pathogenic mutations in the plectin gene cause an autosomal recessive form of
muscular dystrophy associated with skin blistering (epidermolysis bullosa simplex). The
plectin-integrin and plectin-actin binding is Ca2+ dependent and is regulated by calmod-
ulin. Spectrin-alpha also interacts with calmodulin, in a Ca2+-dependent manner. This can
be important in the light of a possible Ca2+ deregulation in UCMD. The upregulation of
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three actin-binding proteins together with the downregulation of TSP1 suggests that these
proteins play an important role in the mechanism involved in increasing number of focal
adhesion in UCMD fibroblasts. Also, the altered amount of several microtubule associated
proteins, stathmin, microtubule associated protein 4 and tubulin-specific chaperone A, is
not surprising as the extracellular network has indirect connections with the cytoskeleton
(actin, intermediate filaments and microtubules) via the focal adhesions.
5.6 Conclusion
We present here the first proteome analysis in UCMD cultured skin fibroblast. Our results
provide new insights into the pathophysiologic mechanisms in UCMD. The most important
findings were differences in protein expression linked to (i) ER collagen-chaperone function
and collagen synthesis and (ii) focal adhesion points that form an important link between
the ECM and the intracellular side of the cells. Proteins involved in pathways linked to a
mitochondrial defect and to impaired autophagocytic flux [30] which have been implicated
earlier in UCMD muscle fibers were not found as differentially regulated in our proteomics
experiment in fibroblasts. This suggests that different pathophysiologic mechanisms might
be at play in the two important cell types in UCMD, as already proposed by others [29].
As a further step we suggest a proteomic analysis in muscle cells. We hypothesize that in
UCMD fibroblasts pathological alterations in ECM (ColVI, fibronectin) affect the mechan-
otransduction signaling function of the focal adhesions. More focal adhesions are formed
as compensatory mechanism. These alterations cause changes in signaling functions impor-
tant for dynamic remodeling of the membrane-associated cytoskeleton which is necessary
for cell adhesion, motility and strength. The structural changes may affect the mechanical
strength in muscles and tendons in UCMD patients.
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6.1 Introduction
For more information on PXE we refer to chapter 2.4, p51. Briefly, Pseudoxanthoma elas-
ticum (PXE) is a multisystem genetic disorder characterized by progressive alterations in
connective tissues, primarily calcification and fragmentation of elastic structures in skin,
eyes, and cardiovascular system [1; 2]. However, alterations in collagen fibrils and several
other matrix constituents in elastic tissues indicate that the gene defect in PXE leads to a
rather complex and widespread alteration in the connective tissue.
PXE is caused by mutations in the ABCC6 gene which are inherited in an autosomal
recessive manner. The gene encodes ABCC6/MRP6 (multidrug resistance protein 6), a
protein belonging to the family of ATP-binding cassette transporter proteins [3]. In PXE
clinical signs and ultrastructural findings suggest alterations of soft connective tissues in
the whole body [4]. In that way PXE is now thought to be a metabolic disorder with its
primary molecular defect in the liver, resulting secondary to a more generalized connective
tissue disorder. Postulating that the absence of functional ABCC6 primarily in the liver
results in a persisting imbalance in certain circulating metabolite(s)/factor(s) that are phys-
iologically present to prevent aberrant mineralization under normal calcium and phosphate
homeostatic conditions [5; 6]. The cells in peripheral organs may serve as a target of the
metabolic alterations that facilitate the mineralization of the connective tissues [7; 8]. Ad-
ditional mechanisms have been suggested to contribute to the phenotypic presentation of
PXE. Fibroblasts are reported to suffer from a mild chronic oxidative stress [9]. It has been
demonstrated that cultured skin fibroblasts from patients with PXE show increased matrix
metalloproteinase-2 (MM-2) involved in the degradation of extracellular matrix in normal
physiological processes, suggesting an enhanced degradative potential of PXE fibroblasts
[10].
Similarities between PXE and PXE-like syndrome, where patients demonstrate a vi-
tamin K dependent coagulation factor deficiency, suggest that the ABCC6 deficiency in
PXE patients may result in reduced concentrations of vitamin K or its derivatives in serum
causing reduced activation of anti-mineralization proteins.
In general, a major impediment is the lack of knowledge of the precise pathophysiologi-
cal mechanism leading from the mutations in ABCC6 to the mineralization of the peripheral
connective tissues. Once the identity of molecules involved in this molecular process has
been elucidated, more specific approaches to counteract the mineralization processes of this
metabolic disorder can be developed.
The objective of our study was to provide additional proteomics based insight into
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the cellular mechanism of PXE. To reach this objective, a quantitative iTRAQ based LC-
MALDI method was used to compare the proteome in cultured skin fibroblasts derived from
PXE patients with control fibroblasts.
6.2 Materials and Methods
6.2.1 Patients and fibroblast cultures
All patients were diagnosed with PXE and were all homozygous for the same mutation
p.R1141X. Fibroblasts from four different PXE patients were used together with fibroblasts
of four matched control.
Fibroblasts from skin biopsies were cultured in Medium 199 with Earle’s salts and L-
glutamine (PAA Laboratories, Linz, Austria) supplemented with fetal bovine serum (10%),
kanamycine (1%) and penicillin-streptomycin (1%, Gibco, Carlsbad, California) and were
maintained at 37◦C 5% CO2. All fibroblast samples were grown until 90% confluence
before harvesting the cells. Cells were washed with 3.5 mM Tris, 140 mM NaCl, 0.02%
EDTA, centrifuged at 1200 rpm for 20 min at 4◦C, and dry pellets were stored (-80◦C) until
use.
6.2.2 iTRAQ reagent labeling and peptide separation
Proteins were extracted by re-suspending each cell pellet in 500 µl lysis buffer, containing
0.05 M triethyl ammonium bicarbonate (TEAB), and protease inhibitor cocktail (Roche,
Vilvoorde, Belgium). The cells were sonicated, and the supernatant was collected after
centrifugation at 13000 g for 20 min at 4◦C. Protein concentrations were measured by the
Bradford protein assay (Thermo Scientific, San Jose, California). Equal amounts of protein
(50 µg) from each cell lysate were used. The iTRAQ labeling was performed according
to the manufacturer’s protocol using solvents included in the kit (AB SCIEX, Foster City,
California). The peptide samples were added to the different labels of the 8-plex iTRAQ
kit (AB SCIEX) as follows: Patient 1: 113, patient 2: 114, patient 3: 115, patient 4: 116,
control pool 117, patient pool, 118. (A technical replicate of the control pool was included
(119) to get an idea of the technical variability). The labels are added in excess to acquire
full labeling. Labeling was confirmed for all samples before combining the samples. After
combining the iTRAQ-labeled samples, the mixture was vacuum dried and dissolved in 20
mM HCOONH4, 2% ACN at pH 10.
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The labeled peptide mixture was separated as described bij Mussche et al [11] and in
Chapter 3 (p76).
6.2.3 Nano-liquid chromatography and mass spectrometry analysis
Off-line LC-MS was done as described by Mussche et al [11] and in Chapter 3 (p76). Each
MALDI target plate (each LC-run) was analyzed twice by reinterpretation of the MS spectra
with a method containing an exclusion list from initial MS/MS data to avoid analyzing
peptides more than once. All first dimension fractions were separated and analyzed twice
by LC-MS.
6.2.4 Database searching and data analysis
Data analysis was performed with the software package Mascot Daemon [12] (version
2.3.01, Matrix science). All MS/MS spectra were processed against the Uniprot Homo
sapiens database (version 06 02 2012). Search parameters included iTRAQ labeling at the
N-terminus and lysine residues, cysteine modification by MMTS, digestion by trypsin (in-
cluding two missed cleavages allowed) and methionine oxidation as a variable modification.
Normalization of the ratios was performed by the median ratio. A significance threshold
of p<0,05 was used for peptide identification and an ion score cut off of 30. Protein ratios
were calculated by the weighted average of the peptide ratios. Only unique peptides were
selected for quantification with a peptide threshold of at least identity. Using the built in
decoy function, searching a concatenated database containing both forward and shuffled
decoy sequences allowed estimation of the false discovery rate. The results were exported
to Excel for further analysis. The ratios of patients to the control pool were considered and
accepted as significantly regulated when the ratios of all four patients samples showed a
significant value at the 95% confidence level. An additional ratio cutoff of 1.2 (in min 2 of
4 patients) was applied.
The biological function, interactions and localization of the differentially regulated pro-
teins were studied based on information in databases such as Uniprot, neXtProt, STRING
[13], and the Panther GO classification system [14].
6.3 Results and Discussion
Total cell lysate protein extracts from eight fibroblast cell cultures (four controls and four
patient cultures) were trypsinized and iTRAQ-labeled followed by RP-RP LC and MALDI-
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TOFTOF MS/MS analysis for identification and quantification. All RP-LC MALDI-TOF-
TOF runs were analyzed using the MASCOT software, searched against 25756 proteins
in the Uniprot homo sapiens database, resulting in the identification of 14282 peptides
leading to 1134 proteins (with >95% confidence). Searching a decoy database containing
both forward and shuffled sequences allowed estimation of a false positive rate of 0.25%.
The iTRAQ protein ratios reported here are the weighted average ratios calculated from the
ratios of the individual peptides determined for each protein.
From the total of 1134 proteins identified with >95% confidence, 77 proteins were
found significantly dysregulated at the 95% confidence level (p<0,05) (34 up- and 42 down
regulated) in all four patients samples (the full table of 77 proteins can be found in the
appendix). Consistent with the fact that the cellular soluble fraction was isolated and ana-
lyzed, the majority of identified proteins are intracellular proteins, together with a number
of membrane proteins and extracellular proteins. This is also reflected in the regulated
proteins.
Previous studies have identified a number of proteins that can act as powerful ant-
mineralization factors in serum, including fetuin-A and matrix-gla protein [6]. The pres-
ence of these proteins was demonstrated in association with mineral deposition in the PXE
mouse model [15]. We were not able to identify these proteins in the cultured skin fibrob-
lasts in our study. As we were not focusing on the plasma proteome or the secreted fraction
from the fibroblasts, but instead on intracellular proteins, it is expected that we could not
detect these proteins. Evidently, we need to consider that we only measured protein ratios
and not protein activities.
A gene ontology (GO) database was used (panther database [14]) in order to group
the dysregulated proteins according to their function and/or biological processes in which
the proteins play a role (Figure 6.1). This demonstrates that the proteins play a role in
structural cellular component morphogenesis, metabolism and maintaining a cellular redox
balance, in proteolysis and protease inhibition, and in calcium binding and signaling. Based
on those findings and together with information on interactions (String database) we were
able to detect some proteins and/or groups with possible importance to the PXE disease (a
selection of the full table is shown in Table 6.1).
A first group of proteins are the calcium ion binding proteins and proteins involved in
calcium-mediated signaling. Calcium concentration in blood from PXE patients is nor-
mal [16; 17], thus it is not a change in calcium concentration that cause the calcifications.
An important finding in our study was the downregulation of calumenin. This protein was
already described in PXE as a negative regulator the γ-carboxylase (GGCX). This is one
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Figure 6.1: Pie chart displaying the dysregulated proteins according to their function and/or biolog-
ical processes.
of the two enzymes within the vitamin K-cycle. Several cofactors (including factor II, and
inhibitors of mineralization) are processed via a vitamin K dependent metabolic pathway.
Mutations in this gene have been associated with a vitamin K-dependent coagulation defect
and a PXE-like disorder with multiple coagulation factor deficiency [18]. Other proteins in
this calcium ion binding group exhibit chaperone function, such as calreticulin, isomerases
FKBP1A and FK506bp9 mainly located in the ER. Protein S100-A11 and S100-A6 are
annexin binding proteins involved in calcium homeostasis, dynamics of cytoskeleton con-
stituents and cell growth and differentiation.
Another group of proteins potentially interesting in the light of PXE are proteins in-
volved in proteolysis and/or proteins exhibiting protease inhibitor activity. Among these
are the protease inhibitors alpha-2-macroglobulin en glia derived nexin, which were both
found downregulated. This is interesting for several reasons. It has been demonstrated that
cultured skin fibroblasts from patients with PXE show an increased matrix metalloproteinase-
2 (MMP-2), which is involved in degradation of extracellular matrix in normal physio-
logical processes, suggesting enhanced degradative potential of PXE fibroblasts [10]. We
did not identify MMP-2 itself but detected decreased expression of alpha-2-macroglobulin.
Alpha-2-macroglobulin is synthesized mainly in liver but also locally by macrophages and
fibroblasts. Alpha-2 macroglobulin acts as an antiprotease and is able to inactivate a variety
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Table 6.1: Differentially regulated proteins
Acc.
No.a
Protein name %Covb nc P1/Cd P2/Ce P3/Cf P4/Cg Localizationh
P01023 Alpha-2-macroglobulin 2,9 7 0,48 0,37 0,25 0,40 secreted
P20810 Calpastatin 8,5 7 1,34 1,31 1,03 1,27
P27797 Calreticulin 23,3 31 0,66 0,65 0,77 0,71 ER
O43852 Calumenin 17,5 15 0,72 0,81 0,85 0,77 ER, secreted
P07093 Glia-derived nexin 8,3 5 0,47 0,53 0,43 0,48 secreted
P14314 Glucosidase 2 subunit
beta
20,5 14 0,77 0,69 0,87 0,66 ER
O75874 Isocitrate dehydrogenase
[NADP] cytoplasmic
6 6 1,99 1,57 1,26 1,34 cytoplasm
P40926 Malate dehydrogenase,
mitochondrial
22,8 8 0,56 0,72 0,53 0,78 mitochondrial
matrix
Q14697 Neutral alpha-
glucosidase AB
11,3 14 0,86 0,81 0,83 0,71 ER
P62942 Peptidyl-prolyl cis-trans
isomerase FKBP1A
34,3 5 1,51 1,41 1,39 1,14 cytoplasm
O95302 Peptidyl-prolyl cis-trans
isomerase FKBP9
15,6 16 0,79 0,69 0,86 0,64 ER
O60664 Perilipin-3 28,6 16 1,61 1,56 1,11 1,30 cytoplasm,
membrane
P31949 Protein S100-A11 56,2 9 1,39 1,83 1,37 1,74 cytoplasm,
nucleus
P06703 Protein S100-A6 33,3 11 0,44 0,45 0,62 0,55 cytoplasm,
membrane
P07602 Proactivator polypeptide
= saposin
9,7 18 1,87 1,80 1,99 1,96 lysosome
Q99536 Synaptic vesicle mem-
brane protein VAT-1 ho-
molog
28 20 0,69 0,72 0,62 0,90 cytoplasm
P30048 Thioredoxin-dependent
peroxide reductase,
mitochondrial
15,2 8 0,54 0,40 0,62 0,63 mitochondrion
O43399 Tumor protein D54 37,9 9 1,95 1,84 1,65 1,39 cytoplasm
O60701 UDP-glucose 6-
dehydrogenase
17,2 8 0,60 0,63 0,69 0,68 cytoplasm
a Uniprot accession number.
b % Protein coverage.
c Number of peptides.
d Ratio of PXE patient 1 to Controls (p<0,05).
e Ratio of PXE patient 2 to Controls (p<0,05).
f Ratio of PXE patient 3 to Controls (p<0,05).
g Ratio of PXE patient 4 to Controls (p<0,05).
h Localization.
of proteinases (including serine-, cycteine-, and metalloproteinases). Most important is the
fact that it binds to and inactivates MMP-2 [19; 20]. It also functions as an inhibitor of
fibrinolysis by inhibiting plasmin and kallikrein, and also as an inhibitor of coagulation by
inhibiting thrombin, and may act as a carrier protein as it also binds to numerous growth
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factors and cytokines, such as platelet-derived growth factor, basic fibroblast growth fac-
tor, TGF-β, insulin, and IL-1β. Its downregulation could lead to an increased amount or
increased activity of MMP-2, which could result in alterations in the extracellular matrix.
The second protease inhibitor that was found downregulated in our study was glia de-
rived nexin, a serine protease inhibitor. Those two inhibitors are also involved in coagula-
tion. Glia-derived nexin inhibits factor II (thrombin) that also interacts with γ-carboxylase
(GGCX).
A third protease inhibitor is calpastatin, an inhibitor of calpains, which are a family of
proteases (non specific) involved in cell motility and cell cycle. Two regulatory subunits
and a small subunit of calpain were identified but did not pass the requirement to be in the
final significant list of regulated proteins. Cytosolic aminopeptidase is involved in general
processing and turnover of intracellular proteins.
Besides those proteolytic enzymes and inhibitors, a group of proteins / enzymes found
is involved in metabolic processes. These include proteins of carbohydrate metabolic pro-
cesses (isocitrate dehydrogenase and malate dehydrogenase which are part of the Krebs
cycle and glucosidase 2 subunit beta, UDP-glucose 6-dehydrogenase and neutral alpha-
glucosidase AB which are involved in protein glycosylation) as well as lipid metabolic
process (saposin-D and perilipin-3), in addition to several enzymes exhibiting oxidoreduc-
tase activity. Oxidoreductases are an EC 1 class of enzymes, usually utilizing NADP or
NAD+ as cofactor. These protein changes could indicate that much is demanded of the
metabolism in PXE.
Oxidative stress is a phenomenon observed in PXE cells. Interesting is the finding of
thioredoxin-dependent peroxide reductase. This protects radical sensitive enzymes from
oxidative damage. Downregulation could indicate less protection against oxidative stress.
Two proteins were involved in cell proliferation (tumor protein D54 and transmembrane
glycoprotein NMB), which were previously found in cancer tissue.
To conclude, several proteins could be linked to processes involved in PXE, including
calumenin, chaperones, isomerase FKBP1A and FKbp9, alpha-2-macroglobulin, glia de-
rived nexin. From the result of our study a specific new pathophysiological mechanism can
not be identified yet. Future studies are needed to further clarify the undelying mechanism
in PXE.
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7
General discussion, conclusions and future
perspectives
7.1 Proteomics and fibroblasts
Thanks to its exponential usage in both basic and applied research, proteomics is contin-
uously further developing. Moreover, it has emerged as a useful and essential approach,
not only to enlarge the collection of identified proteins in a given cell type and/or cell com-
partment, but mainly to unveil the biological role of proteins: their function in normal and
pathological conditions, and their interaction with other proteins, as well as with cell and/or
extracellular moieties. In combination with other approaches (i.e. genomics, transcrip-
tomics, glycomics, metabolomics) proteomics becomes even more powerful, disclosing re-
lationships between gene and protein expression, thus enabling a better understanding of
the mechanisms controlling e.g. cell growth, cell fate, and diseases. Within this context,
cultured fibroblasts can provide a valuable source of information as these cells are among
the major actors in formation and remodeling of cell environment. Since there is a contin-
uous cross-talk among cells and their surroundings, a better understanding of the pathways
and endogenous/exogenous factors affecting the fibroblast protein profile will help to trace
the complex network at the basis of a number of major disease processes.
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The research objective of this PhD work was to use cultured skin fibroblasts as a model
cell system for proteomic analysis in a number of different rare genetic disorders. These
rare disorders are usually poorly studied, and the knowledge about their pathophysiological
mechanisms is very limited. Fibroblasts are a representative cell type for several disorders,
including those investigated in this thesis: Giant Axonal Neuropathy, Ullrich Congenital
Muscular Dystrophy and PseudoXanthoma Elasticum. In these three disorders cultured
skin fibroblasts or skin biopsies have already been used previously for diagnostic purposes:
in GAN to detect the vimentin aggregates, in UCMD to assign the intracellular and extracel-
lular ColVI, and in PXE to detect the fragmented elastin and affected extracellular matrix
components. Currently, cultured skin fibroblasts are also used for, for example, the diag-
nosis of oxidative phosphorylation defects [1]. Fibroblasts exhibit several advantages over
other human cells types/tissues. They are among the most accessible normal mammalian
cell types and the most amenable to culture in vitro. A skin biopsy is a less invasive pro-
cedure to obtain patient tissue for analysis as compared to e.g. a skeletal muscle biopsy or
liver biopsy. Moreover, the primary fibroblasts derived from skin biopsies can be cultured
over around 15 passages without the need to immortalize the cells. Disadvantages are that
the amount of patient samples remains limited and that the culturing of the cells takes time.
7.2 Mass spectrometry-based proteomics
At this moment, mass spectrometry-based proteomics is the only high-throughput method
for characterization of complex protein mixtures. Proteomic strategies are very diverse but
they all combine a separation method coupled to mass spectrometry analysis for the final
identification and quantification of proteins.
Due to the broad range of physicochemical properties of proteins the efficiency of strate-
gies that analyze intact proteins is rather limited, which results in lower proteome coverage.
Peptide-centered strategies, on the other hand, characterize proteins through their peptides.
These strategies assume that enzymatic or chemical proteolysis will result in at least one
peptide with analyzable properties representing the protein from which it is derived. The
complexity of peptide mixtures is unfortunately much higher compared to protein mixtures
and thus the outcome of these so-called ‘bottom-up analyses’ depends strongly on the re-
solving power of both the mass spectrometer and the chromatographic separation methods.
Modern proteomics is capable of identifying more than a thousand proteins within a
(sub) proteome, as was the case in our experiments. The end, however, is far from reached.
The enormous size and diversity of eukaryotic proteomes (up to 10,000 different proteins
per cell) still prove to be a considerable challenge for current techniques. The problems
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posed by the wide dynamic range of protein concentrations within cells, and by the hetero-
geneity of proteins due to post-translational processing and modifications remain unsolved.
For a shotgun proteomics experiment of a total cell lysate several peptide fractionation
steps are required. We used an RP-HPLC separation (high pH) in a first dimension that, af-
ter collection of the fractions, was followed by a nanoRP-HPLC separation (low pH) in the
second dimension for each fraction. The offline LC-MALDI approach made it possible to
analyze LC runs a second time in the mass spectrometer (with exclusion of the spectra from
the first measurement) to increase the coverage without repeating the LC separations. Re-
peating LC separations for all fractions also increased the coverage. In total, 1735 different
proteins could be identified in the cellular fraction of cultured skin fibroblasts in our exper-
iments, although the number of proteins we identified in individual experiments fluctuated
between 650 and 1200. Only around 300 proteins were identified in all of the experiments
performed, which illustrates the great diversity of the proteome and the difficulty in study-
ing it even when the same cell type and protocols are used. The differences are due mainly
to small variations in sample preparation. Therefore, it is highly important to perform all
preparation steps at the same time, with exactly the same buffers and reagents.
It is doubtful whether improvements should be expected from mass spectrometric tech-
nology, such as increased sensitivity and dynamic range. Indeed, such advances might no
longer be technically feasible or even necessary, since mass spectrometers already demon-
strate detection limits below the femto-molar range. As stated in Chapter 1, ESI and
MALDI are the two ion sources used for proteomics analysis. nLC-ESI-MS and nLC-
MALDI-MS are known to be complementary techniques and can both be used for itraq anal-
ysis. Although it has been reported that the reporter ion ratios measured by LC-MALDI-
MS were more accurate than those measured by LC-ESI-MS. One reason for this can be
the improved reporter ion ionization efficiency, relative to b and y ion fragmentation, seen
in MALDI-MS, compared to ESI-MS. Another reason appears to be because in MALDI
the reporter ions are measured, normally, only once for each peptide. In ESI analysis mul-
tiple acquisitions are made and those of weaker intensity, from the chromatographic tail,
contribute less accurate ratios [2].
The purity of the sample injected into the mass spectrometer, on the other hand, seems
to be a bigger issue. While the machine may be able to pick up fmoles, less abundant pep-
tides (proteins) might never be found, even if they are in the detectable limit, because more
abundant peptides (proteins) could be masking them. As such, more needs to be expected
within the field of peptide separation techniques. Ultra performance liquid chromatography
(UPLC) instead of HPLC for the chromatographic separations prior to MS is already used
in proteomics although not standard in every laboratory. The main difference between both
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is the higher pressure at which the UPLC functions. This allows the use of columns with
much smaller particles (1-2µm compared to 3-5µm in a standard C18 RP-HPLC column).
By working under higher pressure as well as with smaller column packings the resolu-
tion increases. Smaller peaks and a decrease in retention time are achieved. Although the
performance of small particle size packed columns is excellent, the technical difficulties
associated with the preparation of the columns has accelerated the development of new ap-
proaches such as monolithic column technologies [3]. While most of the chromatographic
supports are particle shaped, monoliths consist of a single piece of highly porous material.
In contrast to porous particles, the pores inside the monolith are open, forming a highly
interconnected network of channels. Different polymer-based monolithic phases have been
developed, and the polymer network is generally formed inside the capillary by a step-wise
chain polymerization reaction. Also the effect of colomn length on the separation perfor-
mance should not be underestimated, eg. longer columns incease the peak capacity which
is important for separation of complex samples [3]. The effect and potential of temperature
controlled separations (60◦C) is another fact that is shown to improve seperation [3; 4]. De-
spite the advantage, temperature control systems are not yet universally used in proteomics.
7.3 Proteomics data analysis
A basic consideration about comparative proteomic analysis and proteomics in general is
the difficulty of assigning a biologically meaningful function to proteins that are not fully
characterized /annotated. Even in the case of well-characterized proteins it may prove hard
to determine to what extent these proteins contribute to the disease. A general workflow
regarding interpretation of proteomics data involves grouping the dysregulated proteins ac-
cording to their localization, function, or pathway, or according to interactions or to com-
mon interaction partners. In some cases, several proteins belong to the same protein group
and are connected to each other or to processes which can be linked to the disease. Other
proteins or processes cannot (yet) be linked to any mechanism known in the literature. Ev-
idently, this does not mean that these proteins are not important, especially when research
on the topic is scarce and previous knowledge is limited. In those situations the result is a
list of proteins that might be if importance in the disease mechanism. This list can be of
great help for future research. Therefore, shotgun-proteomics should not be considered as
the end-point of an experiment but rather as the start of a research. Building further on the
proteomic results, new experiments can then be designed.
In general, the pool of proteins identified in our experiments comes from the soluble
fraction extracted from fibroblasts. The majority are intracellular proteins and only a frac-
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tion are extracellular proteins and membrane proteins (Figure 7.1). Fibroblasts contain
a high amount of structural/cytoskeletal proteins due to their prominent structural role in
connective tissues. Other identified proteins exhibit enzyme activity, nucleic acid binding,
etc. (Figure 7.2).
Figure 7.1: GO (Genontology) classification of all identified proteins in fibroblasts according to the
cellular component.
Figure 7.2: Classification of all identified proteins in fibroblasts according to protein class.
iTRAQ labeling allows the analysis of several samples either within the same exper-
iment or in different experiments. The iTRAQ 4-plex has the advantage of switching the
labels in a second experiment, eliminating potential differences between labels. The iTRAQ
8-plex on the other hand allows for analysis of more samples, biological as well as technical
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replicates, in the same experiment. This reduces the technical variation as all samples un-
dergo the same separation steps on exactly the same time. The use of the iTRAQ 8-plex for
peptide quantification allowed us to analyze different patients and controls within the same
experiment. As the labels are added in excess, a nearly full labeling of all peptides (with
a labeling efficiency around 98% for each of our experiments) is achieved. Four patients
and four controls were used in each case or, in case of the GAN transfection experiment,
three transfected and three non-transfected patients. This allowed us to obtain more reliable
results, e.g. by requiring a protein to be significantly dysregulated in all patients in order to
be included in the final results list and throwing out proteins that showed too much variation
between different patients (cfr. upregulated in one and downregulated in another patient).
It is clear that the number of patients used in our experiments is lower then the number
of patients used in clinical studies. Eg. for biomarker discovery studies cohorts of dozens
of patients are used in order to minimize the effect of biological variation and to be able to
find one biomarker. In that way is it more difficult to obtain significant results compared
to clinical studies. However, the disorders studied in this phd work are rare and both the
number of patients and the amount of tissue or cell material available is very limited. There-
fore, the proteomics studies performed here are aimed at a more cellular level to explore
the disease mechanism. We tried to find significantly regulated proteins that are helpfull in
the formulation of a hypothesis on possible disease mechanisms.
Validation of proteomics data is obviously required. For the majority of human proteins
anti-bodies are available. Western blot (WB) is often used to validate changes in protein
expression found in a proteomics experiment. It should be noted that WB is less sensitive
then mass spectrometry-based proteomics techniques, which can make it difficult for small
changes to be visualized on WB. In our studies we were able to visualize the protein changes
with WB. Another possibility that is regularly used for validation is to confirm protein
changes at the RNA level by means of qPCR (quantitative real time PCR). However, RNA
and protein levels do not always correlate. Another approach (mass spectrometry-based) for
validation is the use of Multiple Reaction Monitoring (MRM) in which a specific peptide
ion and a corresponding fragment ion are selected and can be identified and quantified,
by isotopically-labeled standards that are added to the sample. As stated above, different
mass spectrometric approaches are available to analyse itraq labeled samples. Due to the
complementary of MALDI and ESI it can be usefull to repeat an experiment with the other
technique. Even more interesting would be to use an alternative quantification method, e.g.
a lable free quantification approach to analyse these patients samples. As in our experiments
only four patients are used, repeating the experiment with other patients would definitly be
interesting and important to confirm the biological significance of the results.
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7.4 Conclusions and prospects for the three diseases
Our different analyses revealed several proteins with an altered abundance between patients
and control fibroblasts. Although it sometimes proves difficult to determine to what extent
the identified proteins contribute to the disease, we were able to link several of them to pos-
sible disease mechanisms. For others, future experiments and meta analysis of the literature
are required in order to determine whether and in what way they are linked to each of the
disorders studied.
7.4.1 Giant Axonal Neuropathy
Giant axonal neuropathy is a rare disorder caused by mutations in the gene encoding gigax-
onin, characterized by aggregation of intermediate filaments in different tissues. The aggre-
gations in axons are responsible for improper transmission of signals leading to degradation
of peripheral and central nervous system and subsequent clinical symptoms.
The classical hypothesis is that in GAN due to gigaxonin deficiency gigaxonin inter-
acting proteins are not targeted to and properly degraded by the proteasome. An increase
of these proteins is then hold responsible for aggregation of intermediate filaments by a
so far unknown cellular mechanism (Figure 7.3). The only known interaction partners for
gigaxonin today are three microtubule associated proteins (MAP1B, MAP8 and TBCB).
The first question raised in this phd work was whether the gigaxonin deficiency in GAN
fibroblasts resulted in dysregulation of gigaxonin-interacting proteins, of other proteins in-
volved in pathways leading to filament aggregates when compared to controls. In order
to answer this question, a proteomics setup was developed to perform a quantitative com-
parison of the fibroblast proteome in GAN patients and the fibroblast proteome in controls
(chapter 3). The other question was how gigaxonin deficient fibroblasts would react to the
introduction of the correct GAN gene. Would this be able to reduce the intracellular fil-
ament aggregations, and how does it affect protein expression levels? Are the levels of
dysregulated proteins normalized between patients and controls? Is there any other path-
way that is ‘activated’ due to transfection? These questions were addressed in Chapter 4,
where fibroblast cultures of three GAN patients were transfected with either the correct
GAN gene or with GFP as a control. Following transfection, protein expression profiles
were analyzed and compared for each patient (GAN/GFP), and the amount of aggregates in
human fibroblasts and mice brain was analyzed.
From our results we can conclude that there is no general alteration in expression of
cytoskeletal proteins between GAN patients and control samples. Surprisingly, this in-
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Figure 7.3: Giant axonal neuropathy classical hypothesis. Due to a gigaxonin deficiency (green),
gigaxonin interacting proteins (purple) are not targeted to and properly degraded by the proteasome.
This deficiency is responsible for the aggregation of intermediate filaments (IF).
cludes vimentin itself which is not upregulated in patients. Although we did an effort to
resolubilize the rest cell pellet, the possibility still remains that the dense aggregates were
not fully solubilized. Similarly, after transfection the level of vimentin expression did not
change. This indicates that GAN is caused by alterations in organization and localization
of IF rather than by increase of the amount of cytoskeletal proteins themselves. In line
with these findings we observed dysregulation of several proteins linked to regulation of
the cytoskeletal network organization, with a central role for galectin-1. Thus the gigax-
onin deficiency seems to lead to a dysregulation of proteins involved in regulation of the
cytoskeletal network.
After introduction of the GAN gene in diseased fibroblasts IF aggregates had visibly
shrunk after three-four days. The observed reduction of these aggregates is considered to
be highly important, as this implies that gene therapy could be used as treatment for GAN
patients by slowing down or even preventing deterioration of the peripheral and central
nervous system. At the level of protein expression, three proteins (galectin-1, aminopep-
tidase N (APN), and FK506-binding protein 9) were found to be regulated in the opposite
direction towards normal levels. However, the expression levels of another set of proteins
found to be dysregulated in GAN patients (Chapter 3) remained unaltered after AAV2/GAN
treatment. These results suggest that while some of the dysregulated proteins in GAN can
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rapidly return to homeostatic levels in response to gigaxonin reintroduction, other changes
may take longer to correct or may prove to be irreversible. We can speculate that the pro-
teins that returned to normal in response to gigaxonin reintroduction are important in the
GAN disease mechanism.
The cytoskeleton is not a static structure but a remarkably dynamic, tightly regulated
system that undergoes extensive reorganization under several conditions, such as cell mi-
gration, cell division, differentiation, mechanical stress, etc. We hypothesize that in GAN a
general dysregulation of the cytoskeletal network is occuring and as such protein phospho-
rylation emerges as an important cellular process which could be connected to the disease
mechanism. Most notably the polymerization of vimentin, which has no less than 41 phos-
phorylation sites, is regulated by phosphorylation (kinases) and dephosphorylation (phos-
phatases). A possible hypothesis is that dysregulation of the cytoskeleton network leads to
an abnormal phosphorylation state of vimentin (hyperphosphorylation) that subsequently
results in a massive depolymerization of vimentin filaments and finally in a collapse of the
vimentin network. The unpolymerized filaments could then be collected in the aggresome
near the nucleus where they form the typical aggregates (Figure 7.4). Cytoskeletal organi-
zation is also strongly influenced by extracellular factors. It has already been demonstrated
that a great variation in vimentin aggregation occurs in fibroblast cultures depending on
the amount of serum in the culture [5], although this could be a nonspecific reaction due
to stress and starvation resulting from low serum conditions. Recently, however, it was
shown that cells grown on poly-lysine coated plates display differences in vimentin aggre-
gates (unpublished data by Dr. Gray). This suggests that aggregation is directly influenced
by connections to the extracellular matrix or by adhesion. Further research is needed to
investigate in which way the cluster formation is triggered or can be influenced.
Gigaxonin (KLHL16) is a member of the KLHL family. Like gigaxonin, some of the
KLHL-family members act as a substrate adaptor protein for cullin-3-based ubiquitination,
e.g. keap1 (KLHL19). Damage of keap1 by oxidative stress results in disruption of the
keap1-Cul3 ubiquitination system and build-up in the cytoplasm of undegraded free NRF2,
a transcription factor responsible for transcription of many anti-oxidative genes. Through
a similar mechanism alteration of kleip (KLHL20) results in an increase of HIF2alpha and
transcription of hypoxia inducing genes. It is reasonable to assume that there could be a
binding partner of gigaxonin which functions in a way similar to keap1 and kleip. Un-
der normal conditions this protein is then most likely ubiquitinated and degraded by the
proteasome, while under certain conditions (stress, migration, mitosis, ...) it is no longer
ubiquitinated but instead retains its function, e.g. kinase activity leading to depolymeriza-
tion of the filaments (necessary for cytoskeletal reorganization). This would be the case for
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Figure 7.4: Our results show that in fibroblasts the gigaxonin deficiency leads to a disturbed regu-
lation of the cytoskeleton (green), with a potential central role for galectin-1 in this regulation. This
could possibly also be influenced or regulated by extracellular factors (blue). A possible hypothesis
(red) is that this dysregulation leads to abnormal phosphorylation of IF resulting in depolymerization
and subsequently collapse into aggregates.
‘normal individuals’. In GAN patients, however, the protein is in no condition ubiquitinated
due to the absence of the adaptor protein, and therefore would fulfill its function non-stop.
If such a hypothetical protein was a kinase or a transcription factor activating a kinase, this
could lead to hyperphosphorylation and subsequently irreversible depolymerization and ag-
gregation of intermediate filaments (Figure 7.5).
Up till now only three proteins were shown to interact with gigaxonin (not necessarily
ubiquitinated by this contact), but it is likely that there are more. Candidates for gigaxonin
binding partners should preferably be expressed in all tissues, play a role in reorganiza-
tion of the cytoskeleton and probably differ in their degree of ubiquitination. Our list of
dysregulated proteins (Chapter 3) contains a few possible candidates, such as zinc finger
protein 207, a transcription factor, mostly present in nucleus but also in cytoplasm, which
is ubiquitinated and which was upregulated in the proteome of GAN cells. Further research
is needed concerning the gigaxonin interactin proteins.
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(A) Hypothetical normal role of gigaxonin
(B) Hypothetical role of gigaxonin in Giant axonal neuropathy
Figure 7.5: Hypothesis for Giant axonal neuropathy. (A) Under normal conditions gigaxonin will
target X for ubiquitination and degradation. Under certain conditions (stress, migration, mitosis, ...?)
they are not ubiquitinated and perform their function, e.g. kinase activity or transcription activity,
leading to depolymerization of the filaments (necessary for cytoskeletal reorganization, e.g. during
cell division). (B) Gigaxonin deficiency. Protein X is not ubiquitinated at all in all circumstances due
to the absence of the adaptor protein, and could fulfill its function non-stop. If such protein would
be a kinase or a transcription factor activating a kinase, this function could be hyperphosphorylation
leading to irreversible depolymerization and aggregation of intermediate filaments. (Ub=ubiquitin,
X=unknown gigaxonin interacting protein, p=phosphorylation).
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Future perspectives
Phospho-proteomics is an upcoming and very challenging part in the proteomics field based
on specific targeting and selection of phosphorylated peptides in a sample. In the light of the
discussion and conclusion in the above paragraphs, the analysis of the phospho-proteome
could be of great interest for GAN.
The same holds true for ubiquitinated proteins. Gigaxonin is an adaptor protein that tar-
gets certain proteins to the ubiquitin proteasome system (UPS) for ubiquitination and further
breakdown by the UPS. Gigaxonin deficiency could alter the amount of ubiquitination of
proteins, and specific targeting/selection of ubiquitinated proteins in GAN fibroblasts and
comparing these to controls will be very interesting.
While the IF aggregates visible on EM and immunocytochemistry consist for the most
part of vimentin filaments, it is possible that other proteins possibly related to the aggrega-
tion process are present in the clusters in low concentrations. To investigate this, it would be
necessary to isolate the aggregates from the cells which is not easely done as these structures
are small and located intracellularly. However, by means of laser capture microdissection
(LCM) it could be possible to shoot out cells/part of cells by a laser directly under the micro-
scope. We were able to test this method on fibroblasts grown on glass slides and stained for
the vimentin aggregates. Unfortunately, the number of cells on the slide proved insufficient
to obtain an adequate amount of proteins that could be solubilized for mass spectrometric
analysis. For this kind of experiments tissue slides are recommended instead of only one
layer of cultured cells. As there are currently GAN mouse models available [6–8], the use
of slides of mice brain tissue could provide an alternative approach.
7.4.2 Ullrich congenital muscular dystrophy
Ullrich congenital muscular dystrophy is a disease characterized by muscle weakness. It is
caused by mutations in the COLVI genes leading to reduced or absent ColVI secretion by
fibroblasts and to disrupted interaction with the basement membrane. The underlying dis-
ease mechanisms remain poorly understood. Current hypotheses were based on a possible
mitochondrial defect leading to cell death. The results of the proteome comparison carried
out in our experiment between controls and patients, all of which carried the heterozygous
de novo p.G284R mutation in the COL6A1 gene, provided both confirmation of previous
hypothesis and some new ideas concerning processes involved in the disease.
The most important findings was a difference in protein expression linked to (i) ER
collagen-chaperone function and collagen I synthesis and (ii) focal adhesion points that
form an important link between ECM and intracellular side of cells. Proteins involved in
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pathways linked to a mitochondrial defect and to impaired autophagocytic flux [9], which
have been implicated earlier in UCMD muscle fibers, were not found to be differentially
regulated in our fibroblasts proteomics experiment. This suggests that different pathophys-
iologic mechanisms might be at play in the two important cell types in UCMD, as already
proposed by others [10].
We hypothesize that in UCMD fibroblasts pathological alterations in the ECM (ColVI,
fibronectin) affect the mechanotransduction signaling function of the focal adhesions lead-
ing to formation of more focal adhesions and more collagen I as a compensatory mechanism
(Figure 7.6). These alterations cause changes in signaling functions which are important for
dynamic remodeling of the membrane-associated cytoskeleton necessary for cell adhesion,
motility and strength. The structural changes may affect the mechanical strength in muscles
and tendons in UCMD patients.
Figure 7.6: UCMD hypothesis: Due to the pathogenic mutations in ColVI a reduced secretion and
incorporation of the ColVI protein in the ECM, or a disturbed connection of the ColVI protein to
the basement membrane is seen. To compensate for this defect, the cell is producing an increased
amount of collagen I (and its chaperones in the ER), and an increased number of focal adhesions at
the cell membrane.
Future perspectives
Fibroblasts are an extremely suitable cell type to study connective tissue disorders as they
are the main extracellular matrix secreting cells. Apart from the obvious importance of the
intracellular pathways, the extracellular space also plays an important role in UCMD. It
would therefore be interesting to investigate the proteins that are secreted by the fibroblasts,
the so-called secretome. Similarly, the observed alteration in the number of focal adhesions
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implies that analysis of the membrane fraction of fibroblasts could provide more informa-
tion on the proposed alteration of signaling functions and connection between cells and
extracellular matrix. In addition, since our results suggest that different pathophysiologic
mechanisms might be at play in the two important cell types in UCMD, being fibroblasts
and muscle cells, a comparative proteomics analysis in muscle cells could give additional
information.
7.4.3 Pseudoxanthoma elasticum
Pseudoxanthoma elasticum is a complex multisystem genetic disorder characterized by al-
terations of connective tissues, primarily calcification and fragmentation of the elastic struc-
tures in skin, eyes, and cardiovascular system. Mutations in the ABCC6 gene, encoding a
fairly unknown transporter, are responsible for this disorder. Several hypothesis have been
proposed but lack of knowledge of the precise pathophysiological mechanism leading from
mutations in ABCC6 to the elastic fiber mineralization of peripheral connective tissues
remains a limiting factor. More information on the ABCC6 transporter will be of great
importance. Once the identity of the molecules transported through the ABCC6 transporter
has been elucidated, more specific approaches to counteract the mineralization processes of
this metabolic disorder can be developed. Therefore more research is required.
Our proteomics experiment sought to find some pathways or proteins that are already
known to be involved in PXE confirming the importance of the experiment, and to find new
proteins that might play a role in the process. The most important findings where a downreg-
ulation of calumenin, already described in PXE as it negatively regulates the γ-carboxylase,
together with dysregulation of other calcium related proteins, as well as proteins involved
in proteolysis and/or proteins exhibiting protease inhibitor activity, and proteins involved
in metabolic processes. However, PXE seems to be a very complex disease with a lot of
different factors paying a role. Thereby, the disease is not localized to a specific cell type
of tissue. A lot of questions still remain. With this proteomics result in mind we are con-
vinced that in the future new facts and evidence will come to the surface confirming these
proteomics results and their link to PXE.
7.5 Overall conclusion
In this PhD work we succesfully used quantitative proteomics to investigate three different
rare genetic disorders, GAN, UCMD and PXE. It is clear that research of other diseases
could benefit from such analysis. Any disorder involving a defect in fibroblasts, or any
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disorder in which fibroblasts play an important role, such as connective tissue disorders,
could benefit from a proteomics approach to provide additional information about proteins
and pathways involved in the disease.
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Summary
In the PhD work presented here, three genetic disorders are studied: Giant Axonal Neu-
ropathy (GAN), Ullrich Congenital Muscular Dystrophy (UCMD) and Pseudoxanthoma
Elasticum (PXE). Much work has been done in an effort to gain better insight into the un-
derlying pathophysiological mechanism in these disorders. Cultured skin fibroblasts are
used as a cell model for the disease. Each of these disorders has a clear connection with
fibroblasts. Thus, skin fibroblast cultures are particularly well suited for studying each of
the three disorders.
An iTRAQ-based MALDI-TOFTOF proteomics quantification method was applied to
study the pathogenic alterations in the cultured skin fibroblasts from patients with GAN,
UCMD or PXE. The iTRAQ-labeled peptides were separated by 2D-LC and subjected to
MS/MS analysis. Identical peptides derived from different samples have the same mass.
These peptides share similar chromatographic properties, allowing both peptide identifica-
tion and quantification to be derived from the same MS/MS spectrum. A database search
is then performed using fragmentation data to identify the labeled peptides and hence the
corresponding proteins whilst the iTRAQ mass reporter ion is used to relatively quantify
the peptides.
GAN is a rare autosomal recessive disorder characterized by progressive dysfunction-
ing of peripheral and central nervous system. Morphologically, GAN is characterized by
the presence of giant axons filled with densely packed accumulations of neurofilaments. In
fibroblasts, vimentin aggregates are seen. GAN is caused by mutations in the GAN gene
that codes for gigaxonin. However, is not clear how a defect in gigaxonin can lead to
intracellular aggregations of intermediate filaments in several cell types. In previous stud-
ies, MAP1B, MAP8 and TBCB were shown to bind to gigaxonin that functions as adaptor
protein for ubiquitination of these proteins and their subsequent degradation in the protea-
some. The hypothesis in earlier studies was that a defect in gigaxonin causes accumulation
of these proteins, which in turn causes aggregation of intermediate filaments. One of the
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weak points in this hypothesis was that MAP1B, MAP8 and TBCB are associated with mi-
crotubules and not with intermediate filaments. In GAN mice, an increase of these proteins
was found but this was not confirmed in human studies. The first question we raised was
whether these proteins were increased in GAN fibroblasts when compared to controls and
whether there are other proteins in GAN fibroblasts that might be dysregulated. In Chapter
3, a proteomics setup was developed in order to try to answer these questions by a quan-
titative comparison of the proteome in GAN patient fibroblasts and control fibroblasts. A
second question was how the gigaxonin deficient fibroblasts do react after transfection of
the correct GAN gene. Will this transfection be able to reduce the intracellular filament
aggregations? What about expression levels of proteins that were shown to be dysregulated
in our first experiment? Is there a trend towards normal levels? This was investigated in
Chapter 4.
Among the dysregulated proteins found between GAN patients and controls were ri-
bosomal protein L29, ribosomal protein L37, galectin-1, glia-derived nexin and aminopep-
tidase N. Also, nuclear proteins linked to formin-binding proteins were found to be dys-
regulated. Although the major role of gigaxonin was reported to be in degradation of
cytoskeleton-associated proteins, the amount of 76 cytoskeletal proteins was unaltered.
Several of the dysregulated proteins play a role in cytoskeletal reorganization. In the second
GAN study, treatment of skin fibroblast cultures from three different GAN patients with an
AAV-2 vector containing a normal human GAN transgene significantly reduced the number
of cells displaying vimentin aggregates. A proteomic analysis of these treated cells was
performed, wherein 32 proteins were identified whose abundance changed in response to
gigaxonin gene transfer. The levels of three proteins (galectin-1, aminopeptidase N, and
FK506-binding protein 9) previously identified as being dysregulated in GAN were now
shifted in the other direction.
From our results we conclude that a general alteration in expression of cytoskeletal
proteins between GAN patients and control samples is not seen. This includes vimentin
itself. Similarly, after transfection the level of vimentin expression did not change. This
indicates that GAN is caused by alterations in the organization of the intermediate filaments
rather than by an increase in the amount of structural proteins. In line with these findings,
we observed dysregulation of several proteins linked to the regulation of the cytoskeletal
network organization, with a central role for galectin-1.
After introduction of the GAN gene in diseased fibroblasts, the intermediate filament
aggregates had visibly shrunk. The observed reduction of these aggregates is considered to
be highly important, as this implies that gene therapy could be used as treatment for GAN
patients by slowing down or even preventing deterioration of the peripheral and central
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nervous system. We can speculate that the proteins that modulated in response to gigaxonin
reintroduction are important in the GAN disease mechanism, especially the three proteins
that were found to be regulated in the opposite direction.
We showed that in GAN a general dysregulation of the cytoskeletal network is occuring.
Protein phosphorylation emerges as an important cellular process which could be connected
to the disease mechanism. Most notably the polymerization of vimentin, which has no less
than 41 phosphorylation sites, is regulated by phosphorylation (kinases) and dephospho-
rylation (phosphatases). A possible hypothesis is that dysregulation of the cytoskeleton
network leads to an abnormal phosphorylation state of vimentin (hyperphosphorylation)
which subsequently results in massive depolymerization of vimentin filaments and finally
in collapse of the vimentin network. The unpolymerized filaments could then be collected
in the aggresome near the nucleus where they form the typical aggregates.
UCMD is a genetic disorder caused by mutations in the COL6 genes. Cultured skin
fibroblasts are often used for the diagnosis. Recent experiments demonstrated a latent mi-
tochondrial defect occurring at the mitochondrial permeability transition pore (PTP). An-
other phenomenon that might play a role is an impairment of autophagocytic flux. The
mechanism by which aberrant synthesis and secretion of collagen VI by fibroblasts leads to
muscular dystrophy is poorly understood. In Chapter 5, we compared the patients fibrob-
last proteome to that of control fibroblasts in order to identify dysregulated proteins and
pathways that could help to get more insight into the disease mechanism.
Altered expressions of twenty five proteins located in different cellular pathways were
detected. Changes were detected in (i) proteins that function as ER chaperone for pro-
collagen I and in collagen I itself, (ii) in proteins involved in formation of focal adhesions
(that form an important link between ECM and intracellular side of cells) and (iii) in pro-
teins involved in calcium fluxes. Among the ER proteins that were upregulated in UCMD
fibroblasts were HSP47, cyclophilin B and calreticulin. The dysregulation of the proteins
involved in cell matrix adhesions coincided with an increased number of focal adhesions in
the UCMD fibroblasts. Proteins involved in pathways linked to a mitochondrial defect and
to impaired autophagocytic flux were not found as differentially regulated.
We hypothesize that in UCMD fibroblasts pathological alterations in the ECM affect
the mechanotransduction signaling function of focal adhesions which provokes the forma-
tion of more focal adhesions and more collagen I, as compensatory mechanism. These
alterations cause changes in signaling functions, important for dynamic remodeling of the
membrane-associated cytoskeleton necessary for cell adhesion, motility and strength.
PXE is characterized by typical skin lesions and symptoms due to involvement of the
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eye and cardiovascular system. Characteristic are the progressive alterations of connec-
tive tissue such as calcification and fragmentation of the elastic structures is these organs.
Causal mutations in the ABCC6 gene were identified. The ABCC6 gene codes an ATP-
dependent membrane transporter. The transporter has no apparent relation with ECM pro-
teins or homeostasis and the exact mechanism by which this protein influences the disease
course is still unknown. ABCC6 is expressed in most organs, mainly in liver and kidneys.
It is unclear in which way this protein malfunction would lead to fragmentation of elastin
fibers in skin, eyes and blood vessels. A comparison of the patients fibroblast proteome to
that in controls was performed in order to get more insight in how this defect that lead to
skin abnormalities. This is described in Chapter 6.
An important finding in this study was a downregulation of calumenin. This protein
was already described in PXE as a negative regulator gamma-carboxylase. Other proteins
that were dysregulated were calreticulin, isomerases FKBP1A and FK506bp9, mainly lo-
cated in the ER. Another group of proteins that are potentially interesting are proteins in-
volved in proteolysis and proteins exhibiting protease inhibitor activity. It has been demon-
strated that cultured skin fibroblasts from patients with PXE show an increased matrix
metalloproteinase- 2 (MMP-2), an enzyme involved in degradation of extracellular matrix
in normal physiological processes. We did not identify MMP-2 itself but detected decreased
expression of alpha-2-macroglobulin. Alpha-2-macroglobulin is synthesized mainly in liver
but also locally in macrophages and fibroblasts. Alpha-2 macroglobulin acts as antiprotease
and is able to inactivate a variety of proteases including serine-, cysteine-, and metallopro-
teinases. Most important is the fact that it binds to and inactivates MMP-2. A second
protease inhibitor that was found downregulated was glia derived nexin, a serine protease
inhibitor. The two inhibitors are also involved in coagulation. Glia-derived nexin inhibits
factor II (thrombin) that interacts with gamma-carboxylase. A third protease inhibitor that
was found dysregulated is calpastatin, an inhibitor of calpains.
Samenvatting
In deze doctoraatsstudie werden drie genetische aandoeningen bestudeerd: Giant Axonal
Neuropathy (GAN), Ullrich Congenital Muscular Dystrophy (UCMD) en Pseudoxanthoma
Elasticum (PXE). Om een beter inzicht te verwerven in de onderliggende pathofysiologis-
che mechanismen van deze ziektes werd uitgebreid werk verricht, onder meer door gebruik
te maken van gekweekte huidfibroblasten als ziektemodel. Elk van deze aandoeningen staat
immers duidelijk in verband met deze cellen. Gekweekte huidfibroblasten daarom in het
bijzonder geschikt om deze aandoeningen te bestuderen.
Om de pathogene wijzigingen in de gekweekte huidfibroblasten van patie¨nten met GAN,
UCMD en PXE te bestuderen werd gebruik gemaakt van een iTRAQ-MALDI-TOFTOF
proteomics kwantificatiemethode. De gelabelde peptiden werden gescheiden met 2D-LC
en geanalyseerd met MS/MS. Identieke peptiden afkomstig van verschillende stalen hebben
dezelfde massa en gelijke chromatografische eigenschappen, en door het MS/MS spectra te
vergelijken met een database kunnen de corresponderende eiwitten geı¨dentificeerd worden,
terwijl de iTRAQ reporter ionen relatieve kwantificatie toelaten.
GAN is een zeldzame autosomaal recessieve aandoening gekenmerkt door een pro-
gressieve achteruitgang van het perifere en centrale zenuwstelsel. Vanuit een morfologisch
standpunt wordt GAN gekenmerkt door de aanwezigheid van grote axonen, gevuld met
dicht opeengepakte neurofilamenten. In fibroblasten worden aggregaties van vimentine
waargenomen. GAN wordt veroorzaakt door mutaties in het GAN gen dat codeert voor
gigaxonine. Het is echter onduidelijk hoe een defect in gigaxonine kan leiden tot intracel-
lulaire aggregatie van intermediaire filamenten in verschillende celtypes. In eerdere studies
werd aangetoond dat MAP1B, MAP8, en TBCB, binden aan gigaxonine, dat dienst doet
als een adaptor eiwit voor de ubiquitinatie van deze eiwitten en dus hun afbraak door het
proteasoom. De vroegere hypothese stelde dat een defect in gigaxonine leidde tot een accu-
mulatie van deze eiwitten, met een aggregatie van de intermediaire filamenten tot gevolg.
Ee´n van de zwakke punten van deze hypothese is echter dat MAP1B, MAP8, en TBCB
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niet geassocieerd zijn met de intermediaire filamenten, maar met de microtubuli. De eerste
vraag die we daarom wilden beantwoorden was of er een toename is van deze eiwitten in
GAN fibroblasten in vergelijking met gezonde cellen en of er andere eiwitten in GAN fi-
broblasten significant meer of minder aanwezig zijn? In Hoofdstuk 3 werd een proteomics
setup ontwikkeld voor een kwantitatieve vergelijking van het proteoom van GAN fibrob-
lasten en gezonde cellen om een antwoord te krijgen op deze vraag. Een tweede vraag
die gesteld werd: hoe reageren gigaxonin deficie¨nte fibroblasten op transfectie van het cor-
recte GAN gen? Leidt dit tot een vermindering van de aggregaties van de intracellulaire
filamenten? Wat gebeurt er met de expressieniveaus van de eiwitten die in het vorige exper-
iment gedyreguleerd waren? Worden de normale expressieniveaus hersteld? Een antwoord
op deze vragen werd gezocht in Hoofdstuk 4.
Onder meer ribosomale eiwitten L29 en L37, galectine-1, glia-derived nexine en aminopep-
tidase N waren gedysreguleerd in GAN patieten vergeleken met controles. Daarenboven
werden ook kern eiwitten gelinkt aan formine-bindende eiwitten geı¨dentificeerd als zijnde
gedyreguleerd. Hoewel studies aantonen dat de voornaamste rol van gigaxonine ligt in de
afbraak van cytoskelet-geassocieerde eiwitten, vertoonde geen van de 76 cytoskeleteiwit-
ten gewijzigde expressieniveau’s. Verschillende gedysreguleerde eiwitten spelen echter wel
een rol in de reorganisatie van het cytoskelet. In de tweede GAN studie, waarbij huidfibrob-
lasten culturen van drie verschillende GAN patie¨nten werden behandeld met een AAV-2
vector dat een normaal menselijk GAN gen bevatte, werd een duidelijke vermindering van
aggregaten vastgesteld. Een proteome analyse van de behandelde cellen werd uitgevoerd,
waarbij tweeendertig eiwitten een wijzigde expressie vertoonden in respons op de gigaxo-
nine transfer. De expressie van drie van deze eiwitten (galectine-1, aminopeptidase N, en
FK506-bindend eiwit 9), eerder geı¨dentificeerd als zijnde gedysreguleerd, was nu gewijzigd
in de andere richting.
Uit onze resultaten concluderen we dat in GAN fibroblasten geen algemene verander-
ing in de expressieniveaus van cytoskeletale eiwitten kan worden vastgesteld in vergelijking
met de controles. Dit geldt ook voor vimentine zelf, dat niet opgereguleerd is bij patie¨nten.
Dit kon ook vastgesteld worden na transfectie, wat geen effect had op het vimentine-niveau.
Dit toont aan dat GAN wordt veroorzaakt door wijzigingen in de organisatie van de inter-
mediaire filamenten en niet door een verhoogde hoeveelheid van de eiwitten zelf. Deze
hypothese wordt bevestigd door de vaststelling dat veel van de gedereguleerde eiwitten
gelinkt zijn aan de regulering van de organisatie van het cytoskelet, met een centrale rol
voor galectine-1.
Na de introductie van het GAN gen in aangetaste fibroblasten was er een zichtbare ver-
mindering van de filament aggregaties. Deze observatie is van bijzonder belang, aangezien
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ze impliceert dat gen therapie een mogelijke behandelingsmethode is voor GAN patie¨nten
om de voortgang van het ziekteproces te vertragen of de afbraak van het perifere en het cen-
trale zenuwstelsel te verhinderen. We kunnen speculeren dat de eiwitten die gemoduleerd
zijn na de introductie van gigaxonine een belangrijke rol spelen in het ziektemechanisme
van GAN, in het bijzonder de drie eiwitten die gereguleerd waren in de andere richting.
We toonden aan dat bij GAN een algemene deregulatie van het cytoskelet plaatsvindt.
Eiwit fosforylatie is een belangrijk cellulair proces dat een rol zou kunnen spelen in het
ziektemechanisme. Onder meer de polymerisatie van vimentine, met niet minder dan ee-
nenveertig fosforylatie sites, wordt gereguleerd door fosforylatie (kinases) en defosforylatie
(fosfatases). Een mogelijke hypothese is dat de dysregulatie van het cytoskelet netwerk leidt
tot een abnormale fosforylatiestaat van het vimentine (hyperfosforylatie) dat vervolgens re-
sulteert in een algemene depolymerisatie van de vimentine filamenten en uiteindelijk in
collaps van het vimentine netwerk. De ongepolymeriseerde filamenten komen dan samen
in het aggresoom nabij de kern om de kenmerkende aggregaten te vormen.
UCMD is een genetische aandoening die wordt veroorzaakt door mutaties in de COL6
genen. De diagnose wordt vaak gesteld aan de hand van gekweekte huidfibroblasten. Re-
cente experimenten toonden een latent mitochondriaal defect ter hoogte van de permeability
transition pore (PTP). Een ander fenomeen dat mogelijks een rol speelt is een achteruitgang
van de autofagocytotische flux. Het mechanisme waarbij afwijkingen bij de synthese en
de secretie van collageen VI in de fibroblasten leiden tot spierdystrofie is onvoldoende be-
grepen. In Hoofdstuk 5 vergelijken we het fibroblast proteoom van patie¨nten en controles
om gedyreguleerde eiwitten en pathways te identificeren die meer inzicht kunnen geven in
het ziektemechanisme.
Vijventwintig eiwitten betrokken in verschillende cellulaire pathways vertoonden gewi-
jzigde expressieniveaus. Veranderingen werden gedetecteerd in de niveaus van (i) eiwitten
die fungeren als ER chaperones voor pro-collageen I en collageen I zelf, (ii) eiwitten die
betrokken zijn in de vorming van focale adhesies (belangrijk voor de link tussen ECM and
het IC deel van de cell), en (iii) eiwitten die betrokken zijn in calcium fluxes. ER eiwitten
die opgereguleerd zijn in UCMD zijn onder meer HSP47, cyclofiline B, en calreticuline. De
deregulatie van eiwitten betrokken in cel matrix adhesies kwam overeen met een gestegen
aantal focale adhesies in de UCMD fibroblasten. Eiwitten betrokken in de pathways gelinkt
aan het mitochondriale defect en de autofagocytotische flux vertoonden geen verandering
in hun regulering.
We stellen voor dat, in UCMD fibroblasten, wijzigingen in de extracellulaire matrix de
mechanotransductie signaalfunctie van de focale adhesies beı¨nvloeden, waardoor, ter com-
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pensatie, meer collageen I en meer focale adhesies worden gevormd. Deze wijzigingen
veroorzaken veranderingen van de signaalfuncties die belangrijk zijn voor de dynamische
modellering van het membraangeassocieerde cytoskelet dat nodig is voor cel adhesie, be-
weeglijkheid, en stevigheid.
PXE wordt initiaal gekenmerkt door huidletsels, en later door symptomen met be-
trekking tot de ogen en het cardiovasculaire systeem. Kennmerkend zijn de prograssieve
veranderingen in het bindweefsel zoals calcificatie en fragmentatie van elastische vezels in
deze organen. Mutaties in het ABCC6 gen werden aangetoond. Dit gen codeert voor een
ATP-afhankelijk membraan transporteiwit. Er is geen duidelijk verband tussen deze trans-
porter en de eiwitten van de extracellulaire matrix of de homeostase, en het exacte mecha-
nisme dat aan de basis ligt van deze ziekte is alsnog onbekend. ABCC6 wordt tot expressie
gebracht in de meeste organen, voornamelijk in de lever en de nieren. Het is onduidelijk
waarom een defect in dit eiwit zou leiden tot schade aan de huid, ogen, en bloedvaten. Het
fibroblasten proteoom van patie¨nten werdvergeleken met dat van controles om meer inzicht
te geven in de manier waarop dit defect leidt tot de waargenomen huidafwijkingen. Dit
wordt beschreven in Hoofdstuk 6.
Een belangrijke ontdekking in de studie van de fibroblasten van PXE patienten was
de neerregulatie van calumenine. Dit eiwit werd reeds eerder beschreven in PXE als een
negatieve regulator voor gamma-carboxylase. Andere gedereguleerde eiwitten waren cal-
reticuline, isomerases FKBP1A en FK506bp9, voornamelijk gelegen in het ER. Een andere
groep eiwitten die mogelijk interessant kan zijn zijn eiwitten betrokken in proteolyse en
eiwitten die proteases inhiberen. Er werd reeds aangetoond dat gekweekte huidfibroblas-
ten van patie¨nten met PXE een stijging vertonen van metalloproteinase-2 (MMP-2) in de
matrix. Dit eiwit is een enzyme betrokken in de afbraak van de extracellulaire matrix in
normale fysiologische processen. MMP-2 als dusdanig kon niet geı¨dentificeerd worden in
onze studie, maar we detecteerden wel verminderde expressie van alfa-2-macroglobuline.
Alfa-2-macroglobuline wordt voornamelijk gesynthetiseerd door de lever, maar ook lokaal
door macrofagen en fibroblasten. Alfa-2-macroglubulin doet dienst als een anti-protease en
is niet alleen in staat om een waaier aan proteases, waaronder serine-, cysteine-, en metal-
loproteases te inactiveren, maar bindt en inactiveert ook MMP-2. Ook glia afgeleid nexine,
een serine protease inhibitor, was neergereguleerd. Beide inhibitoren zijn betrokken bij
coagulatie. Glia-afgeleid nexine inhibeert factor II (trombine) dat interageert met gamma-
carboxylase. Een derde protease inhibitor is calpastatine, een inhibitor van calpaı¨nes.
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